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ABSTRACT 
 
Background & Aims: Arrhythmogenic Cardiomyopathy (AC) is a rare inherited 
heart muscle disease associated with mutations in genes encoding mainly 
components of the cardiac desmosome. We performed a comprehensive study of 
genetic variants in a cohort of AC subjects and the assessment of Next Generation 
Sequencing (NGS) strategies for molecular diagnosis of AC. 
Methods: Ninety-nine unrelated index cases, of which 26 sudden cardiac death 
cases, underwent genetic screening for 5 desmosomal genes by denaturing high 
performance liquid chromatography and direct sequencing, whereas 46 probands 
were additionally screened for 3 extra desmosomal genes. A complementary 
analysis for copy number variants (CNVs) was performed by multiplex ligation-
dependent probe amplification and quantitative real-time PCR in the entire cohort. 
A 4-step variant filtering strategy based on mutation type, frequency, evolutionary 
conservation and in silico analysis, was used. Whole Exome and Targeted NGS 
strategies were performed on Illumina platforms in order to test methods efficacy. 
Results: Screening of 8 AC genes and subsequent 4-step variants filtering 
identified 37 different point desmosomal mutations in 42 AC probands (42%). 
The most frequently mutated genes resulted PKP2 and DSP, with “radical” 
mutation type accounting for the 80% of the PKP2 variants. No pathogenic 
mutations were identified in the extra desmosomal genes analyzed. CNVs analysis 
further revealed 3 different large genomic rearrangements in 5 probands (4%), 
increasing to 46 (46%) the number of positively genotyped patients. PKP2 and 
DSP single mutation accounted respectively for 20% and 11% of the cohort, with 
DSP carriers showing a higher risk of sudden cardiac death. Eight multiple 
mutations carriers were observed (8%). NGS approaches identified 4 variants in 
extra desmosomal genes allowing a differential diagnosis in 4 patients. 
Conclusions: A fine variant filtering avoids overrepresentation of putative 
pathogenic mutations and shows that radical and missense mutations should be 
equally interpreted with great caution in the setting of clinical diagnosis. NGS and 
CNVs analysis increased significantly the diagnostic yield in AC genetic testing. 
The genetics of AC is more complex than previously appreciated, with frequent 
requirement for more than one ‘hit’ for penetrant disease. 
8 
 
  
9 
 
SOMMARIO 
 
Introduzione & Scopo: La Cardiomiopatia Aritmogena (AC) è una malattia rara 
del muscolo cardiaco associata a mutazioni a carico di geni che codificano 
principalmente per componenti del desmosoma cardiaco. Abbiamo realizzato 
l`analisi genetica in una coorte di soggetti affetti da AC e lo sviluppo di strategie 
in Next Generation Sequencing (NGS) per la diagnosi molecolare di AC. 
Metodi: Novantanove casi indice, di cui 26 soggetti di morte improvvisa, sono 
stati sottoposti a screening genetico per 5 geni desmosomiali mediante 
cromatografia denaturante in fase liquida ad alto rendimento e sequenziamento 
diretto, 46 probandi sono stati analizzati anche per 3 geni extra desmosomiali. 
Abbiamo inoltre ricercato nell`intera popolazione varianti del numero di copie 
(CNVs) mediante la tecnica MLPA (Multiplex Ligation-Dependent Probe 
Amplification) e PCR quantitativa. La strategia di filtraggio si è basata sul tipo di 
mutazione, frequenza, conservazione, e analisi in silico. Gli approcci NGS 
“Whole Exome” e “Targeted” sono stati eseguiti su piattaforme Illumina. 
Risultati: L`analisi di 8 geni associati alla AC e il successivo filtraggio delle 
varianti ha individuato 37 diverse mutazioni puntiformi in 42 soggetti (42%). I 
geni più frequentemente mutati sono la PKP2 e la DSP, le mutazioni “radicali” 
costituiscono l`80% delle varianti della PKP2. Non sono state riscontrate 
mutazioni patogene nei geni extra desmosomiali studiati. La ricerca di CNVs ha 
identificato 3 diversi riarrangiamenti cromosomici in 5 probandi (4%), portando a 
46 (46%) i soggetti genotipo positivi. Si sono osservate mutazioni singole nei geni 
PKP2 e DSP nel 20% e nell`11% dei soggetti, i portatori di mutazioni nella DSP 
presentano un rischio maggiore di morte improvvisa, 8 (8%) soggetti presentano 
mutazioni multiple. Le analisi mediante NGS hanno indentificato 4 varianti in 
geni extra desmosomiali permettendo la diagnosi differenziale in 4 pazienti. 
Conclusioni: La diagnosi molecolare in ambito clinico rende necessaria 
un`attenta interpretazione del potenziale patogeno tanto delle mutazioni missenso 
quanto di quelle radicali soprattutto dopo il cospicuo aumento di varianti 
identificate con NGS e la ricerca di CNVs. La base genetica di AC è molto più 
complessa di quanto finora apprezzato, con una frequente presenza di più di una 
mutazione per una penetranza completa della malattia.  
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INTRODUCTION 
1.1 Definition and Epidemiology 
Arrhythmogenic Cardiomyopathy (AC) is an inherited disorder of the 
myocardium characterized by progressive adipose and fibrous tissue replacement 
of cardiomyocytes (Nava et al., 1988; Thiene et al., 1988). This process is 
associated with structural and functional changes involving predominantly the 
right ventricle (RV), structural manifestations mainly include ventricular 
dilatation, hypokinesia, and aneurysms of the ventricular wall, that in early 
disease are mostly located in the right ventricular inflow, outflow, and apical 
regions, called the “triangle of dysplasia” (Frank et al. 1978; Marcus et al. 1982; 
Fontaine et al., 1998) (Figure 1.1). 
 
Figure 1.1: a) A case of AC in a 25-years old man who died suddenly. Four chamber cut of the 
heart specimen showing isolated fatty replacement of the right ventricular free wall and translucent 
infundibulum. B) Endomyocardial biopsy of the right ventricular free wall of a 39-years old 
patient who died suddenly, showing cadiomyocytes embedded in fibrous and fatty tissues (from 
Cardiovascular Pathology of Padua). 
 
Clinical manifestations of AC mostly occur between the second and fourth decade 
of life, the mean age at diagnosis is estimated to be approximately 30 years, and 
males are more often affected than females, with an estimated gender ratio of 3:1 
(Nava et al., 2000). 
In the Veneto region, AC is the most common cause of sudden cardiac death 
(SCD) in individuals under the age of 35 and in young athletes (Thiene et al. 
1988, Corrado et al., 1990). 
In this geographic area, the prevalence of AC is estimated to range between 
1:2000 and 1:5000 (Nava et al. 1988), however this value could be higher because 
12 
 
of the presence of many undiagnosed and misdiagnosed cases linked to the 
progressive nature of AC and its variable expressivity. 
 
1.2 Clinical Manifestations 
Progressive structural changes involving myocardium are preceded or 
accompanied by clinical manifestation including T-wave inversion in right 
precordial leads, epsilon waves, the presence of widening of the QRS complex 
observed in resting ECG, late potentials ventricular premature complexes which 
can be registered by signal averaged ECG and by Holter monitoring, respectively 
(McKenna et al., 1994). The most common clinical manifestations in AC are 
related to arrhythmias and conduction abnormalities, in particular ventricular 
tachycardia is a typical characteristic of AC patients that may lead to ventricular 
fibrillation and sudden death (SD) (Marcus et al., 1982; Thiene et al., 1988). 
However often SD can represent the first and only manifestation of AC or in some 
cases minor symptoms might occur making difficult its early identification.  
Natural history of AC can be divided into four phases, based on clinical and 
pathological observations (Thiene et al., 1990; Corrado et al., 2000; Thiene et al., 
2007; Basso et al., 2009). 
1. A “concealed” phase typical of early AC, frequently characterized by the 
absence of clinical symptoms, although subtle structural changes and minor 
ventricular arrhythmia may be recognized. During this phase subjects are 
mainly asymptomatic and they may be at risk of SD, especially during 
physical exercise (Corrado et al., 1990). 
2. The “overt electrical disorder” phase, characterized by the presence of 
functional and morphological abnormalities of the right ventricle (RV) and/or 
left ventricle (LV), usually detectable by cardiac imaging techniques. Patients 
manifest symptomatic ventricular arrhythmia, palpitation, syncope, and pre-
syncope.  
3. The third “right ventricular dysfunctional” phase is characterized by further 
extension of disease involving the RV myocardium that leads to impaired 
contractility and isolated right heart failure. 
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4. The most advanced phase is characterized by LV involvement leading to 
biventricular heart failure, which is difficult to distinguish from dilated 
cardiomyopathy (DCM). However, LV involvement may be detected also in 
earlier phases of the disease (Sen-Chowdhry et al., 2008). 
 
1.3 Diagnostic criteria 
Diagnosis of AC is based on classification of clinical findings into specific 
criteria, divided into major and minor according to specific association with the 
disease, as described in Table1.1. AC criteria were proposed by an International 
Task Force in 1994 (Mc Kenna et al., 1994) to facilitate AC diagnosis and were 
recently modified (Marcus et al., 2010), as the original criteria were highly 
specific but showed low sensitivity especially in evaluating asymptomatic 
subjects or family members affected by an early AC form (Marcus et al., 2010). 
The modified criteria focused on the detection of milder forms of the disease and 
aimed to facilitate the cascade screening of patients’ relatives based on different 
clinical features comprising structural, histological and arrhythmic abnormalities 
along with a detailed familial history of disease and SD. However the clinical 
diagnosis of AC is still complicated, as a single diagnostic test is not enough to 
ascertain the disease. The definitive diagnosis requires the fulfilment of 2 major, 1 
major plus 2 minor, or 4 minor criteria. A borderline diagnosis requires the 
fulfilment of 1 major plus 1 minor, or 3 minor criteria, and possible diagnosis 
fulfilment of 1 major or 2 minor criteria. 
1.3.1 Clinical tests enabling AC diagnosis: 
Baseline electrocardiography (12-lead ECG) findings associated with AC are 
abnormalities of depolarization, conduction and repolarization secondary to 
atrophy of ventricular walls that reflect the pathophysiology of the disease. ECG 
depolarization manifest as T-wave inversion in anterior precordial leads in the 
absence of RBBB (major criterion). Conduction abnormalities detected as 
prolongation of the QRS complex in right precordial leads in the absence of 
RBBB, (>110 ms in leads V1-V3) reflect slow conduction in the RV free wall 
(major criterion). The presence of epsilon wave, that represents a deflection 
between the end of the QRS complex and the beginning of the T wave (major 
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criterion) corresponds to a delayed electric potential that initiates in regions of 
healthy tissue surrounded by fibrofatty tissue indicative of intraventricular 
impulse conduction delay. 
Signal-averaged electrocardiogram (SAECG) allows the registration of low-
amplitude potentials within the end of the QRS complex (late potential) that are 
not wide enough to be evident on the 12-lead ECG. 
Holter monitoring is used to register the electric activity of the cardiovascular 
system for a period of time of normally 24 h, with particular attention to the 
diurnal rhythm fluctuations.  
Echocardiography represents the first-line imaging approach for evaluating 
patients with suspected AC or for screening of family members, allowing serial 
examination with the aim to assess the disease onset and progression.  
Magnetic resonance imaging (MRI) is another non-invasive tissue 
characterization technique that allows the detection of morphological and 
structural abnormalities of the ventricular wall like microaneurysms and allows 
the calculation of RV and LV volumes and ejection fraction (Tandri et al., 2005; 
Sen-Chowdhry et al., 2006; Perazzolo Marra et al., 2014). 
Endomyocardial biopsy is used to detect myocytes in diverse stages of cell death 
and of fibrofatty replacement (major criterion). However a negative biopsy is not 
enough to exclude AC because of the segmental nature of the disease, especially 
during early stages. 
A comprehensive workup also involves the study of a full family history, with 
particular focus on cardiac symptoms, and the design of a detailed pedigree 
describing the occurrence of SD and unexplained heart failure. The value of the 
analysis of the family history and of AC genetic testing has been widely 
recognized and the detection of a pathogenic variants now contributes as a major 
diagnostic criterion for the diagnosis of AC (Thiene et al., 2007; Basso et al., 
2009). 
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Table 1.1: Comparison of original and revised Task Force criteria for diagnosis of AC (from 
Marcus et al., 2010).  
 
1.4 Treatment of AC patients 
AC patients and athletes with probable or definite diagnosis of AC are strongly 
recommended to avoid physical activity and participation to competitive sports 
(Corrado et al., 2000). 
The pharmacological treatment of patients showing mild and tolerated 
arrhythmias is palliative and consists of beta blockers and class I and class III 
antiarrhythmic drugs, targeted against arrhythmias and cardiac insufficiency. In 
particular sotalol has been reported as most efficient pharmacological 
antiarrhythmic treatment in AC (Basso et al., 2004) and amiodarone is 
recommended as add-on therapy if betablockers show to be unsuccessful in 
suppressing ventricular tachycardia (VT) (Sen-Chowdhry et al., 2004). The only 
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effective strategy against malignant ventricular tachyarrhythmias is the 
implantable cardioverter-defibrillator (ICD). ICD implantation is recommended as 
a first-line therapy after cardiac arrest or documented sustained VT, or its use as a 
primary prophylaxis in asymptomatic subjects showing a family history of SD or 
evidence of wide right ventricular (RV) dysfunction. 
 
1.5 Molecular genetics of AC 
To date, AC is considered an autosomal dominant trait showing reduced 
penetrance and expression variability (Nava et al., 1988; McKenna et al., 1994; 
Sen-Chowdhry et al., 2004; van Tintelen et al., 2006). However, compound and 
digenic heterozygosity are often described in patients with severe form of disease 
(Xu et al., 2011; Bauce et al. 2010; Rigato et al., 2013) and, rare autosomal 
recessive forms of the myocardial abnormalities are also observed, associated or 
not to cardiocutaneous syndromes (Naxos and Carvajal syndromes).  
More than a decade elapsed between the recognition of familial AC (Nava et al., 
1988), and the identification of the first disease-causing gene mutation  (McKoy et 
al., 2000, Rampazzo et al., 2002). Linkage analysis and candidate gene 
approaches unmasked the genetic heterogeneity of AC with the identification of 
13 genetic loci (Table 1.2). 
 
The first molecular genetics studies involved the recessive syndromic form called 
Naxos disease. Naxos disease was first described in 1986 as a familial, autosomal 
recessive disease characterized by hair and skin abnormalities, woolly hair and 
palmoplantar keratoderma, and a form of cardiomyopathy showing AC-like 
features (Protonotarios et al., 1986). The typical woolly hair phenotype presented 
at birth, the erythema of the palms of the hands appeared within the first year of 
life, while the cardiac phenotype appeared only during adolescence or early 
adulthood. Nine affected individuals of four families from the Greek island of 
Naxos were originally described. Linkage analysis identified a locus at the long 
arm of the chromosome 17 (17q21.2) (Coonar et al., 1998). Subsequent 
sequencing of Plakoglobin (JUP) gene in affected subjects showed a 2 nucleotides 
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deletion leading to a frame shift effect which introduces a stop codon in the 
protein (McKoy et al., 2000). 
 
Locus Chromosome Gene Protein Inheritance Prevalence Reference 
AC1 14q24.3 TGFβ3 
Transforming Growth 
factor β-3 
AD < 1% Beffagna 
et al., 2005 
AC2 1q.42-43 RYR2 Ryanodine receptor 2 AD < 1% Tiso et al., 
2001 
AC3 14q12-q22 Unknown     
AC4 2q32.1-q32.2 Unknown     
AC5 3p25.1 TMEM43 
Transmembrane 
protein 43 
AD < 1% Merner et al., 
2008 
AC6 10p12-p14 
Unknown 
    
AC7 10q22.3 
Unknown 
    
AC8 6p24 DSP Desmoplakin AD/AR 10-15% Rampazzo et 
al., 2002 
AC9 12p11.2 PKP2 Plakophilin-2 AD/AR 30-40% Gerull et al., 
2004 
AC10 18q12.1 DSG2 Desmoglein-2 AD/AR 3-8% Pilichou et 
al., 2006 
AC11 18q12.1 DSC2 Desmocollin-2 AD/AR 1-5% Syrris et al., 
2006 
AC12 17q21.2 JUP Junction Plakoglobin AD/AR < 1% Asimaki et 
al., 2007 
AC13 10q21.3 CTNNA3 α-T-catenin AD NA van Hengel 
et al., 2012 
AC-like 2q35 DES Desmin 
AD NA Otten et al., 
2010 
AC-like 2q31.2 TTN Titin 
AD NA Taylor et al., 
2011 
AC-like 1q22 LMNA Lamin A/C 
AD NA Quarta et al., 
2012 
AC-like 6q22.1 PLN Phospholamban 
AD NA Van der 
Zwaag et al., 
2012 
Table 1.2: Genes associated with AC or overlap syndromes. AD: autosomal dominant, AR: 
autosomal recessive, NA: not available. 
 
Soon after the identification of the JUP deletion involved in Naxos syndrome, 
another deletion this time in the Desmoplakin (DSP) gene, localized on 
chromosome 6p24.3, was described for another syndromic form, so called 
Carvajal syndrome (Carvajal-Huerta et al., 1998). Carvajal syndrome is an 
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autosomal recessive disorder first described in 1998, in eighteen subjects 
belonging to three families from Ecuador who showed epidermolytic 
palmoplantar keratoderma, woolly hair, and heart involvement. The homozygous 
variant linked to this disorder creates a premature stop codon which truncates 
early DSP protein without the entire C-domain (Norgett et al., 2000; Kaplan et al., 
2004). 
Subsequently, a variety of mutations were associated with dominant forms of AC 
in genes encoding desmosomal components, including: plakophilin-2 (PKP2), 
DSP, desmoglein-2 (DSG2), desmocollin-2 (DSC2), and JUP (Gerull et al., 2004; 
Rampazzo et al., 2002; Pilichou et al., 2006; Syrris et al., 2006; Asimaki et al., 
2007). Thus, AC is now considered a disorder of the desmosome, as causative 
variants affecting different components of the cardiac desmosomes, have been 
reported in approximately 50% of AC subjects (Basso et al., 2012). 
 
1.5.1 Desmosomes 
Desmosome complexes are particularly abundant in tissues subjected to 
mechanical stress like the epithelium and the myocardium, where mediate 
mechanical anchorage of cardiomyocytes by connecting cytoskeleton to cell 
membranes of adjacent cells. In addition to cell adhesion, a function in cell-cell 
communication and tissue differentiation, and apoptosis, has been advanced 
(Chidgey et al., 2001; Merritt et al., 2002). These electron-dense symmetrical 
structures appear as dense membrane-associated plaques intercalated by 30 nm 
intercellular space which is divided by a central midline creating in this way the 
extracellular core domain, known as desmoglea, and the intracellular plaque. The 
intracellular plaque is commonly described as composed of two areas: the outer 
dense plaque, separated by a dense inner plaque (North et al., 1999). The 
desmosomal structure comprises transmembrane adhesive glycoproteins 
(components of the cadherin superfamily) and cytoplasmic proteins (components 
of the plakin and armadillo families). The outer dense plaque is where the 
cytoplasmic domains of the cadherins (DSG2, DSC2) attach to plakins (DSP) via 
armadillo proteins (PKP2 and JUP) (Figure 1.2). The inner dense plaque is where 
plakins attach to the intermediate filaments of the cell. 
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The connection between desmosomal components and intermediate filaments 
provides cellular adhesion and structural integrity.  
 
 
Figure 1.2: Schematic representation of desmosomal components (from Basso et al., 2009). 
 
1.5.2 Desmosomal genes and proteins 
Desmoplakin_DSP (6p24.3) belongs to the plakin protein family that includes a 
large number of proteins such as plectin, envoplakin and periplakin mediating the 
connection of different junctions with the cytoskeleton. 
DSP is composed by an N-terminal domain which has a major role in targeting the 
protein to the membrane, a central coiled-coil rod domain involved in the protein 
dimerization and a C-terminal domain, that interacts directly to the intermediate 
filaments. It is expressed in all tissues containing desmosomes (Leung et al. 2002) 
and an alternative splicing of the DSP precursor mRNA produces two isoforms, 
differing in the length of the central α-helical domains: DSP I composed by 2871 
amino acids and DSP II composed by 2271 amino acids. 
The first pathogenic nucleotide variants described in DSP in families with 
autosomal dominant striate palmoplantar keratoderma without heart disease, were 
heterozygous nonsense (p.Q331X) and splice site (c.939+1G>A) variants 
(Armstrong et al., 1999). Soon after DSP was linked also to the autosomal 
dominant AC form, with the identification of a missense mutation in exon 7 
(p.S299R) involving a high conserved amino acid and affecting a putative 
phosphorylation site (Rampazzo et al., 2002). 
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Since then, more than 100 DSP pathogenic variants have been detected in 5 to 
16% of AC cases, many of them showing LV involvement (Pilichou et al. 2006; 
Fressart et al. 2010; Xu et al. 2010; Cox et al. 2011). 
Plakophilin-2_PKP2 (12p11.21) the predominant protein isotype expressed in 
heart, belongs to the armadillo family of proteins and interacts directly to 
desmosomal cadherins and DSP (Chen et al. 2002). Two alternatively spliced 
mRNA transcripts gives origin to two protein isoforms: transcript 2b (881 amino 
acid long) and transcript 2a (837amino acid long) respectively (Gandjbakhch et 
al., 2011). PKP2 is comprise an amino-terminal head domain and nine armadillo 
repeat motifs and is necessary for heart morphogenesis and proper localization of 
DSP in mice (Grossmann et al., 2004). 
In 2004, Gerull and colleagues described 26 PKP2 different variants in 32 of 120 
AC index patients, and suggested that the lack or aberrant inclusion of PKP2 into 
the desmosomes might affect cell-cell contacts (Gerull et al., 2004).  
Up-to-date more than 120 pathogenic variants of PKP2 have been associated with 
AC accounting for approximately 15 to 50% of reported cases (Gerull et al., 2004; 
Pilichou et al., 2006; Fressart et al., 2010; Xu et al. 2010; Cox et al., 2011). Most 
variants show a dominant inheritance with reduced penetrance, but recessive and 
compound heterozygous variants have also been identified in several patients (Xu 
et al., 2010). Moreover large deletions involving PKP2 have also been described 
(Cox et al., 2011; Li mura et al., 2013; Alcalde et al., 2014; see section 1.7.2). 
Desmoglein-2_DSG2 (18q12.1) is a desmosomal cadherin belonging to the 
cadherin superfamily, which is involved in Calcium dependent cell-cell adhesion. 
In the desmosomes, there are four isoforms of desmogleins (DSG 1–4), showing 
tissue specific expression patterns (Green and Simpson, 2007). DSG2 is expressed 
in all tissues bearing desmosomes but is the only isoform expressed in cardiac 
tissue (Schäfer et al., 1994; Nuber et al., 1995). DSG2 has an intracellular anchor 
domain interacting with DSP, a transmembrane domain, four extracellular 
cadherin domains each one with a binding site to calcium that stabilizes structure 
and function of cadherins and a small signal and a preprotein domain.  
DSG2 was linked for the first time to AC in 2006 with the detection of 9 
pathogenic variants in a small Italian cohort (Pilichou et al., 2006). The majority 
of these variants co-segregating in 8 AC families were missense, located on highly 
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conserved amino acids spread in different domains of DSG2. In this gene was 
described for the first time associated with AC a patient with compound 
heterozygosity (Pilichou et al., 2006). Soon after another study confirmed DSG2 
association with AC by detecting 4 more variants in AC probands (Awad et al., 
2006). 
More than 50 DSG2 variants have been detected in 2 to 20% of AC patients 
(Pilichou et al., 2006; Fressart et al., 2010; Xu et al., 2010; Cox et al. 2011). 
Desmocollin-2_DSC-2 (18q12.1) is a glycoprotein, like DSG2, which belongs the 
cadherin superfamily mediating Calcium dependent cell-cell adhesion. Of the 
three desmocollin isoforms (DSC 1, 2,3), DSC2 is ubiquitously expressed in 
tissues bearing desmosomes and it is the only isoform present in cardiac tissue 
(Green and Simpson, 2007). DSC2 is composed of a signal domain, a preprotein 
domain followed by four highly conserved extracellular subdomains and an 
extracellular anchor domain at the N-terminus.  
In 2006 Syrris and colleagues described the presence of heterozygous frameshift 
variants in DSC2 in 4 affected AC probands not carrying variants in DSP, JUP, 
PKP2 or DSG2 (Syrris et al., 2006). In the same year, a second study involving 88 
probands, identified in 1 AC patient a single heterozygous variant affecting an 
acceptor-splicing site in intron 5 (c.613-2A>G) of the DSC2, that resulted in 
skipping of the first 25 bp of exon 6 leading to a truncated protein (Heuser et al., 
2006). Next 2 heterozygous missense variants in DSC2 were found also in two 
Italian AC patients, resulting in the substitution of amino acids with different 
physicochemical properties and aberrant localization of the protein (Beffagna et 
al., 2007).  
Less than 50 DSC2 nucleotide variants have been reported in about 1 to 3% of AC 
cases (Syrris et al., 2006; Heuser et al., 2006, Fressart et al., 2010, Xu et al., 2010, 
Cox et al., 2011). 
Plakoglobin_JUP (17q21.2), also called γ-catenin, is the major cytoplasmic 
protein of desmosomes which  belongs to the armadillo proteins. It is present both 
in adherens junction and desmosomes, where it binds to the cytoplasmic domain 
of cadherins acting as a linker molecule between the inner and outer parts of the 
desmosomal plaque. JUP is formed by an N-terminal, a central containing highly 
conserved armadillo repeats and a C-terminal domain. 
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JUP was linked only recently to the dominant AC form followed by the 
description of a in frame insertion of a serine residue (p.S39_K40insS) in the N-
terminus of the protein in a small German family (Asimaki et al., 2007).  
Less than 20 JUP variants has been detected in approximately 1% of AC cases 
(Asimaki et al., 2007; Fressart et al., 2010; Xu et al., 2010; Cox et al., 2011). 
 
1.5.3 Extra desmosomal genes and proteins 
Although half of AC probands harbor a mutation in desmosomal encoding genes, 
approximately 1% of these patients carry mutations in non desmosomal genes 
(Alcalde et al., 2014). 
Ryanodine Receptor_Ryr2 (1q43) is the only ryanodine receptor isoform present 
in the heart. Ryr2 is a homotetramer with a molecular weight of 565 kDa, that 
crosses the membrane of the sarcoplasmic reticulum and it is involved in the 
excitation-contraction coupling of the cardiomyocytes, as it induces the calcium 
release from the sarcoplasmic reticulum into the cytoplasm. 
The cardiac ryanodine receptor has been linked to AC2 after the identification of 
six missense variants affecting highly conserved residues in families showing a 
dominant form of AC with effort-induced polymorphic tachycardias (Rampazzo et 
al. 1995; Tiso et al. 2001). The variants identified were supposed to increase the 
phosphorylation of the protein, with the consequent increase of the cytoplasmatic 
calcium. 
Myocardial structural changes were once thought to result from altered 
intracellular calcium levels but the clinical phenotype is now recognized to be that 
of cathecholaminergic polymorphic ventricular tachycardia (CPVT) rather than 
AC, and is now considered a disease phenocopy (Laitinen et al., 2001; Priori et 
al., 2001). 
Transforming Growth Factor-β3_TGFβ3 (14q24.3). In 2005, 2 nucleotide 
variants (c.-36G>A and c.1723C>T) were identified in the AC1 locus 14q23-q24, 
specifically in the 5’ and 3’ untranslated regions of TGFβ3 gene (Beffagna et al. 
2005). 
TGFβ3 is a multifunctional cytokine that belongs to the transforming growth 
factor superfamily, involved in the regulation of fibrosis, proliferation and cell 
adhesion. In vitro expression assays showed two-fold increase of the expression 
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level of mutated gene when compared to wild-type. Thus, mutations in TGFβ3 
were thought to induce myocardial fibrosis, the hallmark AC feature, by 
stimulating the proliferation of mesenchymal cells and the production of 
extracellular-matrix components.  
Although TGFβ3 is known to induce fibrosis, there is no evidence of TGFβ3 
genetic variants causality in AC and no documented upregulation of TGFβ3 in 
vivo, therefore the effect of TGFβ3 variants in AC is still controversial. 
Transmembrane Protein 43 _TMEM43 (3p25.1) was identified within the 2.36 
Mb critical region of AC5 (3p25.1), through haplotype comparison of 15 
clinically affected individuals with autosomal dominant AC from the island of 
Newfoundland in Canada (Merner et al. 2008).  
TMEM43 encodes for a 400 amino acids protein containing a response element for 
PPARγ (an adipogenic transcription factor), which may explain the fibrofatty 
replacement of the myocardium, a characteristic pathological finding in AC. The 
gene product of TMEM43 has been demonstrated to be the protein previously 
known as LUMA, which is a binding partner of emerin and the lamins, associated 
with Emery-Dreifuss muscular dystrophy (Liang et al., 2011). 
Up-to-date the founder effect of one pathogenic variant in TMEM43 (p.S358L) 
was observed in a fully penetrant and lethal form of AC and more recently, 3 
additional variants were described in AC probands from UK without other 
causative variants in desmosomal encoding genes (Haywood et al., 2012).  
Desmin_DES (2q35) is the main intermediate filament in heart muscle cells. The 
protein structure of DES is similar for all intermediate filaments composed by a 
central a-helical rod domain which is flanked by a globular head and a tail 
domain.  
Mutations in DES have been described to underlie a heterogeneous spectrum of 
clinical-overlap syndromes (desminopathies) rather than typical AC (Basso et al., 
2009).  
The first DES mutation (p.R454W) demonstrated to affect the localization of DSP 
and PKP2 at the intercalated disk was identified in a family showing an early 
onset of conduction system disorder without mutations in other desmosomal 
genes. This evidence suggested a link between desmosomal and desmin-
associated cardiomyopathies (Otten et al., 2010). Up to date 10 pathogenic 
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missense mutation have been associated to myopathy disorders with AC 
phenotype.  
Titin_TTN (2q31.2), is a giant myofilament protein composed by 38.138 amino 
acids, essential to maintain structural integrity of the sarcomere. TTN was 
considered a good candidate gene because of the proximity to the locus 2q32.1-
q32.3 (AC4) and its connection with the transitional junctions at the intercalated 
disk.  
Eight unique missense TTN variants were identified in 7 families with AC-like 
phenotype and without desmosomal genes mutations, including a prominent 
p.T2896I variant which showed complete cosegregation in one large family 
(Taylor et al., 2011). 
Lamin A/C_ LMNA (1q22) are intermediate filament-type proteins, the main 
building blocks of the nuclear lamina, that creates a meshwork underlying the 
inner nuclear membrane, and the nuclear interior. 
In 2012 it was reported that mutations in LMNA gene mimic AC phenotype. 
Genetic screening of 186 UK patients with borderline or definite diagnosis of AC 
identified 4 nucleotide variants in 4 (4%) analyzed index cases in the absence of 
other desmosomal gene mutations. ECG findings of these patients showed severe 
structural and conduction abnormalities whereas 2 of them exhibited fibrofatty 
replacement at the endomyocardial biopsy (Quarta et al., 2012).  
Phospholamban_PLN (6q22.1) is a protein involved in calcium homeostasis in 
the sarcoplasmic reticulum of the cardiac muscle cell. Dephosphorylated PLN 
interacts with the SERCA pump inhibiting the Calcium pump activity.  
The founder p.R14del mutation in the PLN was identified in 15% of Dutch 
patients with DCM and in 12% with AC negative for other desmosomal gene 
mutations (van der Zwaag et al., 2012). AC mutation carriers showed typical 
clinical features with RV and LV involvement and consegregation of the mutation 
in a large AC family. 
α-T-catenin_CTNNA3 (10q21.3) is a cytoplasmic molecule necessary for 
dynamic maintenance of tissue morphogenesis, which is involved in cell-cell 
adhesion of contractile cardiomyocytes by binding PKPs and by contributing to 
the formation of the area composit,.  
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CTNNA3, located on 10q21.3, was only recently linked to AC13 by analyzing 76 
AC negative Italian probands for mutations desmosomal-related genes. Up to date 
only 2 variants has been identified, a missense mutation (p.V94D) and an in-frame 
3-bp deletion (p.L765del) , both located in important domains of CTNNA3 
affecting the interaction between the mutant protein and β-catenin (van Hengel et 
al., 2012). 
 
1.6 Mecchanisms in Arrhythmogenic Cardiomyopathy pathogenesis 
Several theories have been advocated in the pathogenesis of AC: dysontogenic, 
degenerative, inflammatory, transdifferentiation, as causative or  secondary 
factors for the trigger and progression of the disease. 
The dysontogenic theory considered AC as a milder form of Uhl’s anomaly, 
which is a congenital heart defect charactherized by hypoplasia of the RV 
myocardium at birth (Dokuparti et al., 2005); at the contrary, in AC has been 
demonstrated that myocyte loss occurs progressively starting from childhood 
(Daliento et al.,1995). 
The degenerative theory which was postulated in 1996, considered AC as a 
consequence of myocyte death, either by necrosis or apoptosis, due to inherited 
ultra-structural defects (Mallat et al., 1996; Valente et al., 1998). Experimental 
data have shown that the key initiating phenomenon in the cascade of events that 
lead to fibrofatty replacement of the normal myocardium is myocyte necrosis 
(Pilichou et al., 2009; Rizzo et al., 2012).  
In the inflammatory theory the disease is considered the result of preceding 
myocarditis, since myocardial inflammation is a common feature in hearts with 
AC (Bowles et al., 2002; Thiene et al., 1991). More recent studies considered that 
viral myocarditis overlay on an already affected heart accelerating the disease 
progression, rather than being involved as a primary factor in the etiology of the 
disease (Calabrese et al., 2006). 
The transdifferentiation theory suggests that cardiac myocytes undergo a 
metamorphosis and switch to the fate of adipocytes (D’Amati et al., 2000). Even 
though this theory seems questionable due to the limited dedifferentiation 
capabilities of adult cardiomyocytes, recent studies supported the idea that 
adipocytes in AC derive from progenitor cells of the second heart field, which 
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give rise to the bulbus cordis and the pulmonary infundibulum (Lombardi et al., 
2009). According to this hypothesis, the progenitor cells of the second heart field 
switch into adipocytes because of suppressed Wnt/β -catenin signaling as a result 
of the JUP translocation to the nucleus (Garcia-Gras et al., 2006). This pathway is 
known to regulate adipogenesis, fibrogenesis and apoptosis, however 
contradictory results are coming from experimental studies regarding the activated 
of this pathway (Li J et al., 2011; Li D et al., 2011; Lombardi et al., 2011). 
Most recently, desmosome disruption in AC was linked to activation of 
Hippo/Yes-associated protein (YAP) pathway. The activation or inhibition of this 
pathway regulates cardiomyocyte proliferation and thus heart size (Chen SN et al., 
2014), suggesting that molecular changes at the intercalated discs in AC patients 
modulate the cros talk between Wnt/β-catenin and Hippo/YAP pathway. 
 
However the role of desmosomal gene mutations in the pathophysiology of 
myocardial injury remains elusive (Basso et al., 2011). Pathogenic variants 
located in the major components of cardiac desmosomes (DSP, DSG2, DSC2, 
PKP2, JUP) may influence desmosome composition and function, organization of 
junction assemblies at the intercalated disc level, or alter in the Wnt/β-catenin 
signalling pathway: 
- The pathogenic effects of desmosomal genes variants may result in the 
incorporation of abnormal protein affecting the correct assembly and function of 
desmosomes (dominant negative effect), or in a insufficient incorporation of a 
normal protein in the desmosomal structure (haploinsufficiency), or in the loss of 
essential protein-protein interactions. Pathogenic variants in the desmosomal 
components may cause the disruption of these structures resulting in the reduction 
of the mechanical contacts between cells. The impairment of the desmosomal 
organization would lead to loss of myocyte adhesion, and a subsequent cell death, 
that could be enhanced by physical activity (Delmar and Mc Kenna, 2010). As the 
cardiac myocytes have a limited regenerative capacity cell death may activate a 
repair mechanism implying replacement by fibrous and adipose tissue. 
Another possible effect of abnormal desmosomal components may result in the 
structural re-organisation of the cardiac junctions known as area composita, which 
comprise both desmosome and gap junction components (Franke et al., 2006). 
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The remodeling of gap junction assembly (Patel et al., 2014; Asimaki et al., 2014; 
Kleber et al., 2014) may lead to impair localization of the gap junctional protein 
connexin 43, resulting in heterogeneous conduction of the electric impulse and an 
increased propensity for arrhythmias. 
- Desmosome components involved in cell-cell adhesion, such as JUP, are also 
mediators in intercellular signaling. Desmosome dysfunction leads to the 
translocalization of JUP from the desmosome to the nucleus, where it suppresses 
the canonical Wnt/β-catenin signaling pathway (Garcia-Gras et al., 2006). This 
would cause increased expression of transcriptional regulators of adipogenesis, 
that have been suggested to mediate the differentiation of second heart field 
cardiac stem cells into adipocytes (Garcia-Gras et al., 2006; Lombardi et al. 
2009). 
 
1.7 Genetic Screening in AC 
1.7.1 Conventional mutation analysis techniques 
Since the 70s direct sequencing developed by Sanger (Sanger et al., 1977) has 
been the method of choice for DNA sequencing. Sanger sequencing is based on 
the amplification of specific DNA regions. Despite the technique underwent 
several modifications and improvements including its partial automation, it 
remains relatively time-consuming and expensive to keep pace with the growing 
need of sequencing larger DNA portions. 
In genetically heterogeneous diseases, the cost and effort of DNA sequencing is 
often considerable and numerous DNA pre-analytic techniques have been 
developed for the detection of point mutations and small deletions. Pre-analytic 
techniques, such as denaturing gradient gel electrophoresis (DGGE), single-strand 
conformation polymorphism (SSCP), chemical cleavage method (CCM), 
denaturing high performance liquid chromatography (DHPLC), all followed by 
direct sequencing of aberrant conformers or elution profiles allowed to minimize 
sequencing to a subset of abnormal PCR products. 
DGGE is a technique developed by Fischer and Lerman (Fischer and Lerman, 
1983) that can identify homoduplex molecules that differ by single bp 
substitutions. In DGGE, double-stranded (ds) DNA is electrophoresed through a 
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gradient of increasing concentration of a denaturing agent (urea or formamide) or 
of increasing temperature. In this electrophoresis gradient, DNA domains 
dissociate according to their melting temperature, resulting in decreased 
electrophoretic mobility. Mutant DNAs denature at a different isoelectric point 
and thus are distinguished from normals. DGGE however appears not suitable for 
the detection of somatic mutations where few mutants allele compete with an 
excess of normal alleles (Nollau et al., 1997).  
SSCP analysis is based on the differential electrophoretic mobility of single-strand 
DNA molecules that differ by a single base (Sidransky et al., 1997). Thermally 
denatured DNA is electrophoresed, and those single stranded DNA fragments that 
take up an altered conformation show up as aberrantly migrating bands on the 
electrophoretic gel. It is relatively simple, quick and cheap. However, for optimal 
results, fragment size should be in the range of 150 to 200 bp (Sheffield et al., 
1993) and SSCP analysis becomes increasingly inefficient at detecting mutations 
with the increasing size of the PCR product. 
In CCM PCR heteroduplexes are incubated with two mismatch-specific reagents: 
Hydroxylamine modifies unpaired cytosine and potassium permanganate modifies 
unpaired thymine. The samples are then incubated with piperidine, which cleaves 
the DNA backbone at the site of the modified mismatched base. Cleavage 
products are separated by electrophoresis, revealing the identity and location of 
the mutation. Compared with other mutation-detection techniques (such as SSCP, 
DGGE) that detect mutations in short DNA fragments and require highly specific 
melting temperatures, CCM has a higher diagnostic sensitivity, and can analyze 
amplicons < or = 2 kb in length (Tabone et al., 2006), although it is technically 
challenging. 
DHPLC technique is based on the detection of heteroduplexes containing a 
mutation or polymorphism by reduced column retention of heteroduplexes 
compared to the respective homoduplexes under partially denaturing conditions 
(Oefner and Underhill, 1995). DHPLC, under optimized conditions, is cost-
effective, highly accurate, rapid, and efficient for mutation detection. A 
disadvantage of DHPLC is the requirement and maintenance of a specialized and 
expensive equipment and optimization of each reaction required achieving the 
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highest sensitivity for mutation detection, moreover it can also be difficult to 
identify homozygotes unless the sample is spiked with a known control. 
For many years the use of techniques such as SSCP or DHPLC analysis together 
with Sanger sequencing was an absolute necessity, due to the lack of affordable 
and high-throughput methods, until the field of genetic screening was changed in 
2008 by the launch of the Next Generation Sequencing (NGS) technology. 
 
1.7.2 Copy number variants 
Copy number variants (CNVs) including deletions, duplications, and other 
complex genomic rearrangements that lead to a change in the number of copies of 
a specific chromosomal region, represent a major source of genetic variability in 
human DNA (Beckmann et al., 2007). CNVs may be benign polymorphic variants 
(Copy Number Polymorphism) or pathogenic variants underlying a wide range of 
disorders (Mendelian or complex diseases) by various molecular mechanisms 
such as gene dosage, gene disruption, gene fusion, position effects (Zhang et al., 
2009). The extent to which copy number variants contribute to human disease is 
still unknown. 
The techniques commonly used for the detection of point mutations, such as direct 
sequencing and DHPLC, usually fail to find CNVs. Different molecular assays 
have been developed to detect CNVs such as, Southern blot, quantitative PCR 
assays (qPCR), Fluorescence in-situ hybridization (FISH), array comparative 
genomic hybridization (CGH-array), single nucleotide polymorphism genotyping 
platforms (microarray analysis), Ligation-dependent Probe Amplification 
(MLPA). 
Traditionally, Southern blots have been used to determine gene copy number 
(Southern et al., 1975). Southern blotting is a powerful method for typing 
structural rearrangements. The principle of the technique relies upon 
fragmentation of DNA with a restriction endonuclease enzyme, followed by gel 
electrophoresis and transfer to a nylon membrane (blotting) (Mellars et al., 2011). 
However, this techniques requires a significant quantity of gDNA, it is laborious 
and time consuming. 
31 
 
Quantitative PCR (qPCR) is a high throughput technique for determining gene 
copy number, it is based on the measurement of PCR amplicon accumulation in 
real time. Amplicon accumulation is measured by fluorescent based chemistry, 
which primarily consists of either DNA intercalating dyes such as SYBR green. In 
qPCR the target DNA is amplified in a quantitative reaction for around 90 min, 
without requiring digesting, blotting or overnight steps. 
FISH is a technique typically used to identify chromosomal abnormalities from 
metaphase or interphase spreads using fluorescent probes. The strength of FISH 
lies in the direct visualization of DNA copy number at the single cell level 
(Cantsilieris et al., 2013), however because of its low resolution (about 5-10 Mbp 
for FISH) short CNVs are still difficult to detect (Duan et al., 2013). 
CGH-array is a technique based on dual hybridization of test and reference DNA 
to either short or long oligonucleotides immobilized on a glass slide (Carter et al., 
2007). The signal ratio between test and reference sample is normalized and used 
to infer copy number. Although this technique allows the determination of 
breakpoints, the resolution of CGH-array, around 1-25 kb with 1 million probes 
for CGH-array (Yoon et al., 2009), still makes difficult the detection of short 
CNVs (Duan et al., 2013). 
SNP microarrays are also hybridization based and have the advantage of 
analyzing both single nucleotide differences and in some cases non-polymorphic 
copy number probes that are not restricted by sequence properties of SNPs 
(McCarroll et al., 2008). The main strength of microarray platforms is the ability 
to screen CNVs on a genome-wide level at relatively low cost in large data sets, 
however there are several limitations: the ability of microarray platforms to 
resolve breakpoints and detect small rearrangements is generally poor, and is 
dependent on probe location and spacing, moreover structural rearrangements that 
do not affect copy number (such as inversions and translocations) are not detected 
(Cantsilieris et al., 2013).  
MLPA is a versatile semi-quantitative method used to determine the relative copy 
number of several nucleic acid sequences in a single multiplex PCR-based 
reaction (Schouten et al., 2002), from relatively low amounts of gDNA. The 
technique relies upon hybridization and ligation of two adjacent oligonucleotides 
to a specific gDNA sequence. The strengths of MLPA lie in the number of loci 
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that can be analyzed in a single reaction, the specificity of the ligation step, the 
reliability and accuracy of CNVs measurement, and the relative low cost for 
conducting large scale association studies. Moreover MLPA, compared to FISH 
and Southern blot analysis, targets short (50-70 nt) fragments allowing also the 
identification of single gene/exon aberrations and it is a low cost and 
straightforward technique compared to CGH-array (Figure 1.3). However it does 
not allow the exact determination of the breakpoints. 
 
 
Figure 1.3: MLPA in comparison to other techniques. MLPA can detect a wide range of genomic 
alterations, from single point mutations to large chromosomal deletions/duplications (from MRC 
Holland). 
 
Recently CNVs have been associated to different cardiomyopathies (Koopmann et 
al., 2006; Bisgaard et al. 2006; Gupta et al., 2010) including AC (Cox et al., 2011, 
Roberts et al., 2013; Li Mura et al., 2013). In the first study, MLPA revealed 3 
PKP2 exon deletions in 3 of the 149 AC cases: rispectivly the deletion of exon 8, 
the deletion of a region including exon 1 and 4 and the deletion of the entire 
coding region of PKP2 gene (Cox et al., 2011). The frequency of CNVs in this 
study was about 2%, comparable to DSG2 or DSC2 mutations in the Dutch 
cohort. Later, Roberts and colleagues described large deletions involving PKP2 in 
2 AC cases identified both by microarray and MLPA analysis. The PKP2 deletion 
including exons 2-14 was identified in one index case and his son, while the other 
AC patient carried a large de novo 7.9 Mb deletion on chromosome 12p12-1p11, 
which comprise the entire PKP2 gene (Roberts et al., 2013). More recently, 
another 122.5 kb deletion in the chromosomal region 12p11.21 encompassing 
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PKP2 was identified in an Italian AC patient and his relatives by SNP-array and 
qPCR analysis (Li Mura et al., 2013). Hence, CNVs screening is now strongly 
recommended when conventional sequencing does not identify pathogenic 
variants in AC-related genes (Alcalde et al., 2014). 
 
1.7.3 Next-generation sequencing (NGS) 
Since the conclusion of the Human Genome Project in 2000, based on Sanger 
technology, which required about 13 years (Lander et al. 2001; Venter et al. 2001) 
and 70 million dollars (Metzker et al., 2010), deep sequencing technologies were 
developed to sequence in short range of time whole genomes and exomes. NGS, 
also known as ‘deep sequencing’ and ‘high-throughput sequencing’, employ new 
sequencing apparatuses able to produce millions of small DNA sequences (reads) 
in a single run. 
In the last years NGS ability to increase throughput and to decrease sequencing 
costs shifted the interest from the research of variants in specific DNA regions to 
the identification of variants from a genome-wide sequencing data. This has led to 
advances in diagnostics and scientific research with the detection of variants 
linked to Mendelian and complex diseases (Sobreira et al., 2010; Rabbnai et al., 
2012; Yang et al., 2013; Krawitz et al., 2014; Nijman et al., 2014). NGS has been 
successfully applied for instance to the identification of genetic defects of a 
variety of disorders such as cancer (Mwenifumbo et al., 2013, Kougioumtzi et 
al.,2014), neurological diseases (Della Mina et al., 2014; Zhao et al., 2013), 
intellectual disability (Iqbal et al., 2012; Tsurusaki et al., 2011), mitochondrial 
dysfunctions (Dames et al., 2013; Tang et al., 2013), cardiovascular diseases 
(Mook et al., 2013; Dorn et al., 2014). 
1.7.3.1 Applications of NGS 
NGS has the potential to focus on the analysis of entire genomes (Whole Genome 
Sequencing-WGS), on the sole coding part of the genome (Whole Exome 
Sequencing, WES) or on specific target genes (Targeted Resequencing). NGS 
technologies may also be employed for the detection of DNA methylation sites 
(Methylation Sequencing, Methyl-seq), for DNA-protein interactions studies 
(Chromatin Immunoprecipitation Sequencing, ChIp-seq), for transcription factor 
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profiling and gene expression quantification studies (RNA-seq), ribosomal 
Sequencing (Ribo-seq), small RNA profiling including microRNAs and promoter-
associated RNAs (sRNA-Seq), thus making possible epigenetic and transcriptome 
analysis. 
Whole Genome Sequencing (WGS) 
With the availability of NGS technologies, WGS experienced a remarkable 
growth in the last few years.  WGS was first applied to bacterial genomes using 
454 technology (Smith et al., 2007) and since then, a large number of different 
genomes have been sequenced. As of January 2014, for instance, the number of 
genome sequencing projects in the Genome Online Database reached 37.540 
(Pagani et al., 2012). In addition to the sequencing of the genomes of different 
organisms, such as animals (Yang et al., 2014; Zhou et al., 2014; Schroyen et al., 
2014), plants (Cao et al., 2011; Matsumoto et al., 2008; Baev et al., 2014; Pacurar 
et al., 2014), bacteria (Fournier et al., 2014; Pylro et al., 2014; Mathers et al., 
2015; Wang et al., 2015) and viruses (Ericsen et al., 2014; Lwande et al., 2014; 
Marcacci et al., 2014), projects to characterize the DNA sequence of individuals 
have gathered pace, and WGS of humans is becoming commonplace (Gonzaga-
Jauregui et al., 2012). Several groups are studying human genomic variation by 
sequencing or genotyping large number of individuals, including multi-institute 
consortia projects such as the 1000 Genomes Project (1000 Genomes Project 
Consortium, 2010), the 10K project (Genome 10K Community of Scientists, 
2009),  the Personal Genome Project (Ball et al,. 2012), the HapMap project 
(International HapMap Consortium, 2003).  
Whole Exome Sequencing (WES)  
Whole exome sequencing (WES) study design can provide a new strategy to 
explore the aetiological roles of rare variants in complex diseases. At first WES 
has been successfully applied to the research setting for the elucidation of 
candidate genes and causal variants in individuals and families with different 
genetic disorders. In 2009, Ng and coll. successfully identified by WES one 
missense mutation in the Myosin Heavy Chain 3 gene (MYH3) among 4 unrelated 
affected individuals with the rare autosomal dominant Freeman-Sheldon 
syndrome (Ng et al., 2009). Since this initial study, a growing number of reports 
have described the successful application of WES in identifying causative variants 
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in disorders with recessive and dominant inheritance patterns as well as in 
disorders caused by de novo variants (Choi et al., 2009; Ng et al., 2010; Vissers  et 
al., 2010; Vilariño-Güell  et al., 2010; Girard et al., 2011; Choquet et al., 2015; 
Schottmann et al., 2015; Menezes et al., 2015). These achievements have led to 
increasing interest in the application of WES in the clinical practice. Among the 
advantages of WES, the selective sequencing of the coding sequence of the human 
genome is less expensive in comparison to WGS since the exome represents only 
about 1% of the genome. In the clinical setting, WES can enable a new approach 
to diagnose patients with an unclear clinical diagnosis and allow the study of the 
entire exome than a relatively small subset of genes traditionally associated with 
the patient's condition. Moreover, genotyping or resequencing the entire exome in 
patients who are negative from classical screening of disease-related genes subset 
enables the research in genes and nucleotide variants not yet associated to the 
disease, together with the possibility of storing NGS data for potential future 
studies. 
However, while attractive, the introduction of WES for clinical laboratories 
remains challenging, especially because of the laborious and accurate process of 
bioinformatics analysis and data interpretation that are required to identify 
candidate genes and causal variants. 
Targeted Resequencing (TR) 
The success of NGS in research resulted in its adoption in clinical care. Although 
WGS and WES are the most comprehensive strategies for genetic analysis, in the 
clinical setting, are still unaffordable. In comparison, TR can reach higher 
coverage of exonic regions of interest while reducing the sequencing cost and 
time. These rapid, accurate, and relatively low cost method allows a high-
throughput, genotype-based approach to molecular diagnosis, infact TR may 
rapidly screen at once large panels of genes associated with a particular phenotype 
or may provide differential diagnosis in diseases that present with atypical 
manifestations, or for which not all genetic variants are known. 
The transfer of NGS from research to diagnostic laboratories already allowed the 
development, validation and implementation of TR Gene Panel assays for the 
NGS-based genetic testing and diagnosis of patients with different disorders 
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(Jones et al., 2013; Blue et al., 2014; Verma et al., 2014; Glod et al., 2014; 
Morgan et al., 2014; Ankala et al., 2014; Sikkema-Raddatz et al., 2013). 
Chromatin Immunoprecipitation Sequencing (ChIp-seq) 
NGS technologies offer the potential to substantially accelerate also epigenomic 
research, including analysis of post-translational modifications of histones, of the 
interaction between transcription factors and their direct targets, of nucleosome 
positioning on a genome-wide scale and of the characterization of DNA 
methylation patterns (Bormann et al., 2010; Fouse et al., 2010; Bhaijee et al., 
2011). Using ChIP-Seq technology, post-translational modifications of histones 
and the location of transcription factors can be studied at the whole-genome level 
(Neff and Armstrong, 2009). Originally ChIP-enriched sequences were analyzed 
using array technology. However limited array content required the selection of 
the sequences to analyze, generally genes promoter and CG-rich regions were 
selected. ChIP-seq technique gains two main advantages from the NGS approach, 
firstly, it is not limited by the microarray content, so that all sequences bound are 
identified, and secondly, it does not depend on the efficiency of probe 
hybridization. Many ChIP-seq studies have been performed, such as the ENCODE 
(Consortium, 2004) and FANTOM5 (Andersson et al., 2004) projects, that 
revealled genome wide profiles and binding sites for a range of DNA binding 
proteins. 
Transcription factor profiling 
The development of NGS technologies has provided a unique opportunity to study 
transcriptional regulatory networks. Transcription factors are essential elements 
that regulate the transcription and the spatio-temporal expression of genes, thereby 
ensuring the accurate development and functioning of an organism. Earlier, the 
quantification of the production of nascent RNAs was achieved by bromo-
uridinating nuclear run-on RNA molecules followed by sequencing (Core et al., 
2008) or by immunoprecipitation of RNA polymerase followed by sequencing of 
the bound RNA fragments (Churchman and Weissman, 2001).  
The use of NGS for transcription factor profiling have greatly advanced the 
understanding of gene regulation and revealed additional mechanisms in the 
regulation of gene expression (Sharma et al., 2013; Driessen et al., 2013), and 
large international consortia (Adams et al., 2012; ENCODE, 2012) and numerous 
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laboratories are generating and releasing such genome-wide datasets into the 
public domain.  
Methylation Sequencing (Methyl-seq) 
NGS has also enabled the mapping of epigenetic marks such as DNA methylation 
and histone modification patterns in a genome-wide manner. Methylation of 
cytosine residues in DNA is the most studied epigenetic marker and is known to 
silence parts of the genome by inducing chromatin condensation (Newell-Price et 
al., 2000).  
Precise genome wide mapping of methylation patterns has been made possible by 
various NGS techniques, including methylated DNA immunoprecipitation (Taiwo 
et al., 2012), MethylC-seq (Lister et al., 2009) and reduced representation bisulfite 
sequencing (Meissner et al, 2005). With respect to the technologies used to isolate 
the methylated sequences, i.e. methylated DNA immunoprecipitationsequencing 
and methylated CpG island recovery assay, NGS-analysis clearly reveals all 
sequences enriched. Many NGS methylation studies have been presented among 
which those of the ENCODE consortium (Consortium, 2004). 
RNA-sequencing (RNA-seq) 
Beyond DNA sequencing and epigenetic analyses, NGS has also enabled the 
global mapping of the transcriptome by RNA-sequencing (RNA-seq). High-
throughput methods have facilitated the detection and quantification of transcripts 
and discovery of novel isoforms. Significant interest also lies in uncovering the 
role of various regulatory factors in controlling the expression of genes, such as 
transcription factors and non-coding RNAs. 
Microarray technologies provided the first practical technique for measuring 
genome-wide transcript levels. However, microarrays were only applicable to 
studying known genes and had significant problems with cross-hybridization and 
high noise levels (Wang et al., 2009). Much more accurate measurement of 
mRNA levels became possible with the introduction of RNA-seq, which was 
developed in both yeast (Nagalakshmi et al., 2008) and mammalian cells (Cloonan 
et al., 2008). This method uses the high-throughput sequencing of cDNA 
fragments generated from a RNA library. It allows precise quantification of 
transcripts and exons, moreover it is a great tool for identifying novel genes and 
RNAs. 
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The ability to detect and accurately quantify transcript levels using NGS 
technologies has significant impacts for research and clinic (McManus et al., 
2010; Li et al., 2014; Shin et al., 2014; Zhao et al., 2014; Liu et al., 2014). 
Ribosomal Sequencing (Ribo-seq) 
The impact of NGS technologies on Ribosomal RNA characterization has been 
noteworthy. Ribosomal Sequencing (Ribo-Seq) was first developed by Ingolia in 
2009 in order to measure the quantities of ribosome-bound fragments by freezing 
ribosomes and using the translation inhibitor cycloheximide 9 (Ingolia et al., 
2009), the mRNA is then digested and the resulting fragments are sequenced to 
reveal mRNA regions occupied by ribosomes. The quantification of ribosome-
bound regions reflects the translation efficiency. 
The successive use of NGS technologies for metatranscriptomic profiling has 
been so successful that at present scientists have access to the full set of coding 
and non-coding RNA in a community of organisms (Bomar et al., 2011; Shi et al., 
2009; Stewart et al., 2011). Sequencing of the small sub-unit rRNA genes have 
also been helpful in the determination of bacterial diversity and structure 
highlighting the microbial diversity of various ecosystems (Taib et al., 2013; 
Toma et al., 2014; Chen et al.,2014). 
Small RNA profiling (sRNA-Seq) 
NGS has also emerged as a direct profiling method for small RNA (sRNA-Seq), 
that in most eukaryotic organisms function as guides in association with specific 
proteins for regulation at the post-transcriptional or transcriptional level. 
Compared to platforms such as microarray or PCR-based assays, sRNA-Seq 
allows semi-open-ended analysis of both known and unknown sRNAs. Most 
initial sRNA-discovery studies used pyrosequencing (Margulies et al., 2005; 
Rajagopalan et al., 2006; Ruby et al., 2006). Subsequently, different NGS 
platforms with higher throughput and improved methods such as short-read 
sequencing-by-synthesis of amplified DNA colonies, that facilitate sequencing 
depth with respect to previous methods (Bentley et al., 2006), were applied for 
sRNA-Seq and resulted in the discovery of an ever-growing number of sRNA 
(Seila et al., 2008; Affymetrix ENCODE Transcriptome Project et al., 2009; Taft 
et al., 2009; Klimczak et al., 2014). 
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1.7.3.2 NGS Platforms 
The main NGS platforms available in the market at present are HiSeq and MiSeq 
sequencers product by Illumina/Solexa, San Diego, CA, USA, Ion Torrent Proton, 
Personal Genome Machine- PGM and Solid3 by Life Technologies, Carlsbad, 
CA, USA, 454 Genome Sequencer-GS FLX and GS Junior System by Roche 
Applied Science, Mannheim, Germany. Each platform employs different 
sequencing chemistries and ampliﬁcation methods, and this causes different 
strength and weakness points. The choice of a platform depends upon the 
expectations of research question, accordingly one may be concerned about the 
performance such as read lengths, data output, accuracy and cost. 
Illumina platforms  
Illumina platforms are based on bridge ampliﬁcation after library preparation and 
the use of reversible dye terminator for sequencing. 
The Genome Analyzer- GA was first introducded by Solexa in 2006 and further 
developed by Illumna, initially reads were very short (3+5-bases) in comparison 
with Sanger sequencing. Since then many technical improvements have been 
made and presently Illumina platforms can produce reads ranging from 100 to 250 
bases, but with high throughput. Read-lengths are however limited by multiple 
factors that cause signal decay and dephasing, such as incomplete cleavage of 
fluorescent labels. 
In early 2010 Illumina launched the HiSeq2000, that mantains the same 
sequencing strategy of the GA and can produce up to 200 Gb of 100-base paired-
end reads in the course of a 8 days run. 
In 2011 Illumina introduced the MiSeq, that implements the sequencing by 
synthesis technology and is similar to the HiSeq system. It is a benchtop 
sequencer, suitable for single-day experiments, that combines the processes of 
cluster generation, sequencing by synthesis, and data analysis into a single 
machine generating up to 5.1 Gb of 150-base paired-end reads per day 
(http://www.illumina.com/). 
The main error type of Illumina technology is substitution, due to the 
simultaneously addition of all the four nucleotides in the reaction mix. However, 
because of the lower cost per sequence than other platforms, interest in amplicon 
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sequencing on Illumina platforms is growing (Guilhamon et al., 2014; Manson-
Bahr et al., 2014; Igartua et al., 2015; Schirmer et al., 2015).  
Roche platforms  
Roche platforms use pyrosequencing and detect chemiluminescent signals of 
pyrophosphate release on nucleotide incorporation. They can produce read lengths 
close to Sanger (400-1000 bp), however, the price per base on the Roche 454 
platform is much higher than other NGS platforms. 
The first commercially successful NGS sequencer was the pyrosequencing 
platform developed by 454 Life Sciences in 2005, with a read length of 100–150 
bp and output reads exceededing 200,000 reads and 20 MB in a single run. The 
454 GS FLX platform launched in 2008 can generate 40 Mb of 400-base paired-
end reads in a 10-hours run. 
The benchtop sequencer 454 GS Junior released by Roche in early 2010 produces 
35 Mb of sequence data from 400 to 600-base paired-end reads in a 10-hours run 
(http://454.com/products/gs-junior-system/). 
The main disadvantage of Roche sequencers is due to the difficulty of the 
pyrosequencing technique to solve long homopolymeric regions, so the principal 
errors are base insertion or deletion in these regions during sequencing, rather than 
substitutions as in the Illumina platforms. On the other hand, thanks to the 
addition of a single dNTP each time, substitution errors are rarely encountered in 
these reads. 
Life Technologies platforms 
Life Technologies uses a similar sequencing method that detects signals of H+ 
ions release due to binding of nucleotides by semiconductor detector (Biswas et 
al., 2014). 
Ion Torrent Proton is a high-capacity sequencer that employs a semiconductor-
based technology interfaced with sequencing-by-synthesis (Rothberg et al., 2011). 
It permits 200-bp reads in 2 hours and can generate up to 10 Gb per run 
(http://www.lifetechnologies.com/). 
Its lower-capacity counterpart, the Ion PGM, released by Ion Torrent at the end of 
2010, is a bench-top sequencer that implements semiconductor sequencing 
technology without requiring fluorescence and camera scanning, resulting in 
higher speed, lower cost, and smaller instrument size. Currently, it enables up to 
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400-bp reads in 2-4 hours and can generate up sequence data form 30Mb to 1 G 
per run (http://www.lifetechnologies.com/). 
The SOLiD system, available from 2007, uses a chemistry based on the polony 
sequencing technique published in the same year as the 454 method (Shendure et 
al., 2005), with the difference that in the SOLiD method base detection of the 
DNA fragments is achieved by sequencing by ligation instead of through 
polymerase reaction. SOLiD can achieve very high-throughput, up to 320 Gb of 
sequence data in 50-base paired-end reads per an 10-day run 
(http://www3.appliedbiosystems.com/). The 2-base enconding system allows to 
determine and to correct almost all sequencing errors. However short read length 
(50 bases) and resequencing only in applications is still its major shortcoming 
(Liu et al., 2012). 
1.7.3.3 Limitations of NGS 
Despite the numerous advantages of the NGS technologies, thare are still 
technical limitations, expected to decrease in the next few years. 
Limitation in the read lengths remains among the major technical drawbacks. 
Although recent sequencers achieve up to 1000 bases, the average length ranges 
between 100 and 400 bases, and short read-lengths are known to involve more 
complicated analyses. Reads are assembled using overlapped ends to build longer 
stretches of DNA, which are attached to each other until the assembly of an entire 
chromosome. Short reads include shorter overlapping ends, which makes the 
accurate determination of the previous and subsequent reads difficult. Therefore, 
the analysis and assembly efforts required increases by several folds for short 
read-lengths in comparison to longer lengths. 
Another challenge concerns reads coverage. Reads produced by NGS do not 
completely cover the entire target region, either exome or a gene set: some 
sequences such as GC-rich sequences can be difficult to capture and some 
sequences cannot be targeted at all because of insufficient or inadequate probes. 
Moreover uneven capture efficiency across exons influences the reads depths of 
specific exons. Although the off-target hybridization value is often important 
(20%) not all sequences can be aligned with the reference sequence to allow SNP 
calling.  
42 
 
Furthermore, NGS creates lots of background noise, consisting in mainly 
sequencing errors, which can be platform-specific since technically linked to the 
sequencing chemistrie implemented in a particular sequencing platform (Coonrod 
et al., 2012). The most common error type in NGS is substitution, which 
complicates the distinction of a true single nucleotide variant. The indel 
(insertion/deletion) error is another common error type especially in the Ion 
Torrent and SOLiD platforms. Errors can also arise from mistakes during the 
library preparation and sequencing or during the alignment. For instance read 
misalignments often arise in presence of repetitive regions and pseudogenes. 
Another limitation of NGS is the difficult detection of structural variants, such as 
copy-number variants, inversions and translocations. However recent studies 
show the sucelssufull identification of CNV from NGS data (Zhao et al., 2013; 
Wang et al., 2014; Duan et al., 2014; Horpaopan et al., 2015). 
Another issue concerns the reproducibility of data, regarding data replication and 
verification. The possibility of obtaining different mutation patterns from two 
NGS experiments carried out by different groups without any overlap between the 
two sets of mutations (Agrawal et al. 2011; Stransky et al. 2011) suggests data 
reproducibility as a major limit of NGS (Faita et al., 2012; Nekrutenko et al., 
2012). 
Furthermore, one of the more evident challenges of NGS is the huge amount of 
data that require proper analysis and storing. Storage of computational data is 
becoming an expensive problem, hampered by increasing data volumes and 
frequent updates of analysis methods and tools (Lampa et al., 2013). Long term 
archiving of large amounts of data is becoming an important task, as scientists are 
reluctant to discard raw data since improved algorithms may help extract further 
information from them in the near future.  
Management, filtering and prioritization of variants and clinical interpretation of 
genetic findings require expertise. NGS data management and interpretation 
require a large extent of bioinformaticians and biologists who have learnt basic 
bioinformatics. 
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1.7.3.4 NGS and Cardiomyopathies 
NGS represents a valuable approach for the molecular analysis of genetically 
heterogeneous disorders, such as inherited cardiomyopathies, and SD-associated 
disorders. These diseases are linked to multiple causative genes, often showing 
rare and private variants segregating within small families, and whose direct 
sequencing would be laborious, time consuming and expensive. 
In the last years linkage analysis performed in large families and genome-wide 
association studies performed in diverse populations have been successful in 
detecting causal loci, genes and variants of inherited cardiomyopathies. However, 
the wide locus and allelic heterogeneity typical of cardiomyopathies requires to 
fully sequencing the whole coding region of several genes, making NGS the most 
appropriate technique for this purpose. 
Although cardiomyopathies usually present different clinical features, they exhibit 
some level of genetic and, especially in their end-stage, phenotypic overlap. For 
instance the detection of causative variants in desmosomal genes sometimes also 
occur in DCM patients in addition to ACM patients (Posch et al., 2008; Elliott et 
al., 2010; Zhang et al. 2011; Garcia-Pavia et al., 2011; Garcia-Pavia et al., 2013), 
so that variants in the same gene or gene set correspond to a wider phenotypic 
spectrum. Thus, NGS allows a differential diagnosis approach for correctly 
identifying patients with unclear clinical characteristics.  
With different NGS approaches genomic regions of interest can be targeted to 
enable clinical approach for the diagnostic purposes. Cardiomyopathy associated 
genes are sequenced by performing customized targeted sequencing on NGS 
platforms and forming a panel and presented as diagnostic tool for the 
cardiomyopathy in a clinical setup (Biswas et al., 2014). 
Different NGS approaches, such as targeted resequencing or WES have been 
successful in ﬁnding causative mutations in different cardiomyopathies.  
A study involving 223 unrelated probands with Hypertrophic cardiomyopathy, 
using targeted resequencing of 41 cardiovascular genes, reported 152 distinct 
candidate variants in sarcomeric or associated genes (89 novel) in 143 patients 
(64%), and an additional 94 candidate variants (73 novel) in desmosomal, and 
ion-channel genes in 96 patients (43%) (Lopes et al., 2013). 
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Another study described the use of NGS in order to search for de novo genetic 
variants in 2 unrelated infants presenting with recurrent cardiac arrest and 
prolonged QTc interval. The 2 parent-child trios were investigated by WES and 
follow-up candidate gene screening was performed on an independent cohort of 
82 subjects with long-QT (LQT) syndrome without mutations in LQT genes. 3 
heterozygous de novo mutations were detected in calmodulin1 (CALM1) or 
calmodulin 2 (CALM2) in the 2 probands and in 2 additional subjects with 
recurrent cardiac arrest. Additional biochemical studies were performed to 
determine the functional consequences of these mutations (Crotti et al., 2013). 
A recent study identified a novel disease-causing variant in α-actinin 2 by targeted 
resequencing 48 disease genes for HCM, which was shown to segregate with the 
cardiomyopathic trait in an Italian family with HCM. (Girolami et al., 2014), 
emphasizing the potential of NGS approach in diagnostic screening. 
1.7.3.5 NGS and AC 
The potential of NGS in the identification of causal mutations also in AC or 
overlap syndromes has been so far highlighted by different reports. 
Hedberg and coll., using WES, identified a heterozygous mutation p.P419S in 
DES gene in a Swedish family affected by autosomal dominant myofibrillar 
myopathy with Arrhythmogenic Cardiomyopathy. The mutation was then 
detected by Sanger sequencing in 17 additional affected family members 
(Hedberg et al., 2012). 
Another study describing the NGS application to extend the genetic analysis in an 
AC proband who was negative for mutations in five desmosomal genes revealed a  
heterozygous missense mutation p.T351A in LDB3. This result was confirmed by 
subsequent Sanger DNA sequencing, which also detected the mutation in other six 
relatives with a definite or borderline diagnosis of AC. This study highlights the 
usefulness of NGS to point to new causative genes in AC (Lopez-Ayala et al., 
2014). 
Moreover, the efficiency of NGS in detecting mutations in AC is emphasized in a 
very recent study. Gréen and coll. designed and validated a NGS test panel for 
parallel sequencing 10 genes in AC patients. All the samples were successfully 
sequenced and mutations found by Sanger sequencing were also found using 
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NGS, which showed a sensitivity varying from 99.3% to 100%, and a specificity 
varying from 99.9% to 100%, depending on the bioinformatics pipeline (Gréen et 
al., 2015). 
1.7.3.6 NGS and Molecular Autopsy 
The identification of the molecular basis of SD during molecular autopsy has the 
potential to highlight the causes of death and especially permit cascade screening, 
genetic conselling and clinical management of at-risk family members. NGS 
application at post mortem will enable a comprehensive analysis of all known SD-
associated genes or even the entire exome or genome from a relative small 
quantity of DNA, and in a cost-effective way. 
NGS-based molecular autopsies have already been successful in detecting genetic 
causes of SD. 
Campunzano and coll. describe the genetic analysis of 104 SD-related genes using 
a NGS custom panel for a case of sudden infant death syndrome (SIDS) after 
negative autopsy. NGS identified seven variants in 6 different genes in the index 
case, two of them were previously described as pathogenic. Familial segregation 
showed that the index case’s mother carried 5 of the 6 genetic variants, this last 
inherited from his father; the sister carried 3 of the 6 variants identified in the 
index case. This study underlines the utility of NGS to identify potentially genetic 
variants and the crucial role of familial genotyping to clarify the pathogenic role 
of unknown variants and to identify other genetic carriers at risk of SCD 
(Campuzano et al., 2014).  
Another study performed by the same group described the application of NGS to 
identify the genetic cause of SD in a juvenile cohort with no-conclusive cause of 
death after comprehensive autopsy. Twenty-nine cases were analyzed, low quality 
DNA cases were analyzed for 7 main SD- associated genes using Sanger 
technology, while good quality cases were analyzed for 55 SD-associated genes 
using NGS technology. They identified 35 pathogenic and/or potentially 
pathogenic genetic variants in 12 cases (41.37%): 10 genetic variants in genes 
encoding cardiac ion channels were identified in 8 cases (27.58%), and 25 genetic 
variants in genes encoding structural cardiac proteins in 9 cases 
(31.03%).(Campuzano et al., 2014).  
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Loporcaro and coll. describe the use of WES as an efficient and cost-effective 
approach to incorporate molecular studies into the conventional postmortem 
examination. WES and gene-specific surveillance of 90 known major cardiac 
channelopathy/cardiomyopathy genes were performed on a sudden death victim 
after inconclusive autopsy.  WES analysis revealed the p.R249Q mutation in the 
myosin heavy chain 7 gene (MYH7) previously associated with familial 
hypertrophic cardiomyopathy (HCM) and SD. Six additional family members 
were found to be at risk for HCM and were recommended to clinical follow-up, 
however no clinical signs were described. (Loporcaro et al., 2014).  
Another study describes the application of NGS to estimate the frequency of 
pathogenic variants in the genes most frequently associated with SD. Fifteen SD 
cases and 29 patients with channelopathies were analyzed for 34 SD associated 
genes. Likely pathogenic variants were identified in three out of 15 (20 %) 
forensic SD cases and in 12 out of 29 (41 %) patients with channelopathies, 
highlighting the potential of NGS to increase the diagnostic rate significantly in 
the clinical setting (Hertz et al., 2014). 
A recent study by Bagnall and coll. describes the use of WES to identify a causal 
mutation in a family with cardiac disease showing phenotype heterogeneity. This 
approach detected the p.A119T mutation in the alpha-actinin-2 (ACTN2) gene that 
segregated with disease, highlighting the value of WES in the cardiac genetic 
testing in families with mixed clinical presentations (Bagnall et al., 2014). 
Another recent study reports post-mortem WES and gene-specific analysis of 117 
SD susceptibility genes for 14 SD victims. Overall, 8 ultra-rare variants (7 
missense, 1 in-frame insertion) in 6 genes absent in 3 publically available exome 
databases were identified in 7 of 14 cases (50%). Of the 7 missense alterations, 2 
(p.T171M in Voltage-Dependent L-Type Ca2+ Channel Alpha 1 Subunit-
CACNA1C, p.I22160T in TTN) were predicted damaging by 3 independent in 
silico tools. This study emphasize the utility of WES to detect rare genetic 
variants underlying SD, and the complexity of accurate interpretation of each 
variant (Narula et al., 2014). 
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1.7.3.7 Interpretation of the clinical significance of variants in NGS 
The detection of novel genetic variants is rapidly increasing with the introduction 
of high throughput technologies into the clinical diagnostics, making challenging 
the interpretation of variants’ clinical significance. 
Although the lack of a comprehensive and collectively-accepted interpretation 
protocol, variants classification is aided by available interpretation guidelines 
(Kazazian et al., 2009), recently improved and updated (Richards et al., 2008). 
American College of Medical Genetics (ACMG) recommends a correct 
annotation and a standardized terminology to report nucleotide variants (den 
Dunnen et al., 2000) and to assess their pathogenicity carefully evaluating a string 
of parameters such as evolutionary conservation, population studies, functional in 
vitro studies, clinical presentation, family history and co-segregation. 
The availability of reliable databases collecting genetic variants and information 
on genotype-phenotype associations help to discern between benign variants and 
disease-causing variants, by reporting for instance whether a specific variant had 
been already described in another patients. A number of established public 
databases focusing on inherited diseases report information on genotype-
phenotype associations are available, such as the Human Gene Mutation Database 
(HGMD) (Stenson et al., 2013), ClinVar (http://www.ncbi.nlm.nih.gov/clinvar/) 
(Landrum et al 2014). Several web-based, gene-centered, locus-specific databases 
have also been developed, such as the Leiden Open Variation Database (LOVD) 
(Fokkema et al., 2005), that provides a flexible, freely available tool for gene-
centered collection and display of DNA variants. In particular, comprehensive 
information about all known AC-associated variants are collected and shared in 
the ARVD/C database since 2009 (van der Zwaag et al., 2009). Further, the 1000 
Genomes Project and Exome Variant Server (EVS) report million of single 
nucleotide variants (SNVs) obtained from deep sequencing of large population 
cohorts (1000 Genomes Project Consortium, 2010; Exome Variant Server, 2011), 
and also report information about the variant frequencies in the population. 
1.7.4 Assessing pathogenicity of desmosomal genetic variants 
The evaluation of the DNA variants has to be extremely accurate in AC cases 
because disease-associated genes have high background genetic variation rate. A 
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recent study demonstrated that the overall yield of mutations among AC cases was 
58% versus 16% in controls (Kapplinger et al., 2011) by proving that previous 
AC-associated pathogenic genetic variants are present in the general population. 
Specifically, missense mutations were hosted by 16% of controls versus a similar 
21% of AC cases. This poses several challenges to interpreting the AC genetic 
test, as 1 in 6 healthy individuals would meet current criteria for a so-called 
positive AC genetic test result, even with proper qualification of these rare 
“mutations” with the clinically ambiguous designation as a “variant of uncertain 
significance.” Another study provided confirmatory data by reporting that 18% 
(38 genetic variants) of previously reported AC pathogenic genetic variants were 
identified in the Exome Sequencing Project (ESP) population (1 nonsense and 37 
missense) (Andreasen et al., 2013). It is noteworthy that convincing family co-
segregation was reported in only 1 of these 38 pathogenic genetic variants and 3 
variants had also functional characterization showing significant differences 
between mutant and wild-type transfected cells. Thus far, 190 pathogenic 
missense genetic variants have been associated with AC, all reported in Human 
Gene Mutation Database (HGMD) and distributed as follows: distributed as 
follows: 56 in DSP ,49 in DSG2 ,48 in PKP2, and 24 in DSC2. From all reported 
missense pathogenic genetic variants associated with AC, only 62 % predicted to 
be deleterious by in silico platforms, using PROVEAN (Protein Variation Effect 
Analyzer) (http://provean.jcvi.org/ index.php). Moreover, 57 % are predicted to be 
deleterious using Condel (CONsensus DELeteriousness score of non- 
synonymous single nucleotide variants) (http://bg.upf.edu/ condel/analysis), 
which integrates five different platforms (Polyphen-2, SIFT, MAPP, LogR Pfam 
E -value, and Mutation Assessor). 
On the other hand, “radical” mutations (insertions or deletions, splice junction 
mutations, and nonsense mutations) in the Kapplinger study, were significantly 
more prevalent in AC cases compared with controls (50 % vs 0.5 % respectively, 
p=9.8x10-44), indicating that the presence of this type of genetic variant has a high 
likelihood of being associated with AC pathogenicity (Kapplinger et al., 2011). 
Notably, “radical” mutations constituted the majority (75 of 102, 73.5%) of 
genetic alterations identified in mutation-positive AC cases.  
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Thus far, 155 “radical” mutations have been associated with AC, all reported in 
HGMD, and distributed as: 75 in PKP2, 52 in DSP, 16 in DSG2, and 12 in DSC2. 
Despite of being reported in the HGMD database, not all “radical” genetic 
variants denote a pathogenic role in clinical practice, especially if no family 
segregation has been reported. A recent study in Japanese population with 35 AC 
cases showed that carriers with PKP2 premature stop codon developed the disease 
at a significantly younger age than other mutations carriers (Ohno et al., 2013), 
while another more recent study performed in European population suggests later 
onset in carriers with PKP2 premature stop codon (Alcalde et al., 2014).  
Hence, the most particularly weakness to misclassification are mutations 
identified in large cohorts of individual unrelated probands (without data on 
familial segregation). For this purpose guidelines in genetics (Kazazian et al., 
2009; Richards et al., 2008), highly recommend to perform accurate in silico 
analysis, in vitro assays, and, as key point, co-segregation studies in families to 
assess the pathogenicity on AC.  
1.7.5 Assessing pathogenicity of extra desmosomal genetic variants  
In the last 4 years, extra desmosomal genes have been also associated with AC 
however all together have a lower incidence of <5% of AC patients (Alcalde et 
al., 2014). Extra desmosomal genes associated with AC are a heterogeneous group 
of genes with different functions and the underlying mechanism in AC needs still 
to be clarified. It is interesting that most of extra desmosomal genes encode 
cytoskeleton-associated proteins such as, DES, LMNA, CTNNA3, and TTN, 
previously described in other cardiomyopathies, i.e. DCM (Garcia-Pavia et al., 
2013). Therefore, recent studies support the concept of “Arrhythmogenic 
Cardiomyopathy” as an entity encompassing DCM an AC, given by the evidence 
that extra desmosomal genes are commonly associated with DCM and AC, 
whereas desmosomal genes had not yet been associated with any other 
cardiomyopathy (Saffitz et al., 2011). Contradictory studies have been published 
since then regarding the incidence of desmosomal mutations in other 
cardiomyopathies (Posch et al., 2008; Elliott et al., 2010; Zhang et al. 2011; 
Garcia-Pavia et al., 2011; Garcia-Pavia et al., 2013; Lopes et al., 2013). 
Consequently, assessing pathogenicity in extra desmosomal genes without 
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cascade family screening, clinical data and/or is in vitro assays is problematic, 
since overlapping symptoms are common among inherited cardiomyopathies.  
1.7.6 Clinical implications of genetics  
Genetic screening is gaining ground in the identification of patients and family 
members at increased risk of AC. Identification of a misclassified genetic variant 
in cardiomyopathy patients might lead to erroneous risk stratification, 
misdiagnosis of family members and this could have potentially devastating 
clinical consequences. It is therefore important that variants being reported as 
causative of cardiomyopathies are truly disease causing in order to avoid 
overrepresentation of AC-associated genetic variants. 
Genetic information in AC is helping to provide a potential cause of the 
pathology, but clinical findings still remains the main basis for diagnosis and 
treatment of patients. Thus, the identification of a potential pathogenic genetic 
variant cannot override clinical judgment regarding AC diagnosis. In addition, 
lack of pathogenic genetic variant in the setting of convincing clinical evidence 
neither should call the diagnosis into question nor rule out the disease (Kapplinger 
et al., 2011). All AC diagnosed patients or suspicious of suffering AC should be 
genetically analyzed, and for all genes associated with AC due to reported 
digenic/compound cases (Nakajima et al., 2012; Barahona-Dussault et al., 2010). 
Identification of the pathogenic genetic variant may help to clarify the cause of the 
disease, and posterior familial genetic analysis may identify genetic carriers that 
could remain asymptomatic but at risk of SD. The lack of ‘gold standard’ tool in 
clinical diagnosis makes genetic testing a complementary tool in diagnosis, even 
though lacks clear pathogenic interpretation. Determining the pathogenicity of a 
genetic variant is the main genetic challenge in current clinical practice. 
Establishing solid potential therapeutic and prognostic implications of gene 
variants associated with AC is not available due to lack of clinical-genetic 
correlations. Despite being accepted that “radical” variants should be considered 
more dangerous than missense variants due to truncation of proteins associated 
with AC (Kapplinger et al., 2011), genetic results should be interpreted with 
extreme caution and by multidisciplinary teams including at least cardiologists 
and geneticists.   
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AIM OF THE STUDY 
 
AC is a clinically and genetically heterogeneous disorder associated with 
arrhythmias and sudden death, in particular in young adults and athletes. 
Mutations in the desmosomal genes DSP, PKP2, DSG2, DSC2, JUP have been 
associated with the disease in approximately 50% of total cases. Since SCD may 
occur as the first symptom of the disease, an early genetic diagnosis is highly 
relevant for the identification of affected subjects and especially of genetically 
affected relatives before the manifestation of the clinical phenotype.  
The overall aim of the present investigation was the development of a fast, cost-
effective and comprehensive screening strategy for the molecular diagnosis of 
AC. 
Specific objectives of the present study include: 
1. Assessment of the spectrum and prevalence of desmosomal mutations in a 
large cohort of unrelated index cases,  
2. Assessment of the presence and prevalence of large genomic structural 
rearrangements (CNVs) in a large cohort of unrelated index cases, 
3. Analysis of potential disease causing mutations pathogenicity, 
4. Evaluation of mutation type role in the development of AC, 
5. Comprehensive genotype-phenotype study in order to stratify the risk of 
developing the disease in asymptomatic mutation carriers, 
6. Investigation of Next Generation Sequencing (NGS) potential and 
limitations, 
7. Application of NGS for molecular diagnosis in AC patients, extending the 
spectrum to genes not related with the disease. 
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2. METHODS 
 
2.1 Cohort and Clinical Examination 
The study involved a total of 99 subjects with a clinical or post mortem diagnosis 
of AC referred to the Referential Clinical Genetic Centre of Arrhythmic 
Cardiomyopathies in Padua.  
Twenty-six probands were sudden death victims enrolled from the Registry of 
Cardio-Cerebro-Vascular Pathology, Veneto Region, Venice, Italy. For the rest 73 
probands, Arrhythmogenic cardiomyopathy clinical diagnosis was based on 
established major and minor criteria revised by the European Society of 
Cardiology and the Federation of Cardiology Task Force (Marcus et al., 2010). 
Clinical evaluation included physical examination, 12-lead ECG, signal-averaged 
ECG, cardiac magnetic resonance imaging, 24-hour ambulatory ECG monitoring. 
Exercise tests and electrophysiological studies were performed when considered 
necessary. AC diagnosis was considered definite when 2 major, or 1 major and 2 
minor criteria, or 4 minor criteria from different categories, were fulfilled; 
borderline when 1 major and 1 minor or 3 minor criteria from different categories 
were fulfilled; possible: when 1 major or 2 minor criteria from different categories 
were fulfilled. When possible, the first-degree and second-degree relatives from 
families where a disease-causing variant was detected were called for prospective 
evaluation and genetic screening. Written informed consent was obtained from all 
study participants before blood sampling and genetic screening.  
Variants frequency, type, and localization were compared to a group of 500 
unrelated healthy ethnically matched volunteers (1000 alleles).  
 
2.2 DNA Extraction 
Genomic DNA (gDNA) isolation was obtained from different matrices including 
whole blood, frozen myocardial tissue, formalin-fixed and paraffin-embedded 
(FFPE) tissue through specific onboard protocols of MagNA Pure Compact 
System (Roche Applied Science, Mannheim, Germany), an automated benchtop 
device that uses the magnetic bead technology for nucleic acids isolation. The 
MagNA Pure Compact performs all nucleic acids isolation steps preventing cross-
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contamination between samples. It automatically pipets into the sample a pre-
aliquoted volume of lysis buffer containing chaotropic salts and proteinase K, 
nucleic acids are bound to the surface of the magnetic glass beads and after 
several washing steps the purified DNA is eluted in DNasi-free H20.  
2.2.1 DNA extraction from blood 
gDNA extraction was carried out  from 200 µl of whole blood by using Nucleic 
acid isolation kit I (Roche Diagnostics GmbH, Mannheim, Germany) on the 
MagNA Pure Compact System by setting the ``DNA_Blood_100_400`` protocol 
on the machine software. The typical DNA yield from 200 µl of human whole 
blood using the ``DNA_Blood_100_400`` protocol and an elution volume of 100 
µl is 6 µg. 
2.2.2 DNA extraction from frozen and FFPE tissue 
gDNA extraction was performed from approximately 5 mg of snap frozen tissue 
or from 2 FFPE section with 8µm thickness by using Nucleic acid isolation kit I 
(Roche Applied Science, Mannheim, Germany) with the ‘’DNA-culture Cells’’ 
protocol. Paraffin removal from FFPE tissue, commonly achieved by consecutive 
washes of xylene and ethanol, revealed to be unnecessary when using this 
protocol. An initial pre-treatment step was performed to enhance cell lysis. Briefly 
200 µl of MagNA Pure Compact DNA Lysis buffer (Roche Applied Science, 
Mannheim, Germany) was added in the tissue sample and  a 2 min disruption on a 
Tissue Lyzer System (Qiagen Venlo, Limburg, The Netherlands) was carried out 
at 25 Hz. The homogenized sample was then incubated with 20 µl of Proteinase K 
(20 mg/mL; Roche Diagnostics GmbH, Mannheim, Germany) for 10 min at 56 °C 
and transferred on the MagNA Pure Compact workstation. The typical DNA yield 
using the “DNA-culture Cells” protocol from 5 mg of snap frozen tissue and an 
elution volume of 50 µl is 14 µg, and the typical DNA yield from 2 FFPE section 
(8µm thickness) is 4 µg. 
2.2.3 DNA extraction from saliva 
The 500 µl saliva sample was mixed with 200 µl of MagNA Pure Compact DNA 
Lysis buffer and, after vigorous mixing by vortex, incubated at 56 °C for 10 min. 
The lysate was then transferred on the MagNA Pure Compact workstation and 
55 
 
extracted with the Nucleic acid isolation kit I (Roche Diagnostics GmbH, 
Mannheim, Germany) and the “DNA_blood_external_Lysis” protocol. The 
typical DNA yield from 500 µl of saliva is normally 6 µg, comparable with the 
yield from whole blood extraction. 
 
2.3 RNA Extraction 
RNA extraction was obtained from whole blood or frozen myocardial tissue, 
when available, by using the MagNA Pure Compact System. RNA was eluted in 
50 μL of RNasi free H20 and stored at -80 °C. 
2.3.1 RNA extraction from blood 
RNA was isolated from 200 µl of whole blood by using RNA isolation kit I 
(Roche Diagnostics GmbH, Mannheim, Germany) and 20 µl of DNasi (Roche 
Diagnostics GmbH, Mannheim, Germany) on the MagNA Pure Compact System 
according to the “RNA_Blood’’ protocol. The mean RNA yield from 200 µl of 
human whole blood is 1µg. 
2.3.2 RNA extraction from frozen tissue 
RNA was isolated from approximately 5 mg of snap frozen tissue on the MagNA 
Pure Compact System employing RNA isolation kit I and 20 µl of DNasi (Roche 
Diagnostics GmbH, Mannheim, Germany) following the “RNA_Cells” protocol. 
The pre-treatment step was performed as previously described after adding the 
samples with 200 µl of MagNA Pure Compact RNA Lysis buffer (Roche 
Diagnostics GmbH, Mannheim, Germany). The typical RNA yield using the 
“RNA_Cells” protocol from 5 mg of snap frozen tissue and an elution volume of 
50 µl is 15 µg. 
 
2.4 Nucleic acids Quantification 
Nucleid acid isolation is followed by a quantity and quality (purity, integrity) 
check prior before downstream preparation steps. DNA quantification allows 
standardization of the PCR input material and  is crucial in NGS DNA library 
preparation since  influence run quality and efficiency. 
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2.4.1 Spectrophotometric method 
Nucleic acids quantification is performed by spectrophotometers by measuring 
absorption of ultraviolet light at the wavelength of 260 nanometers and applying 
the Lambert-Beer law that correlates absorbance, molar extinction co-efficient and 
nucleic acids concentration. Absorbance measurements were carried on a 
Nanovue spectofotometer (GE Healthcare Life Sciences, UK) by directly 
pipetting onto the pedestals 2 µl of the DNA or RNA sample dissolved in DNasi 
or RNasi-free H20, after an initial blank measurement. Nanovue automatically 
calculates the nucleic acids concentration by applying specific extinction 
coefficients (50 for dsDNA, 40 for RNA).  
The ratio A260/280 and A260/230 are used as indicators of the sample purity. The 
A260/280 ratio of the nucleic acid sample is generally used as indicator of protein 
contamination. Infact the 280 nm is the absorbance wavelength of aromatic amino 
acid side chains and phenol groups. Pure DNA should present a ratio 260/280 
between 1.8 and 2, pure RNA should present a ratio 260/280 between 2 and 2.2. 
The A260/230 ratio is generally used as indication of organic contaminants. The 230 
nm is the absorbance wavelength of many organic compounds (i.e. phenol, 
TRIzol, and chaotropic salts present in the most common lysis buffers. In pure 
samples the ratio A260/230 should be between 2 and 2.2. 
2.4.2 Qubit Fluorometer 
The quantity and quality of DNA was further assessed by using Qubit 2.0 
Fluorometer (Invitrogen, Life technologies, Carlsbad, CA, USA) in combination 
with dsDNA BR Assay kit (Invitrogen, Life technologies, Carlsbad, CA, USA) 
for DNA measurements and RNA Assay kit (Invitrogen, Life technologies, 
Carlsbad, CA, USA) for RNA measurements according to the manufacturer’s 
instructions. Briefly, 1 µl of the sample is mixed with 200 µl of working solution 
containing specific fluorescent dyes, composed by 199 µl of dsDNA BR buffer or 
RNA buffer and 1 µl of dsDNA BR reagent or RNA reagent respectively. After an 
incubation of 2 min the measurement is performed on the Qubit 2.0 by setting the 
DNA or RNA protocol. The Qubit 2.0 is a benchtop fluorometer that uses 
fluorescent dyes that specifically bind to either DNA or RNA therefore it is able 
to selective quantify either DNA or RNA. Moreover, as the DNA dye exclusively 
57 
 
binds to double strand DNA (dsDNA), it further allows the selective 
quantification of dsDNA that will be exclusively used for downstream 
applications, minimizing the effect of contaminant RNA and ssDNA. 
2.4.3 Agilent Bioanalyzer 
The Agilent Bioanalyzer 2100 (Agilent, Santa Clara, CA, USA) is a 
microfluidics-based platform that can perform quantification and quality control 
of nucleic acids by an electrophoretic separation of samples on micro channels 
containing fluorescent dyes. One μl of DNA or RNA samples is sufficient for 
analysis on 2100 Bioanalyzer with the DNA 1000 chip (Agilent, Santa Clara, 
Carlsbad, USA) and the RNA Nano Chip (Agilent, Santa Clara, Carlsbad, USA). 
All the assays were performed according to the manufacturer’s guide. Briefly, 
DNA  and RNA chips were prepared by adding 9 μl of gel matrix to the assigned 
well under pressure, and 9 μl of gel-dye mix to the next 2 wells. After adding 5 μl 
of marker to each well, 1 μl of DNA or RNA ladder and 1 μl of each sample were 
added to the separate wells. Chips were then vortexed for 1 min at 2400 rpm on a 
IKA vortex mixer and were run on the Agilent 2100 Bioanalyzer. The run data 
were analyzed by Agilent 2100 expert software version B.02.08.SI648(SR2). 
The DNA 1000 Kit allows the separation with high resolution, sizing and 
quantification of dsDNA fragments ranging from 25 to 1000 bp. The Agilent 
RNA Nano kit evaluates the ratio between the 18S and the 28S ribosomal 
subunits, and the presence of degraded small RNA fragments, in order to calculate 
a RNA integrity value (RIN) that expresses an estimation of the integrity of the 
RNA sample. RIN values range from 10 (intact) to 1 (totally degraded) (Figure 
2.1) 
 
Figure 2.1: Samples range from intact (RIN10) to degraded (RIN2) (from www.chem.agilent.com) 
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2.4.4 Agarose gel 1% 
The integrity of isolated gDNA is checked by on a 1% agarose gel. The presence 
of a strong single band indicate high quality and integer dsDNA, on the contrary a 
smear indicates the presence of degraded DNA. 
 
2.5 Genetic Screening 
The entire cohort of 99 AC probands was screened for pathogenic variants in five 
desmosomal encoding genes (DSG2, DSC2, DSP, PKP2, JUP),  whereas only 46 
AC subjects were subsequently screened for causative variants in 3 extra-
desmosomal genes (CTNNA3, DES, PLN).  
Each exon and exon-intron boundaries of the 8 genes was amplified by 
polymerase chain reaction (PCR) and analyzed by denaturing high-performance 
liquid chromatography (DHPLC) and Sanger sequencing. 
2.5.1 Polymerase chain reaction (PCR) 
PCR is a method developed by Mullis in the 80s (Mullis et al., 1990) that allows 
the exponential amplification of specific target DNA regions (Figure 2.2). A PCR 
reaction requires: template DNA, deoxynucleotide triphosphates (dNTPs), 
oligonucleotide primers flanking the target DNA sequence, DNA polymerase 
enzyme, reaction buffer and magnesium. PCR is composed by different 
consecutive reactions: 
1 Template denaturation by heating DNA at 95 °C, 
2 Annealing temperature (Ta) usually ranges from 55 to 65 °C; oligonucleotide 
primers may align on the target region of the single strand DNA. 
3 Elongation at 72 °C, the DNA polymerase synthesizes new strands of DNA 
starting from the 3’ of annealed primers. The newly synthesized DNA of the first 
cycle will be the template of the next and so on, reaching a million-fold increase 
of the DNA quantity at  the end of the reaction. 
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Figure 2.2:  Schematic representation of the PCR reaction 
2.5.1.1 Standard PCR 
Amplification reactions were carried out in a final volume of 12.5 μl containing 
50 ng of template (final concentration 4ng/μl), 1X of PCR buffer, 1.5 mM MgCl2, 
0.2 mM of dNTPs, 0.8 μM of forward and reverse primer, and 0.32 U of Taq 
DNA polymerase (Life Technologies, Carlsbad, CA, USA). For some amplicons, 
amplification was enhanced by the use of 1μl of Dimethyl sulfoxide (DMSO) in 
the reaction mix. DMSO destabilizes the double helix structure by hydrogen 
binding to the major and minor grooves of DNA and reduces secondary structure 
formation in the DNA template, thus facilitating primers annealing. 
Amplification reactions were performed on Mastercycler Pro (Eppendorf, 
Hamburg, Germany) at specific Ta for every PCR product, optimized  based on 
the GC content of the sequence and melting temperatures (Tm) of primers. 
Briefly, each sample was denatured at 95 °C for 10 min to allow the activation of 
the hot start DNA polymerase, and exposed to 40 amplification cycles of 
denaturation for 30 sec at 95 °C, annealing for 30 sec at a range of Ta comprised 
between 55 °C and 65 °C and extension at 72 °C for 30 sec; followed by a final 
extension step of 7 min at 72 °C to enhance the amplicon elongation. 
The specificity and the amplification yield of some PCR products was enhanced 
by the use of touch-down PCR (TD-PCR). 
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TD-PCR protocols set annealing temperatures above the anticipated melting 
temperature of a primer/template pair and then decrease the annealing temperature 
of subsequent cycles stepwise. The initial annealing temperatures of the first few 
cycles is higher than the expected Tm of primers, and then for the subsequent 
cycles the temperature progressively decreases to lower Ta to allow the correct 
hybridization of primer to the template. Thermal cycling conditions used for TD-
PCR are as follows: an initial incubation at 95 °C for 10 min; followed by 10 
cycles at 95 °C for 30 sec, annealing temperature stepdowns every cycle of 1 °C 
(from 70 °C to 60 °C); extension at 72 °C for 30 sec. The successive 30 cycles are 
performed at a Ta of 60 °C with denaturation and extension steps as above; 
followed by the final extension at 72 °C for 7 min. 
PCR products (ranging from 150-700 bp) were analyzed on 2% agarose gel. 
2.5.1.2 GC rich PCR  
GC rich amplicons were amplified by using AmpliTaq Gold 360 Master Mix kit 
(Life Technologies, Carlsbad, CA, USA) containing all premixed PCR 
components according to the manual. Amplification reactions were performed in a 
final volume of 12.5 μl by adding 7 μl of mix, 2.5 μl of GC solution provided, 2 μl 
of forward and reverse primer to 50 ng of template DNA. 
2.5.1.3 Primers design 
The oligonucletide primers used for both amplification for subsequent Sanger 
sequencing were designed by PRIMER 3 software (http://primer3.ut.ee/) (Rozen 
and Skaletsky, 2000), on the following reference sequences retrieved from the 
University of California Santa Cruz (UCSC) Genome Browser 
(http://genome.ucsc.edu/): 
DSG2 gene has 15 exons and spans on ~51 kb of chromosome 18q12.1, 
NM_001943 is the unique DSG2 transcript variant. 
DSC2 gene contains 17 exons and spans on ~36 kb of  chromosome 18q12.1, 
NM_024422 represents the transcript variant DSC2a. 
DSP gene contains 24 exons and spanson ~45 kb of chromosome 6p24.3, 
NM_004415 represents the longest transcript variant type 1, DSP. 
PKP2 genecontains 14 exons and spans on ~106 kb of chromosome 12p11.21, 
NM_004572 represents the predominant and longest isoform in the heart. 
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JUP gene contains 14 exons and spans on ~32 kb of chromosome 17q21.2, 
NM_002230 represents transcript variant 1. 
CTNNA3 gene contains 18 exons and spans on ~ 10kb of chromosome 10q21.3, 
NM_013266 represents the transcript variant 1. 
PLN gene has 2 exons and spans on ~ 12kb of chromosome 6q22.31, NM_002667 
is the unique PLN transcript variant. 
DES gene contains 9 exons and spans on ~ 8kb of chromosome 2q35, 
NM_001927 is the unique DES transcript variant. 
Primers pairs (length 18-22 bases) were designed to maintain a Tm comprised 
between 58 and 62 °C, a maximum Tm difference of 1 °C, self complementarity, 
that is the tendency of a primer to bind to itself, and pair complementarity, that is 
the tendency of the left primer to bind to the right primer comprised between 3 
and 0 and when possible a GC content below 60%. 
The designed primers were analyzed using different bioinformatics tools in order 
to check their reaction specificity and accuracy. They were aligned by BLAST 
(http://blast.be-md.ncbi.nlm.nih.gov) and BLAT (http://genome-
euro.ucsc.edu/cgi-bin/hgBlat) on the genome reference sequence (GRCh37/hg19) 
in order to verify their specific annealing and avoid the presence of SNPs in 
predicted PCR primer binding sites. To confirm the amplicon length and Tm, they 
were also checked by in silico PCR tool on UCSC website (http://genome-
euro.ucsc.edu/index.html), and then produced by Invitrogen (Life Technologies, 
Carlsbad, CA, USA).  
2.5.2 Agarose gel 
For standard 2% agarose gel electrophoresis, 2 g of agarose were added to 100 ml 
of 1X Tris-Acetate-EDTA (TAE) buffer. The solution was heated in a microwave 
to dissolve agarose, gel was added with 5 µl of Nancy-520 DNA Gel Stain 
(Sigma-Aldrich, Saint Louis, MO, USA), cast in a sealed tray and a proper comb 
was inserted. Aliquots of 5 μl of PCR product and 3 μl bromophenol blue loading 
dye were mixed and loaded into each gel well. In addition, 2 µl of DNA Marker 
VIII (Roche Applied Science, Manheim, Germany) were loaded in order to 
determine the fragment sizes. Electrophoretic run was performed at 100 V in 1X 
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TAE buffer. Visualization was achieved on a LAS mini 4000 (Fujifilm, Tokyo, 
Japan). 
 
2.5.3 Denaturing High Performance Liquid Chromatography (DHPLC)  
DHPLC is a pre analytical technology that can detect the presence of single 
nucleotide variants and small insertions and deletions (Oefner and Underhill et al., 
1995). It separates heteroduplex molecules from homoduplex molecules by ion-
pair reverse-phase liquid chromatography on a column containing nonporous 
alkylated polystyrene-divinylbenzene particles. Heteroduplexes are made by 
double stranded amplification products composed by two almost complementary 
strands, containing a mismatch at the variant level, derived from two heterozygous 
alleles. The four configurations possible for heterozygous DNA are shown in 
figure 2.3. The analysis is performed under partial denaturation temperature, the 
slow DNA renaturation allows the formation of homoduplexes and 
heteroduplexes. The samples are run into the buffer flow that contains 
triethylammonium acetate (TEAA) and acetonitrile. The positively charged 
portion of TEAA interacts with the negatively charged phosphate group of DNA, 
that binds to the hydrophobic chromatographic column. With an increasing linear 
acetonitrile gradient injected into the column, the DNA binding capacity to the 
TEAA ions decreases and the DNA fragments are released. Heteroduplexes, 
because of the mismatch, have a lower column binding affinity and thus a reduced 
retention time with respect to the homoduplexes. Eluted samples pass through the 
UV detector, that registers absorbance at 260 nm over time. In absence of DNA 
variants all the homoduplex molecules will show the same retention time and will 
elute as a single peak, on the contrary if a DNA variant is present, the 
chromatogram will show two or four peaks. 
DHPLC was used to investigate the presence of variants in the 8 target genes, the 
analysis was performed using a Transgenomic WAVE System (Transegenomic, 
USA) with a DNASep HT Cartridge column.  
After PCR reactions, amplified fragments were denatured at 96 °C for 5 min, and 
then slowly cooled at room temperature to allow the formation of the 
heteroduplexes. Exons longer than 500 bp were splitted in more amplicons to 
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allow DHPLC analysis. The optimal temperature for fragments analysis was 
calculated using Navigator Software (Transgenomic, USA). Runs were carried out 
at flow rate of 0.9 ml/min with the mutation detection application. 
Samples with abnormal DHPLC profiles were purified and sequenced. 
 
 
Figure 2.3: Differences between homoduplex and heteroduplex (modified from  
http://www.transgenomic.com) 
 
2.5.4 Purification of PCR products  
Before sequencing, PCR products were purified by a treatment with Exonuclease 
1 (EXO) and Shrimp Alkaline Phosphatase (SAP) enzymes, to eliminate residues 
of primers and dNTPs from the previous PCR reaction, as they could interfere 
with the subsequent sequence reaction. 
The purification reaction was carried out with "Illustra ExoProStar 1-Step" kit 
(GE Healthcare Life Sciences, UK) by mixing 5 µl of PCR product and 2 µl of 
reaction mix, containing SAP enzyme that dephosphorylates dNTPs and EXO that 
hydrolyzes residual primers and aspecific oligonucleotides that could have been 
amplified during the PCR. The reaction conditions were: an incubation at 37 °C 
for 30 min followed by 80 °C for 15 min to inactivate the enzymes. 
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2.5.5 Direct sequencing  
The DNA sequencing method developed by Sanger in the 1970s (Sanger et al., 
1977) is based on the DNA chain-termination by chemically altered bases called 
di-deoxynucleotidetriphosphates (ddNTPs) carrying four different fluorophores. 
The method requires the presence of normal deoxynucleoside triphosphates 
(dNTPs), and dideoxynucleotide triphosphates (ddNTPs) lacking a 3’-hydroxy 
group that, when incorporated into a newly synthesized DNA fragment, terminate 
the DNA strand elongation at specific bases (A, C, T, or G). This process 
produces DNA fragments with different sizes that can be separated by capillary 
electrophoresis and detected with laser-induced fluorescence (Figure 2.4). 
 
 
Figure 2.4: Schematic representation of the Sanger sequencing technology 
 
Sequencing reactions were performed with BigDye terminator v3.1 Cycle 
Sequencing Kit (Life Technologies, Carlsbad, CA, USA) following the 
manufacturer’instructions. 1 µl of each purified PCR products was mixed with 2 
µl of sequencing buffer at a final concentration 1X, 1 µl of BigDye Terminators 
solution (containing dNTPs, fluorophore-conjugated ddNTPs, and polymerase), 
10 pm of forward or reverse primer in a total volume of 10 µl. Sequencing 
reaction was performed as follows: 96 °C for 1 min, 30 cycles of 96 °C for 10 sec, 
55 °C for 5 sec, 60 °C for 2 min 30 sec. Fluorescent-labeled sequences were then 
cleaned-up to eliminate unincorporated big dye terminators, dNTPs, and salts 
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using by ethanol/EDTA precipitation. Briefly, 50 µl of EtOH 96% and 2 µl of 
EDTA 125 mM were added to each sample, they were incubated at room 
temperature for 20 min and centrifuged at maximum speed for 15 min at 20 °C. 
samples were washed with 150 µl of EtOH 96% and resuspended in 10 µl of H20. 
5 μl of sequence reaction were mixed with 15 µl of Hi-Di Formamide (Life 
Technologies, Carlsbad, CA, USA), denatured for 5 min at 95 °C and submitted to 
sequencing analysis on an ABIPRISM 310 Genetic Analyser (Life Technologies, 
Carlsbad, CA, USA). 
2.5.5.1 Sequences Analysis 
CHROMAS software (Technelysium) was used to view Sanger sequencing 
electropherograms, while comparison with genomic sequences (GRCh37, hg19) 
obtained from UCSC Genome Browser (http://genome.ucsc.edu/) was done by 
SeqMan II (DNASTAR, Madison, WI, USA). AlaMut software (Interactive 
Biosoftware, Rouen, France) was used to evaluate nucleotide variants by 
integrating information from different sources (in silico prediction algoritms, 
conservation, literature infos etc). 
Human Genome Variation Society (http://www.hgvs.org/) recommendations (den 
Dunnen and Antonarakis, 2000) was used for nucleotide variant nomenclature. 
Whenever a putative pathogenic variant was detected, the presence of the variant 
was confirmed by performing a new DNA extraction, PCR and sequence reaction. 
For every novel nucleotide variant detected, 500 ethnically matched unrelated 
control subjects were screened for the presence of the variant in the healthy 
population. Screening of control subjects was performed by DHPLC with Rapid 
protocol and Sanger sequencing whenever an abnormal DHPLC pattern was 
observed. 
Sequence nucleotide variants found in dbSNP database 
(http://www.ncbi.nlm.nih.gov/SNP/) were considered  known polymorphisms and 
their frequency in the general population was determined by the data  available 
from the Exome Variant Server (NHLBI GO Exome Sequencing Project, 
http://evs.gs.washington.edu/EVS/) and in the 2188 control chromosomes 
available from the 1000 Genomes Project. Intronic variants located less than 50 bp 
from the exon boundaries were in silico analyzed at least by three different 
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algorithms (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer), to predict 
a possible effect on the splicing sites of the transcript.  
2.5.6 Filtering and prioritization of variants identified by Sanger sequencing 
In order to identify potential causal variants, nucleotide variants were prioritized 
by 3 different  filters, based on 
a. the frequency of variants in the population,  
b.  the conservation of the amino acid residue among species,  
c. and the pathogenetic predition of the variants obtained from in silico 
analysis. 
2.5.6.1 Variant Filtering based on Frequency  
The first filter applied to exclude common variants in the general population is 
based on the frequency of the nucleotide change in our group of healthy controls,  
the current default global population according to the data available in the 
freeware variant databases developed as results of the 1000 Genomes Project and 
the NHLBI Exome Sequencing Project (ESP),  and  literature information.   
The 1000 Genomes dataset (phase 1, released in the May 2011, 
http://www.1000genomes.org/) provide genotype data from 1094 worldwide 
individuals. The Exome Variant Server (http://evs.gs.washington.edu/EVS/) 
contains exome sequence data on a total of 6503 individuals: 2203 African-
Americans individuals and 4300 European-Americans.  
These databases provide the minor allele frequency (MAF) of each variant in the 
respective populations. Referring to those frequency data we classified variants as: 
pathogenic when they are detected with a MAF < 0.02%; rare variants when  
MAF is comprised between 0.02%  and 0.1%; and polymorphisms when they are 
present with a frequency > 0.1%. 
We arbitrary set up frequency cut-off frequency to 0.02% to classify a variant as 
‘mutation’ given that the prevalence of  AC in the Veneto Region is estimated as 
1:5000 (0.0002, 0.02%). Based on the frequency of AC in the general population, 
the estimated number of individuals in the ESP data (European-Americans 
section) that can be expected to be affected by AC is 1. 
Coding and splicing variants that did not fulfill this criterion, were excluded to be 
potential pathogenic and were considered to be rare variants if present in 
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population and in control alleles with MAF comprised between 0.02% and 0.1% , 
or as polymorphisms when MAF was > 0.1%. 
2.5.6.2 Variant Filtering based on the conservation of nucleotides and amino 
acids among species 
The second filter is based on the phylogenetic conservation of the substituted 
amino acid. The relationship between the level of evolutionary conservation of an 
amino acid and its functional importance is well know, so variants occurred at the 
level of conserved nucleotide and/or amino acids are predicted to be less tolerated. 
The analysis was performed using AlaMut that integrates both nucleotide and 
amino acid evolutionary conservation information, with PhastCons and phyloP 
scores and ClustalW alignments. The PhastCons and PhyloP scores are 
conservation scores derived from the multiple alignment of different vertebrate 
species, ClustalW is a tool that performs multiple sequence alignment of DNA or 
proteins. Amino acids conserved among  mammals and almost all lower animals 
were classified as ‘Highly conserved`, amino acids conserved among mammals 
and a few lower animal were classified ‘moderately conserved’, amino acids 
conserved among almost all mammals and no lower animals were classified as 
‘weakly conserved’, and amino acids not conserved among mammals or other 
lowere species were classified as ‘not conserved’. 
Nonsense variants, frameshift variants and variants located on the splice site (±1, 
±2) which respectively introduce in premature stop codon, distrupt the transcript's 
reading frame, interfere with the correct splicing processes were considered 
potentially pathogenic.  
2.5.6.3 In silico analysis  
The third filter is a combination of statistical algorithms which aim to evaluate a 
string of variant-specific features, as proposed by van Spaendonck-Zwarts and 
coll. (van Spaendonck-Zwarts et al., 2013). 
In silico analysis of  missense variants is  taking into account the outcome of 
different prediction tools: 
 Polyphen-2 (http://genetics.bwh.harvard.edu/pph/). Polyphen is a tool that 
predicts the possible impact of an amino acid substitution on the structure and 
function of a protein (Adzhubei et al., 2013). Three outcomes are possible: 
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probably damaging (the variant is expected with high confidence to affect 
protein structure), possibly damaging (the variant supposed to affect protein 
structure), benign (the variant is not expected to have any effect on protein 
structure). 
 Sorting Intolerant From Tolerant (SIFT) 
(http://sift.jcvi.org/www/SIFT_enst_submit.html). SIFT is a tool that predicts 
the possible impact of an amino acid substitution on the protein function. (Ng 
and Henikoff 2001). It classifies amino acids substitutions as tolerated or 
deleterious. 
 Grantham Score. The Grantham score expresses the difference in the 
physicochemical properties of the amino acids (side chain atomic 
composition, polarity, molecular volume) (Grantham et al., 1974). Grantham 
score is comprised between 0 and 215. A high score indicates a great 
difference in chemical properties between the two amino acids and thus a 
greater impact on protein structure.  
 Align-Grantham Variation with Grantham Deviation (A-GVGD) 
(http://agvgd.iarc.fr/). It combines the biophysical characteristics of amino 
acids and protein multiple sequence alignments to predict where missense 
substitutions fall in a spectrum from enriched deleterious to enriched neutral. 
There are 7 possible outcomes: C0, C15, C25, C35, C45, C55, C65. A higher 
score indicates likely deleterious substitutions. 
 BLOSUM (BLOcks SUbstitution Matrix) 62. It is an identity scoring matrix 
based on local alignments of protein sequences. (Henikoff and Henikoff, 
1992). Scores for each position are derived from observations of the 
frequencies of substitutions in blocks of local alignments in related 
proteins.  In the BLOSUM62 matrix, the alignment from which scores were 
derived was created using sequences sharing no more than 62% identity. The 
Blosum62 substitution matrix contains scores for all possible exchanges of 
one amino acid with another, where the lowest possible score (-4) indicates a 
low probability of substitution, and the highest score (11) indicates a high 
probability of substitution in the alignments. A high score indicates 
substitutions affecting conserved amino acids and thus likely deleterious. 
69 
 
 Conservation among species was evaluated using ClustalW 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/). It was used to align amino acid 
sequences among different species in order to evaluate the conservation of the 
changed amino acids. 
 Conservation between isoforms was evaluated using ClustalW. It was used to 
align amino acid sequences of different isoforms in order to evaluate the 
conservation of the changed amino acids. 
 Frequency in control population is based on the minor allele frequency of the 
variant given by the Exome variant server and in a number of controls. 
 In silico evaluation of splicing is based on at least three different Splice Site 
prediction softwares (SpliceSiteFinder, MaxEntScan and GeneSplicer) using 
AlaMut. 
 Family information was considered when available  
 Evidences from functional analysis were considered when available from the 
literature reporting in vitro studies or animal models. 
When a feature was not available, it was not calculated and considered for the 
final classification. 
In silico analysis of nonsense and frame-shift variants do not consider the first 6 
steps and are based on general features of the variant, predictions about functional 
effects, splice predictions, and frequency in a control population. Family 
information about co-segregation, functional analysis and phenotypic features 
were considered when available. 
Variants are classified as follows based on a specific score: 
 (putative) pathogenic: with proven co-segregation in the family . 
 % score ≥ 70%: Variant of unknown clinical significance (VUS) likely to be 
pathogenic (VUS3)  
 45% ≤ % score < 70%: VUS of uncertain significance (VUS2) 
 25% ≤ % score < 45%: VUS unlikely to be pathogenic (VUS1) 
 % score < 25%: Not pathogenic (VUS0) 
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2.5.6.4 Final assessment of the variants’ pathogenicity  
The final pathogenicity of variants was assessed further integrating information 
from a detailed literature review about each variant and family cosegregation 
analysis.  
A variant was considered disease-causing mutation when it fulfilled at least one of 
the following criteria: 
-  Previously associated with AC 
-  Not detected in a large healthy ethnically matched control population 
-  Cosegregated in the family with the disease phenotype. 
 
2.6 Multiplex Ligation-dependent Probe Amplification (MLPA) 
Multiplex ligation-dependent probe amplification (MLPA) is a method based on 
the multiplex amplification of specific probes developed for the relative 
quantification of nucleic acid sequences (Schouten et al., 2002) that allows the 
detection of copy number variants of specific target regions.  
MLPA analysis were performed in the Cardiovascular Genetics Laboratory 
(University of Padua), after a preliminary study on 8 samples carried out in the 
Cardiogenetics Laboratory (UMCG, University of Groningen). 
To investigate for large deletions/duplications within desmosomal genes, MLPA 
was performed by using “SALSA MLPA P168 ARVC-PKP2 probemix kit” 
(MRC-Holland, Amsterdam, The Netherlands) according to the manufacturer’s 
instructions. The probemix contains oligonucleotide probes for every exon of 
PKP2 (NM_004572.3) and its promoter, 6 probes for exons 1, 5, 7, 9, 21, 24 of 
DSP (NM_004415.2), 3 probes for exons 2, 9, 12 of JUP (NM_002230.2), 3 
probes for exons 1, 7, 17 of DSC2 (NM_004949.3), 3 probes for exons 1, 6, 15 of 
DSG2 (.NM_001943.3). It also contains 3 probes for exons 1, 6, 7 of TGFβ3 
(NM_003239.2) and 2 probes for exons 3 and 97 of RYR2 (NM_001035.2). It also 
contains nine control fragments and eight reference probes located on different 
chromosomes. 
The technique is based on the simultaneous amplification of probes after 
hybridization on targets and can be divided in five distinct steps (Figure 2.5): 
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1) DNA denaturation 
2) DNA hybridization with the oligonucleotide probes. MLPA probe pairs 
are composed by two oligonucleotides, that are contiguous to the region of 
interest and hybridize to immediately adjacent target sequences. 
3) Ligation reaction. Only when both probes are hybridized can be ligated 
and trigger PCR reaction 
4) PCR reaction. Probes contain at their 5’ and 3’ ends specific sequences 
complementary to universal PCR primers, so a universal pair of primers is 
used for the subsequent amplification step. 
5) Analysis of PCR products by capillary electrophoresis. 
One extremity of the 2 probes of every oligonucleotide pairs is conjugated with a 
fluorescent marker, and the other one contains a "stuffer" sequence different in 
length between the different probes, thus allowing the simultaneous analysis of 
several targets, as sequences differing for even one nucleotide can be recognized.  
The amount of ligation products is directly proportional to the input DNA due to 
the specific amplification of probes correctly hybridized and ligated. 
 
 
Figure 2.5: Outline of the MLPA recation (modified from Schoutern et al., 2002). After 
hybridisation to the target sequence in the DNA sample, the oligonucleotide probes are 
enzymatically ligated. Ligation products are amplified using PCR primers for sequences X and Y. 
Amplification products from each probe have a unique length and are separated by electrophoresis. 
Relative amounts of probe amplification products, in comparison to a reference DNA sample, 
correspond to the relative copy number of the target sequences. 
 
Briefly, the entire MLPA procedure comprise the following reaction steps: 
1. DNA denaturation. 
5 μl DNA sample were denatured for 5 minutes at 98 °C 
2. Hybridization of probes to the DNA sample. 
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3ul of Hybridization  mix (1.5 μl SALSA probemix and 1.5 μl MLPA ) was 
added to the samples, followed by an incubation at 95 °C for 1 minute and 
hybridisation at 60 °C for 16 hours 
3. Ligation. 
32 μl of ligase master mix (3 μl Ligase Buffer A + 3 μl Ligase Buffer B + 25 
μl water + 1 μl Ligase-65 were added to the sample, followed by incubation at 
54 °C for 15 minutes and 5 minutes at 98 °C to inactivate the ligase enzyme 
4.  PCR amplification of ligated probes. 
10 μl of polymerase master mix (7.5 μl water + 2 μl PCR Primer mix + 0.5 μl 
SALSA Polymerase) was added to the samples, followed by PCR reaction: 35 
cycles of 30 s at 95 °C, 30 s at 60 °C, and 60 s at 72 °C, final 20 min at 72 °C) 
5. Capillary electrophoresis of PCR products. 
1 μl of MLPA reaction was mixed with formamide and loaded on an ABI310 
Sequencer (Applied Biosystems, Foster City, CA), using ABI POP-4 polymer, 
and GS400HD size standard. 
In each run, 1 healthy control sample was included every 7 samples, and negative 
controls (water) to exclude contamination were included.  
2.6.1 Run Quality control and data analysis 
The MLPA reaction products were run on ABI310, and GeneMapper software 
(Applied Biosystems) was used in order to check that the run was successful, data 
were analyzed by the Coffalyser Software (MRC Holland, Amsterdam, The 
Netherlands). 
This software first performs an evaluation of raw data by checking the DNA 
amount, denaturation, ligation efficiency and includes a baseline correction and 
peak identification. 
The probemix, in addition to the target and reference probes, contains nine control 
probes, that probes prooduce, after the reaction, the DNA Denaturation Fragments 
(D-fragments, 88 nt and 96 nt), the Quantity Fragments (Q-fragments, at 64-70-
76-82 nt), the 92 nt benchmark probe, and the X and Y fragments (100 and 105 
nt) (Table 2.1).  
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The D-fragments and Q-fragments were visualized and analysed for every sample. 
The D-fragments (88nt and 96 nt) peak area was less than 40% lower than the 
92nt fragment, indicating the execution of a correct denaturation step. The Q-
fragments peak areas was verified to be lower (< 33%) than the 92 nt control 
fragment, indicating that the DNA amount in the reaction was enough and the 
ligation reaction was successful. Whenever a technical problem occurred, the 
entire MLPA reaction procedure was repeated. 
The D-fragments hybridize to GC rich genomic sequences that are difficult to 
denature, they therefore work as positive controls for the denaturation step. If the 
88nt and 96 nt fragments are lower (< than 40 %) than the 92 nt control fragment, 
a denaturation problem occurred. The Q-fragments are fragments that do not need 
hybridization to DNA or ligation to be amplified during the PCR step. If the Q-
fragment signals are higher (> 33%) than the 92 nt control fragment, the DNA 
amount in the reaction was not sufficient or the ligation step failed.  
 
Table 2.1 : Internal references probes (modified from MRC-Holland). 
 
The presence of large deletions in the target genes can be observed from raw data, 
and are verified by the subsequent data analysis performed by Coffalyzer software 
(Figure 2.6), which performs 2 normalization steps: 
- an intra-sample normalization, where the probe peaks are compared to the ones 
of the reference probes, within each sample, 
- an inter-sample normalization, where the probe peaks in the target sample are 
compared to the ones of the control samples. 
This process allows the calculation of final probe ratios, called Dosage quotient 
(DQ). A DQ is close to 1 indicates a wild type sample, when it is close to 0.5 it 
indicates an heterozygous deletion (1 allele) and when it is close to 0 it indicates 
an homozygous deletion, as indicated by the MRC-Holland (Table 2.2).  
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Table 2.2: Relation Dosage Quotients and Copy Number (based on normal status of 2 copies) 
Dosage Quotient Distribution Copy Number Status (modified from MRC-Holland). 
 
 
 
 
 
 
 
Figure 2.6: a) Comparison between electropherograms of a test sample (bottom) and a reference 
sample (top) showing the decrease of three probes in the test sample (arrows). b) Probe ratios of 
the same test sample calculated by Coffalyser.Net software after analysis of the two samples: 
arranging probes by chromosomal location shows a reduced copy number for the three adjacent 
probes in the test sample. (modified from MRC-Holland) 
 
2.7 Quantitative real-Time PCR (qPCR) 
Deletions detected by MLPA were validated by relative quantitative PCR (qPCR) 
performed on gDNA on an Light Cycler 480 II (Roche Applied Science, 
Mannheim, Germany) by SYBR Green-based quantification according to the 
manufacturer’s protocol (Figure 2.7). The reactions were prepared in a final 
volume of 20 μl with 1x Master SYBR Green I (Roche Applied Science, 
Maanheim, Germany), 20 pmol of forward and reverse primers and 100 ng of 
gDNA (5 ng/μl). The amplification was carried out under the following 
conditions: an initial preincubation of 95 °C for 10 min followed by 45 cycles of 
denaturation at 95 °C for 30 sec, annealing at 60 °C for 20 sec and extension at 72 
°C for 10 sec, and a final extension of 72 °C for 10 min. qPCR experiments runs 
were carried out in triplicate and included a negative control. The housekeeping 
gene GAPDH was used as reference. Primers for exons 2, 9, 15 of DSG2; 2, 6, 15 
of DSC2; 2, 7, 13 of PKP2 were developed by the Primer3, primers were designed 
to have a Tm around 60 °C and produce amplicons approximately 200 bp long. 
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After the amplification, melting curve analysis and a run on agarose gel were 
performed to verify the absence of aspecific products. The copy number 
differences between the samples were calculated by the Crossing threshold (Ct) 
method. Ct values were automatically calculated by the LightCycler software, 
using the second derivative maximum. The efficiency of each PCR reaction was 
automatically determined by the formula: E = 10−1/slope . For relative 
quantification, the ratio of the target gene or exon with respect to the 
housekeeping gene of the patient’s sample is then divided by the ratio of a control 
sample. 
 
Figure 2.7: PCR in the presence of SYBR Green I. a) SYBR Green I dye only fluoresces when it is 
bound to dsDNA and excited by blue light. SYBR Green I does not bind to single-stranded DNA, 
so fluorescence is minimal during denaturation. b) As dsDNA forms and is synthesized, SYBR 
Green I binds the dsDNA and the fl uorescent signal from the bound SYBR Green I (green light) 
increases. c) At the end of elongation, all DNA is double-stranded, the maximum amount of SYBR 
Green I is bound and the fluorescent signal is at its maximum for that PCR cycle. Therefore, the 
fluorescent signals from SYBR Green I are measured at the end of eachelongation phase (modified 
from  http://lifescience.roche.com/). 
 
2.8 Transcript Analysis 
2.8.1 Reverse transcription 
Total RNA was isolated from from peripheral lymphocytes of the patient and 
reverse transcribed.  
200 ng of total RNA was mixed with 1 µl of 50 µM  random hexamers (Life 
Technologies, Carlsbad, CA, USA), 1 µl of 10 mM dNTP mix hexamers (Life 
Technologies, Carlsbad, CA, USA) and H2O to a total volume of 10 µl and 
incubated on a thermal cycler at 65 °C for 5 min. 2 µl of 5X first strand buffer 
(Life Technologies, Carlsbad, CA, USA), 1 µl of 40U/µL RNaseOUT (Life 
Technologies, Carlsbad, CA, USA) and 2 µl of H2O were added to the mix, mixed 
by pipetting and heated at 42 °C for 2 minutes. 1 µl of SuperScript III Reverse 
Transcriptase (200 U/µL) (Life Technologies, Carlsbad, CA, USA) was added and 
mixed by pipetting to start the retrotranscription. The reaction mix was incubated 
at 42 °C for 50 min, followed by inactivation at 72 °C for 15 min.  
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2.8.2 PCR 
Targeted regions of the cDNA were amplified with the standard PCR protocol, 
with specific primers flanking the deleted region, located on exon 3 and exon 5 of 
PKP2, developed using Primer3 software (F 5’-
3’AGCCCGTCACTCAGAACAG, R 5`-3`ATGCCACGAAGCTGGTTA). PCR 
products were run on 2% agarose gel and bands were excised from the gel.  
2.8.3 DNA extraction from agarose gel 
Extraction of DNA fragments from agarose gel allows to select the correct band 
and to remove the excess of primers and dNTPs coming from the previous PCR. 
Extraction was performed by using QIAquick Gel Extraction Kit (Qiagen Venlo, 
Limburg, The Netherlands) based on the absorption of nucleic acids to silica-gel 
particles in presence of salts, according to the manufacturer`s protocol.  
Briefly, the DNA band was excised from the agarose gel, dissolved in 3 volumes 
of QC buffer and incubated at 50C C for 10 min, before adding 1 volume of 
isopropanol. Dissolved gel extracts were transferred on a QIAquick spin column 
that was centrifuged at 17,000 x g for 1 min, discarding the flowthrough. The 
column was washed with 600 µl of PE buffer and centrifuged for 1 min at 
17,000g. it was placed on new collection tube and re-centrifuged for 3minutes at 
17,000g to remove residual ethanol. Purified DNA was eluted in 20 μl of H2O. 
5 μl of purified DNA were used to set up a sequencing reaction as previously 
described. Sequence run was carried out on an ABI310 Sequencer (Life 
Technologies, Carlsbad, CA, USA)  and analyzed using Chromas (Technelysium), 
Seqman II (DNASTAR, Madison, WI, USA), and AlaMut (Interactive 
Biosoftware, Rouen, France) softwares . 
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2.9 Next Generation Sequencing (NGS) 
2.9.1 The NGS Workflow  
Different NGS platforms are commercially available with different sequencing 
approaches, however the workflow can be summarized as follows. 
1) DNA fragmentation and library preparation: gDNA is randomly fragmented 
and universal adaptors are ligated to the produced fragments in order to enrich 
targeted regions of the genome by hybridization. 
2) Sequencing: parallel polymerase chain reaction and sequencing of the target 
DNA fragments produce clonally clustered amplicons. Sequencing methods vary 
and consist of several NGS technologies, including reversible terminator 
reactions, pyrosequencing, sequencing by ligation and real-time sequencing. 
These sequencing methods, applied on the enriched target samples, originate 
millions of reads. These reads are expected to cover the portions of the reference 
genome that was targeted, and the number of reads covering every target 
nucleotide is called coverage. Multiple algorithms have been developed in order 
to align the obtained sequences with the reference sequence. 
3) Alignment: reads are aligned to a reference genome (resequencing) or 
assembled (de novo sequencing) (Flicek et al., 2009). The standard formats for 
storing aligned reads from NGS experiments are the SAM/BAM file formats. The 
sequence alignment/map (SAM) file format is used to store sequence data and 
alignment information for short read sequence, a binary encoding of a SAM 
format file in the BAM file. IGV can be used to view SAM and BAM files, which 
are used to store read alignments in a smaller file size (Li et al., 2009), or Variant 
Call Format (VCF) files. IGV allows to view through large sets of reads and to 
observe the overall coverage throughout the target region, to zoom into the 
sequence till the nucleotide level. The Burrows-Wheeler Aligner (BWA) for 
instance is the most used next-generation sequence alignment program that uses 
the Burrows-Wheeler transform to align paired-end short reads to the genome. 
The resulting aligned sequence is then analyzed in search of nucleotides that vary 
from the human reference genome and are identified as SNPs, on a process called 
SNP Calling. Commercial software packages, such as CLC bio (CLC Genomics 
Workbench), offer a complete solution from importing a FASTQ file to creating 
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alignments and calling variants. SNP discovery tools include programs such as the 
Genome Analysis Toolkit Unified Genotyper. 
 4) SNP calling: highlights nucleotides different from the reference sequence. 
A NGS projects typically identifies 20000 to 30000 variants per exome, reflecting 
the great amount of genetic variation of the human genome. This makes the 
identification of disease causing variants among the thousands of variants very 
challenging. This process is further complicated by the necessity of distinguish 
true variants from sequencing errors or false-positive variants. Many filtering 
methods have been developed to prioritize variant and facilitate the research of the 
causal ones. All prioritization methods consider the possible effect of the 
nucleotide variant on the protein, and that the variant is expected to be particularly 
rare in the population. There are several freely available variant databases 
providing information on variants such as their frequency in different populations. 
In particular, raw sequence data from the 1000 Genomes Project and the Exome 
Sequencing Project, available from several sources, provide useful information for 
identifying common polymorphisms from NGS projects. 
2.9.2 The Illumina workflow 
Illumina sequencers are based on sequencing-by-synthesis using a fluorescently 
labeled method. The general workflow includes library preparation, single 
molecule amplification by bridge PCR and reversible terminator sequencing-by-
synthesis. 
The process starts with DNA library preparation, where DNA is randomly 
fragmented, and Illumina-specific adaptors are ligated at both ends of the 
fragments.  The fragments are attached on a oligo-derivatized surface of a flow 
cell, that contained oligos that bound with the adaptors. Amplification of the 
clusters is called bridge amplification: DNA polymerase is used to produce 
clusters of approximately one million copies of the original fragment. During 
sequencing the four labeled nucleotides are simultaneously added to the flow cell 
channels with the DNA polymerase, to be incorporated into the cluster fragments. 
The four nucleotides are labeled with base-specific fluorescents, the label contains 
a 3’-OH group, that inhibits the fluorescent, the polymerase ligates the fluorescent 
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labeled nucleotides in the clusters and the 3’-OH group detaches and the 
fluorescence is detected. Illumina sequencer produces reads around 100 bases. 
2.9.3  Next Generation Sequencing - Whole Exome Sequencing (WES) 
Whole Exome Sequencing (WES) of 12 out of the 99 genotyped subject was 
performed in collaboration with BMR Genomics (Padua, Italy) in 2 consecutive 
sequencing runs, each including 6 samples. 
WES is composed by three main steps: library preparation, sequencing, 
bioinformatic data analysis of results including SNP Calling. 
2.9.3.1 Library preparation 
Libraries were constructed according to the Illumina recommendations, and 
enriched for the coding regions of 20846 genes using the TruSeq DNA Sample 
Preparation kit (Illumina, San Diego, CA, USA) according to the “low sample 
protocol”, used to process a maximum of 48 samples at one time. 
 The protocol for the library preparation is composed by different steps (Figure 
2.8). 
 
Figure 2.8: Overview of the WES sample preparation workflow (modified from 
www.illumina.com/). 
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- DNA Fragmentation 
According to TruSeq Exome Enrichment recommendation the final library should 
contain DNA fragments of 200-300 bp average insert size: 1 μg (52.5 μl at 20 
ng/μl) of gDNA was sheared on a Covaris S220 (Covaris, Woburn, MA, USA) 
using the following settings: Duty cycle 10%, Intensity 5.0, Bursts per second 
200, Duration 120 sec, Mode Frequency sweeping, Power 23W, Temperature 6 
°C, according to the manual. After a brief centrifugation at 600g for 5 sec, 50 μl of 
fragmented gDNA were transferred to every well of a PCR plate.  
- End Repair 
Covaris shearing produces dsDNA fragments with 3’or 5’ overhangs, therefore 
this process is necessary to change the overhangs resulting from fragmentation 
into blunt ends.  
40 μl of End Repair Mix (Illumina) was added to each well of the plate containing 
the fragmented DNA, mixing thoroughly. The 3' -5' exonuclease activity of the 
End Repair Mix removes the 3'overhangs and the polymerase activity fills in the 
5' overhangs. The plate was incubated on the thermal cycler for 30 min at 30 °C.  
The sample clean up was performed according to the following procedure: 160 μl 
of AMPure XP Beads were added to each well of the plate containing the End 
Repair Mix and the plate was incubated at room temperature for 15 min. The plate 
was placed on the magnetic stand at room temperature for 15 min, and the 
supernatant was discarded from each well. After two washing steps with 80% 
EtOH, the plate was dried at room temperature for 15 minutes, and the dried pellet 
was resuspended in 17.5 μl of Resuspension Buffer. 15 μl of the clear supernatant  
was transfer from each well of the plate to the corresponding well of the new PCR 
plate. 
- 3' Ends Adenylation 
This process adds a single adenine nucleotide to the 3’ ends of the blunt 
fragments, in order to avoid their ligation to one another during the adapter 
ligation reaction. 
Briefly 2.5 μl of A-Tailing Control and 12.5 μl of A-Tailing Mix were added to 
the bottom of each well of the plate, the plate was incubated on the thermal cycler 
for 30 min at 37 °C. 
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- Adapters Ligation 
During this step multiple indexing adapters are getting ligated to the ends of the 
DNA fragments, preparing them for hybridization on a flow cell. On the 3’ end of 
the adapter a  single timine nucleotide is located, to provide a complementary 
overhang for ligating the adapter to the fragment. 2.5 μl of Ligase Control, 2.5 μl 
of DNA Ligase Mix and 2.5 μl of each thawed DNA Adapter Indexes were added 
to each well of the plate, the volume was adjusted to 37.5 μl and the plate was 
incubated on the thermal cycler for 10 min at 30 °C. Then 5 μl of Stop Ligase Mix 
were added to each well to inactivate the ligation, and the volume was adjusted to 
42.5 μl. 
The clean up was performed as previously described, the dried pellet was 
resuspended with 22.5 μl Resuspension Buffer, and 20 μl of the clear supernatant 
were transferred to a new PCR plate. 
- Ligation Products Purification and size selection 
This step is performed to purify the products of the ligation reaction and to 
remove unligated adapters, adapters that may have ligated to one another, and in 
order to select a size‐range of sequencing library for the subsequent cluster 
generation. For exome enrichment, a 200–300 bp insert size target was chosen. 
This process was carried out by an elettrophoretic run on a 2% agarose with SyBr 
Gold gel in 1X TAE Buffer. 7 μl of 4X Loading Buffer were added to each well 
of the plate, 17 μl of Resuspension Buffer and 7 μl of 4X Loading Buffer were 
added to 3 μl of DNA ladder. The ladder solution was loaded in one lane of the 
gel, and the samples on the other lanes of the gel. The gel was run at 120 V 
constant voltage for 120 min. After the gel visualization, the bands from the gel 
spanning from 300–400 bp were excised. DNA extraction was carried out 
following the instructions of the MinElute Gel Extraction Kit. Briefly, the gel 
slices were incubated in the QG solution at room temperature until they have 
completely dissolved and purification was performed on one MinElute spin 
column, eluting in 25 μl of QIAGEN EB. 20 μl of each sample from the MinElute 
collection tube were transferred to a new PCR plate. 
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- DNA Fragments Enrichment 
In this step a PCR is performed with specific primers that anneals to the ends of 
the adapters, therefore DNA fragments that have adapters on both ends are 
selectively enriched and the DNA library is amplified. 
5 μl of thawed PCR Primers and 25 μl of thawed PCR Master Mix were added to 
each well of the plate. Amplification was carried out in the thermal cycler as 
follows: 98 °C for 30 sec, 10 cycles of 98 °C for 10 sec, 60 °C for 30 sec, 72 °C 
for 30 sec and 72 °C for 5 min. The Clean Up of the PCR products was performed 
as previously described. The pellet was resuspended in 32.5 μl of Resuspension 
Buffer and 30 μl of the supernatant were transferred on a new PCR plate. 
- Library Validation  
Quality control analysis of the sample library includes quantification of the DNA 
library templates and quality control. 
Quantification 
An accurate quantification of DNA library is essential to create optimal cluster 
densities across every lane of the flow cell and obtain high quality sequencing 
data.  
Successful enrichment (at least 10 μg) was verified by qPCR according to the 
Illumina Sequencing Library qPCR Quantification Guide. Briefly, a 100-fold 
dilution of the 2mM qPCR control template was prepared. 100 μl of 0.1% Tween 
20 were added to 100 μl of the diluted template and a titration curve of six 2x 
serial dilutions was prepared (20 pM, 16 pM, 8 pM, 6 pM, 4 pM, 2 pM, 1 pM). 
Then 998 μl of 0.1% Tween 20 were added to 2 μl of the library template to make 
a 500-fold dilution (~4 pM), three independent dilutions of the library template 
were prepared to make triplicate measurements. 18 μl of the SYBR reaction mix ( 
10 μl of 2XKAPA SYBR FAST Master Mix Universal, 0.2 μl of 10 μM qPCR 
Primer 1.1 and 2.1, 7.6 μl of Nuclease-free Water) were added to each well of the 
plate, 2 μl of the control template dilutions, the unknown library dilutions, or 
water were added to each well. The plate was placed on the qPCR machine  with 
the following conditions: 95 °C for 10 min (Hot start), and 40 cycles at 95 °C for 
10 sec, 60 °C for 30 sec. finally,  qPCR results are analyzed and the initial 
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concentration of the unknown library templates is automatically calculated based 
on the standard curve.  
Quality Control 
The size of the enriched fragments was checked by running 1 μl of 1:100 diluted 
library aliquot of the enriched library on a 2100 Bioanalyzer (Agilent, Santa 
Clara, CA, USA) using a DNA 1000 chip as previously described. 
- Libraries Pooling 
Multiplexed DNA libraries are normalized to 10 nM and then pooled in equal 
volumes for the cluster generation. The concentration of sample library were 
normalized to 10 nM, then 10 μl of each normalized sample library were 
transferred to be pooled on a new PCR plate. 
2.9.3.2 Sequencing 
Cluster generation was achieved according to the Illumina Cluster Generation 
User Guide. 
In this procedure the template is attached to the surface of an oligonucleotide-
coated flow cell and amplified to produce a cluster bound to the surface of the 
flow cell. Cluster generation workflow includes cluster amplification, 
linearization, blocking, primer hybridization. during cluster amplification the 
sample is hybridized on the flow cell and amplified, then the amplified sample is 
prepared for sequencing: one of the two adapters are cleaved off from the surface 
of the flow cell, the 3’ OH ends of the linearized dsDNA clusters is blocked, 
dsDNA is denatured and sequencing primers can hybridize. 
Briefly the template DNA is denatured with 0.1 N NaOH to a DNA concentration 
of 20 pM, and added with Hybridization Buffer. The DNA library was sequenced 
on a flow cell with paired end 2x100 bp run a on an HiSeq2000 (Illumina, San 
Diego, CA, USA). 
 Data Analysis 
Image acquisition, and image and signal processing were performed during the 
run. A first data analysis was performed using the Illumina software package for 
Illumina Systems. Consecutive analysis was performed by using three different 
pipelines. 
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- A first pipeline mapped the read sets obtained against the human reference 
genome NCBI37/hg19 using Burrows-Wheeler Aligner tool (BWA), a freeware 
software package that efficiently aligns short sequencing reads against a large 
reference sequence, and  required a previous indexing of the reference. PCR 
duplicates were removed and all alignment BAM files (Binary Alignment/Map) 
have been indexed and filtered. BAM files can be uploaded on Integrative 
Genomics Viewer  (IGV) software, visualization tool for interactive exploration of 
large, integrated genomic datasets (Robinson  et al., 2011). 
Genome Analysis ToolKit (GATK) was used for base quality score recalibration 
and realignment. Variant calling was performed with GATK Unified Genotyper 
by using default parameters, according to the GATK recommendations, and 
produced Variant Caller Format files (VCF; Danecek et al., 2011) from BAM 
files. Annotation was carried out by uploading VCF files on the web version of 
the variant annotation program ANNOVAR (Wang et al., 2010). ANNOVAR 
provides for every variant allele frequencies available from dbSNP, 1000 
genomes, and the Exome Sequencing Project. It also provides predictions of their 
effects on the amino-acid sequence, and pathogenicity prediction scores from 
SIFT, Polyphen, MutationTaster, MutationAssessor,  and  attaches annotations of 
conserved regions. 
The number of reads on target, that is the number of reads mapping on the exome, 
was calculated from the total sequenced reads and the reads resulting after 
filtering and mapping. The average coverage was calculated as: the total bases 
aligned on the exome/ total bases of the exome. 
- A second pipeline was the Illumina suite. HiSeq reads were mapped with 
ELANDv2 to the hg19 reference sequence, a mapping tool included in the 
Illumina software package that performs multiseed and gapped alignment of 
paired reads, using default parameters. Variant calling was performed with 
Consensus Assessment of Sequence And VAriation (CASAVA) with default 
parameters. CASAVA is a Linux application principally developed to call alleles, 
SNPs,indels.  It also automatically generates a range of statistics (mean depth and 
percentage target coverage). CASAVA outputs were  imported into “Genome 
Studio” for visualization. 
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-The third analysis was carried out by using CLC Genomics Workbench,  an 
analysis package for analyzing, comparing, and visualizing next generation 
sequencing data. CLC carried out aligment, filtering, and variant calling by 
applying default parameters. 
The sensitivity of WES with respect to Sanger sequencing was calculated 
considering the number of variants correctly identified by WES with respect to the 
total number of variants of the samples. The specificity was calculated 
considering the false positives calls of WES among the 719885 true negative 
bases. 
2.9.4  Next Generation Sequencing - Targeted Resequencing (TR) 
Targeted resequencing (TR) for 55 genes associated with different 
cardiomyopathies was carried out on 2 genotyped subjects at the University of 
Groningen. 
2.9.4.1 Library preparation 
Library preparation and enrichment were carried out by using the SureSelectXT 
Target Enrichment System for Illumina Paired-End Sequencing Library, 
according to the manufacturer’s instructions (Figure 2.9). 
- DNA Fragmentation  
3 μg of high-quality gDNA were diluted with Tris-EDTA Buffer to a total volume 
of 130 μl and sheared on a Covaris S220 (Covaris, Woburn, MA, USA), using the 
following settings: Duty cycle 10%, Intensity 5.0, Bursts per second 200, 
Duration 80 sec, Mode Frequency sweeping, Treatment Time 360 sec, 
Temperature 4 °C, according to the manual. The target peak for base pair size is 
between150 and 200 bp. 
The sample was purified by using the QIAquick protocol (Qiagen, Hilden, 
Germany), according to the following procedure. Briefly 5 volumes of Buffer PB 
were added to 1 volume of sample, the sample was transferred on a QIAquick spin 
column to bind DNA on the silica membrane, and centrifuged for 30 sec, 
discarding the flow-through. DNA was washed by adding 750 μl of Buffer PE to 
the column and centrifuged for 30sec. DNA was eluted  in 20 μl of nuclease-free 
H2O. 
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Figure 2.9: Overview of the TR sample preparation workflow (modified from 
http://www.genomics.agilent.com/). 
 
- Quality control 
The quality of the library was assesse with the 2100 Bioanalyzer using a DNA 
1000 chip and reagent kit, according to the Agilent DNA 1000 Kit Guide. The 
electropherogram should show a distribution with a peak height comprised 
between 150 and 200 bases. 
- End Repair 
End repair was performed by combining 48 μl of each DNA sample with 100 μl 
of End Repair Mix (35.2 μl of Nuclease-free water, 10 μl of 10X End Repair 
Buffer, 1.6 μl of dNTP Mix, 1 μl of T4 DNA Polymerase, 2 μl of Klenow DNA 
Polymerase, 2.2 μl of T4 Polynucleotide Kinase). Every tube was incubated in a 
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thermal cycler for 30 min at 20 °C. Repaired DNA was purified using the 
QIAquick protocol , according to the previously described protocol.  
- 3' Ends Adenylation 
Fragment dA tailing was performed by adding 20 μl of reaction mix (11 μl of 
Nuclease-free water, 5 μl of 10× Klenow Polymerase Buffer, 1 μL of dATP, 3 μl 
of Exo(-) Klenow) to 30 μl of each end repaired blunt DNA sample. Reactions 
were incubated on a thermal cycler for 30 min at 37 °C, DNA was purified using 
the QIAquick protocol. 
- Adapters Ligation 
Ligation of the adaptors was performed by adding 37 μl of the reaction mix (15.5 
μl of Nuclease-free Water, 10 μL of 5X T4 DNA Ligase Buffer, 10 μl of 
SureSelect Adaptor Oligo Mix, 1.5 μl of T4 DNA Ligase) to 13 μl of each DNA 
sample. A 10:1 molar ratio of adaptor to genomic DNA insert is used, based on 
the initial DNA quantity of 3 μg. Samples were incubated for 15 min at 20 °C on a 
thermal cycler and purified by using Agencourt AMPure XP beads. 
- Size Selection 
The size selection was performed on a LabChip XT DNA Assay (750 chip, 
Caliper Life Sciences, Hopkinton, MA, USA) according to the manual. The 
LabChip XT XT DNA assays are based on traditional gel electrophoresis using a 
microfluidic network on a chip. Briefly, DNA samples are mixed with a sample 
buffer and loaded into each wells of the chip. DNA fragments are 
electrophoretically separated  and stained with an intercalating dye. Sizing and 
concentration for the sample is determined using a ladder and an internal marker. 
After every step, the fragments were purified following to the QIAquick protocol. 
- Library Amplification  
Briefly, 50 μl of the reaction mix (15 μl of Indexing Adaptor-ligated library, 21 μl 
of Nuclease-free water, 1.25 μl of SureSelect Primer, 1.25 μL of SureSelect ILM 
Indexing Pre Capture PCR Reverse Primer, 10 μl of 5X Herculase II Rxn Buffer, 
0.5 μl of  100 mM dNTP Mix, 1 μl of Herculase II Fusion DNA Polymerase) were 
added to 15 μl of each DNA sample. A third of the adaptor-ligated fragments are 
used for amplification. Samples were incubated in a thermal cycler with the 
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following program: 98 °C for 2 min, 10 cycles of 98 °C for 30 sec, 65 °C for 30 
sec, 72 °C for 1 min, and 72 °C for 10 min. DNA was purified by using the 
QIAquick protocol. 
- Quality control 
Quantity, quality and size distribution of the PCR products were assessed with 
2100 Bioanalyzer with the Agilent DNA 1000 Kit. The electropherogram should 
show a distribution with a peak size approximately 250 to 275 bp. Figure 3 
Analysis of amplified prepped library DNA using a DNA 1000 assay. The elec-
tropherogram shows a single peak in the size range of 250 to 275 bp. 
SureSelect hybridisation buffer was prepared according to the manufacturer 
instructions and heated to 65 °C for 5 minutes to prevent precipitate formation. 5 
μl of SureSelect capture library and 2 μl of 25% RNase block were mixed and 
placed on ice. 500 ng of DNA prepped library in a volume of 3.4 μl were added to 
the second row in the PCR plate, combined with 5.6 μl SureSelect block mix, 
heated on a thermal cycler at 95 °C for 5 min and held at 65 °C. Maintaining the 
tubes at 65 °C, 40 μl of hybridisation buffer were added to the first row in a PCR 
plate and temperature was maintained at 65 °C for additional 5 minutes. 7 μl of 
the capture library mix were added to the third row in the PCR plate, holding the 
tubes at 65 °C for additional 2 min. 13 μl of hybridisation mix were transferred 
from the first raw of the plate to the SureSelect capture library mix contained in 
the third raw, and the entire contents of each prepped library mix in the second 
raw was transferred to the hybridization solution in the third raw of the plate. The 
hybridization mixture was incubated for 24 hours at 65 °C. 
- Streptavidin bead capture 
Magnetic beads prepared by adding 200 of μl SureSelect binding buffer and 
vortexing tubes for 5 sec. Tubes were placed on a magnetic rack and beads 
allowed to settle before removing the supernatant, beads were washed 3 times and 
resuspended in 200 μl of SureSelect binding buffer. After the 24 hour incubation 
at 65 °C, the hybridisation mixture was added directly into the streptavidin bead 
solution. Tubes were incubated for 30 min at room temperature. Beads were 
separated by placing tubes on a magnetic rack and the supernatant was removed. 
Beads were then washed with 500 μl of SureSelect wash buffer 1, incubating at 
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room temperature for 15 min. After spin centrifuging, tubes were placed on a 
magnetic rack and the supernatant was removed. The second washing stage was 
performed by resuspending the beads in 500 μl of SureSelect wash buffer 2 and 
incubating tubes at 65 °C for 15 min. Beads were separated on a magnetic rack 
and the supernatant was removed. This step was repeated twice. 50 μl of 
SureSelect elution buffer was then added to the beads, that were vortex mixed and 
incubated at room temperature for 5 min. 
- Addition of Index Tags by Post-Hybridization Amplification 
The amplification reaction mix (22.5 μl of Nuclease-free H2O, 10 μl of 5X 
Herculase II Rxn Buffer, 0.5 μl of 100 mM dNTP Mix, 1 μl of Herculase II 
Fusion DNA Polymerase, 1 μl of SureSelect ILM Indexing Post Capture Forward 
PCR Primer, 10 μl of PCR Primer Index 1 through Index 16) was prepared 
according to the manufacturer’s instructions and kept on ice. 35 μl of the reaction 
mix and 1 μl of the appropriate index PCR Primer (Index 1 through Index 16) 
were added to each tube, containing 14 μl of each DNA. The tubes were incubated 
in a thermal cycler  with the following parameters: 98 °C for 2 min, 10 cycles of 
98 °C for 30 sec, 57 °C for 30 sec, 72 °C 1 min, and 72 °C for 10 min. Reactions 
were purified using using the QIAquick protocol, with a final elution volume of 
15 μl. 
- Libraries Pooling 
Multiplexed DNA libraries were normalized to 10 nM and combined such that 
each index-tagged sample is present in equimolar amounts in the pool.  
2.9.4.2 Sequencing 
3μl of the 10 nM multiplexed sample pool was diluted with 16 μl of Buffer EB 
(10mM Tris-Cl, ph 8.5), added with 1 μl of 2 N NaOH solution and incubated for 
5 minutes at room temperature. A 2 mM PhiX sample was also denatured with 1 
μl of 2 N NaOH. To 8 μl of denatured library, 992 μl of Hybridization Buffer 
were added to give a library concentration of 12 pM. The library and the PhiX 
were further diluted with Hybridization Buffer to give a concentration of 4 pM 
and and 1% of PhiX was added into the sample. The MiSeq reagent cartridge was 
prepared and 600 μl of the library were loaded into the cartridge. The flow cell, 
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the hybridization manifold, and the tube strip holder were installed onto the 
Cluster Station. A 150 bp paired-end reads was performed on a MiSeq sequencer, 
according to the manufacturer’s instructions. 
Data Analysis 
MiSeq Reporter generates intermediate analysis files in a FASTQ format, files 
have been demultiplexed (separated by sample), so that every file contains 
sequences of one sample. FASTQ files have been exported and were analysed 
using the NextGENe software (Softgenetics, PA, USA) with default parameters, 
which derived a consensus sequence for each sample. NextGENe software 
performed quality control of sequencing data, the removal of PCR duplicates and 
reads filtering for wrong orientation, wrong insert size, one mate or both mates 
unmapped, and for multiple hits on the reference genome, and output reads were 
aligned to the human reference genome NCBI37/hg19. The NextGENe software 
output VCF files that were uploaded on Cartagenia Bench Lab (Cartagenia, 
Leuven, Belgium), a commercial software set up in house that uses an automated 
filtering procedure in order to prioritize variants. Cartagenia BenchLab applies 
various filters developed by the Cardiogenetics laboratory to the large numbers of 
variants from NGS platforms in order to select only candidates that meet specific 
filtration criteria and to identify clinically relevant variants. The filters take into 
consideration the presence and the frequency of the variants in several public 
databases (1000 genomes, EVS, dbSNP), and an in house variant database. The 
output of the filtering pipeline is normally composed of a dozen of variants. 
The sensitivity and specificity of TR with respect to Sanger sequencing were 
already assessed (Sikkema-Raddatz et al., 2013). 
2.10 Statistical Analysis 
Kruskal Wallis test was used to assess the significance of differences between 
subgroups. A 2-tailed probability value <0.05 was regarded as statistically 
significant. 
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3. RESULTS 
3.1 Cohort 
Ninty-nine unrelated index cases with a clinical diagnosis of AC, 77 males, 22 
females; ratio 4:1; average age at diagnosis 41±17 years (range 12-78), referred 
for molecular genetic screening to the Cardiovascular Genetics Laboratory 
(University of Padua) between years 2012 and 2014. 
 
Index cases N=99 
Autopsy diagnosis N=26 
Gender: 
male, n (%) 
  26 (100%) 
Age    28±11 (12-60) 
 LD  N=13 22±6 (17-40) 
 RD  N=0  
 BIV N=13 29±12 (15-60) 
Clinical diagnosis N=73 
Gender: 
male, n (%) 
51 (70%) 
Age 41±17 (12-78) 
Cardiac 
transplantation 
 14 (14%) 
2010 AC criteria Definite  63 (87%) 
 Borderline  3 (4%) 
 Possible  7 (9%) 
  I Global and/or Regional 
Dysfunction and Structural 
Alterations 
60 (36M, 24m) 
  II Fibrofatty replacement 
on endomyocardial biopsy, 
n (%) 
6 
  III Repolarization 
abnormalities, n (%) 
44 (36M,8m) 
  IV 
Depolarization/Conduction 
Abnormalities 
32 (7M,25m) 
  V Arrhythmias 55 (22M, 32m) 
  VI Family History 14 (9M, 5m) 
Table 3.1: Demographic (sex, age) and clinical characteristics of 99 patients. LD- left dominant 
pattern of AC, RD- right dominant pattern of AC, BIV- AC with biventricular involvement.  
 
Seventy-three of the 99 subjects were enrolled at the Referential Clinical Genetic 
Centre of Arrhythmic Cardiomyopathies (Cardiology Unit), of which 14 
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underwent cardiac transplantation and the rest 26 of the 99 index cases were 
enrolled at the Veneto Registry of Cardio-Cerebro-Vascular Pathology 
(Cardiovascular Pathology Unit).  
Clinical diagnosis of AC was defined according the 2010 Task Force major and 
minor criteria (Marcus et al., 2010), as previously described. Diagnostic criteria 
classified the 73 clinically affected index cases as follows: 63 definite, 3 
borderline, 7 possible (Table 3.1). Twenty-six SCD probands, all males, with an 
abnormal disease pattern were grouped based on morphological features as AC 
with left dominant form (n=13) and AC with biventricular involvement (n=13). 
 
3.2 Genetic screening of 5 desmosomal and 3 extra desmosomal genes 
All 99 subjects underwent genetic screening for 5 desmosomal encoding genes, 
whereas 3 extra desmosomal genes were investigated in 46 of the 99 subjects. 
DNA was extracted from blood in 76 samples, from frozen myocardium in 9 
samples, and from FFPE myocardium in 14 samples. Screening was performed by 
DHPLC, followed by Sanger sequencing of DNA samples showing abnormal 
elution pattern and GC rich amplicons. 
DHPLC analysis detected overall 193 anomalous elution profiles and subsequent 
direct sequencing confirmed the presence of nucleotide variants within the 8 genes 
as follows: 69 (36%) were located in DSP, 37 in DSG2 (19%), 35 in PKP2 (18%), 
19 in DSC2 (10%), 13 in JUP (7%), 12 in DES (6%), 7 in CTNNA3 (4%) and 1 
only in PLN.  
Seventy-two of the 193 (37%) variants were intronic, 6 (3%) resided in splicing 
sites and 3 (2%) were located in the untranslated regions (UTR) of the gene. The 
rest 112 (58%) variants were located within the coding regions, of which 60 
(54%) were missense, 37 (33%) synonymous, 9 (8%) frame shift, 6 (5%) 
nonsense.  A summary of nucleotide variants detected in the 8 genes is reported in 
table 3.2 (in appendix), and in figure 3.1. 
Variants in DSP 
Genetic screening of all 24 DSP gene exons identified 69 (36%) variants in 99 
index subjects of which 23 were intronic, 2 were splicing site variants, 2 were 
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located in the UTR, 18 were missense, 19 synonymous, 3 frameshift and 2 
nonsense. 
Variants in PKP2 
The 14 exons of PKP2 gene were examined for variants in all 99 index subjects. 
A total of 35 (18%) variants were identified, 10 of them were intronic, 2 were 
located on splicing sites, 14 of them were missense, 4 frameshift, 1 synonymous 
and 3 nonsense. 
Variants in DSG2 
The 15 exons of DSG2 gene were examined for variants in all 99 index subjects. 
A total of 37 (19%) variants were identified in DSG2, 18 of them were intronic, 2 
were located on splicing sites, while 16 were located within the coding region. 
Twelve of them were missense, 4 synonymous, 1 nonsense variant that was found 
in homozygosity. 
Variants in DSC2 
The 14 exons of DSC2 gene were examined for variants in all 99 index subjects. 
A total of 19 (10%) variants were identified, 6 of them were intronic, and the 
remaining 13 were located in the coding region. 8 variants were missense, 1 
frameshift, 4 synonymous, 0 nonsense. Eighteen of the 19 nucleotide variants 
were found in heterozygosis. 
Variants in JUP 
The 14 exons of JUP gene were examined for variants in all 99 index subjects. A 
total of 13 (7%) variants were identified, 5 of them were intronic, 1 was located in 
the UTR, and the remaining 7 were exonic: 6 variants were missense and 1 was 
synonymous. 
Variants in DES 
The 7 exons of DES were examined for variants in all 46 index subjects. 12 (7%) 
variants were identified, 4 intronic variant and 8 missense exonic variants . 
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Variants in CTNNA3 
The 14 exons of CTNNA3 gene were examined for variants in 46 index subjects. 7 
(3%) variants were identified, 5 of them were intronic, and the 2 exonic variants 
were missense. 
Variants in PLN 
Ninty-nine index AC cases underwent genetic screening for the unique coding 
exon of PLN, but only an intronic variant was identified. 
 
 
Figure 3.1: The 193 variants detected in 8 genes, sorted per gene and type (intronic, missense, 
synonymous, frameshift, nonsense, splicing, UTR). 
 
3.2.1 Variants filtering  
A first filtering step based on the position and function of nucleotide variants, 
excluded 72 of the 193 unique variants due intronic localization without predicted 
functional effects on the normal splicing of the transcript, 3 variants were 
excluded due to UTRs localization and 37 synonymous variants were excluded as 
not changing the functional properties of the protein. The rest 81 variants are 
listed below (Tabe 3.3, Figure 3.2). 
 
Gene cDNA change 
Predicted 
protein 
change 
Ex dbSNP ID Type 
Index case/ 
tot 
Reference 
DSP c.88 
G>A 
p.V30M 1 rs121912998 M 2/99 Yang et 
 al., 2006 
DSP c.423-1 
G>A 
r.spl 4  Sp 1/99 Bauce et  
al., 2005 
DSP c.448 
C>T 
p.R150X 4  N 1/99 Pilichou et  
al., 2014 
DSP c.897  
C>G 
p.S299R 7 rs121912992 M 1/99 Rampazzo 
 et al., 2002 
DSP c.913 
A>T 
p.I305F 7 rs17604693 M 7/99 Rampazzo et 
 al., 2002 
DSP c.939+1 
G>A 
 7  Sp 1/99 Sen-Chowdhry  
et al., 2008 
DSP c.2203 
G>A 
p.G735S 16  M 1/99 Novel 
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DSP c.2956 
C>T 
p.Q986X 21  N 1/99 Campuzano et  
al., 2013 
DSP c.3297_3298 insTTGT p.C1100LfsX11 23  Fs 1/99 Novel 
DSP c.3774 
C>A 
p.D1258E 23  M 1/99 Rampazzo 
 et al., 2008 
DSP c.3862 
A>C 
p.K1288Q 23 rs138907450 M 1/99 Bao et  
al., 2013 
DSP c.4372 
C>G 
p.R1458G 23 rs28763965 M 1/99 Cox et  
al., 2011 
DSP c.4535 
A>G 
p.Y1512C 23 rs2076299 M 2/99 Yu et al., 
 2008 
DSP c.4961 
 T>C 
p.L1654P 23  M 1/99 Rampazzo et al., 
2008 
DSP c.4973 
 C>T 
p.S1658F 23 rs202084959 M 1/99 Rigato et  
al., 2013 
DSP c.5134 
A>C 
p.N1712H 23  M 1/99 Novel 
DSP c.5178 
C>A 
p.N1726K 23 rs147415451 M 1/99 Klauke et 
al., 2010 
DSP c.5213 
G>A 
p.R1738Q 23 rs6929069 M 13/99 Den Haan  
et al., 2009 
DSP c.5218 
G>A 
p.E1740K 23 rs142885240 M 2/99 Cox et  
al., 2011 
DSP c.5498 
A>T 
p.E1833V 24 rs78652302 M 2/99 Gehmlich  
et al.,2010 
DSP c.5511 
dup 
p.R1838SfsX19 24  Fs 1/99 Novel 
DSP c.6701 
A>G 
p.N2234S 24  M 63/99 Novel 
DSP c.7039 
A>G 
p.I2347V 24  M 1/99 Rigato et  
al., 2013 
DSP c.7461_7464 
del 
p.D2489MfsX17 24  F 1/99 Novel 
DSP c.7622 
 G>A 
p.R2541K 24 rs142078450 M 1/99 Rampazzo 
 et al., 2008 
PKP2 c.76 
G>A 
p.D26N 1 rs143004808 M 5/99 van Tintelen  
et al., 2006 
PKP2 c.83 
del 
p.S29AfsX10 1  Fs 1/99 Novel 
PKP2 c.109 
A>T 
p.K37X 1  N 1/99 Novel 
PKP2 c.147_150 
del 
p.T50SfsX61 1  Fs 3/99 Novel 
PKP2 c.175 
C>T 
p.Q59X 1  N 2/99 Rigato et 
 al., 2013 
PKP2 c.184 
 C>A 
p.Q62K 1 rs199601548 M 1/99 Van Tintelen 
 et al., 2006 
PKP2 c.209 
G>T 
p.S70I 1 rs75909145 M 4/99 Koopman 
 et al., 2007 
PKP2 c.535 
C>A 
p.H179N 3  M 1/99 Novel 
PKP2 c.1012 
A>G 
p.T338A 3 rs139851304 M 1/99 
 
Bhuiyan et  
al., 2013 
PKP2 c.1097 
T>C 
p.L366P 4 rs1046116 M 21/99 Koopman  
et al., 2007 
PKP2 c.1576 
A>G 
p.T526A 7  M 1/99 Ostrowska Dahlgren 
et al., 2012 
PKP2 c.1583 
C>T 
p.T528M 7  M 1/99 Novel 
PKP2 c.1592 
T>G 
p.I531S 7 rs148240502 M 2/99 Lahtinen et 
 al., 2008 
PKP2 c.1643 
del 
p.G548VfsX15 7  Fs 2/99 Gerull et 
 al., 2004 
PKP2 c.1820 
G>A 
p.C607Y 9  M 1/99 Novel 
PKP2 c.1841 
T>C 
p.L614P 9  M 1/99 Ma et al.,  
2013 
PKP2 c.2009 
del 
p.N670TfsX14 10  Fs 1/99 Basso et  
al., 2006 
PKP2 c.2111 
G>A 
p.G704E 10  M 1/99 Novel 
PKP2 c.2119 
C>T 
p.Q707X 10 rs397517017 N 1/99 Basso et 
 al., 2006 
PKP2 c.2145+3_+6 
dup 
 10  I 1/99 Novel 
PKP2 c.2299+1 
G>T 
 11  Sp 1/99 Novel 
PKP2 c.2365 
A>G 
p.I789V 12  M 1/99 Novel 
PKP2 c.2489+1 
G>A 
 12 rs111517471 Sp 1/99 Gerull et 
 al., 2004 
PKP2 c.2552 
C>T 
p.T851M 13 rs146118033 M 1/99  
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DSG2 c.44 
T>A 
p.L15Q 1  M 1/99 Bhuiyan  
et al., 2009 
DSG2 c.166 
G>A 
p.V56M 3 rs121913013 M 2/99 Syrris et 
 al. 2007 
DSG2 c.245 
G>T 
p.G82V 4  M 1/99 Novel 
DSG2 c.378+2 
T>G 
 4  Sp 1/99 Cox et 
 al., 2011 
DSG2 c.722 
C>T 
p.A241V 7  M 1/99 Novel 
DSG2 c.797 
 A>G 
p.N266S 7 rs121913011 M 1/99 Pilichou 
 et al., 2006 
DSG2 c.875 
G>A 
p.R292H 8 rs185821167 M 1/99 Jiménez-Jáimez 
et al., 2014 
DSG2 c.877 
A>G 
p.I293V 8 rs2230234 M 21/99 Posch et  
al., 2008 
DSG2 c.1543 
G>A 
p.V515I 11 rs2230235 M 1/99  
DSG2 c.1652-1 
G>T 
 12  Sp 1/99 Novel 
DSG2 c.1672 
C>T 
p.Q558X 12  N 1/99 Pilichou et  
al.,  2006 
DSG2 c.2137 
G>A 
p.E713K 14 rs79241126 M 8/99 Basso et  
al., 2006 
DSG2 c.2318 
G>A 
p.R773K 14 rs2278792 M 18/99 Yu et al., 
 2008 
DSG2 c.2368 
C>T 
p.H790Y 15 rs114544564 M 1/99 Den Haan  
et al., 2009 
DSG2 c.2759 
T>G 
p.V920G 15 rs142841727 M 1/99 Syrris et al., 2007 
DSC2 c.32 
A>G 
p.N11S 1 rs868333 M 1/99 Den Haan 
 et al., 2009 
DSC2 c.536 
A>G 
p.D179G 5  M 2/99 De Bortoli  
et al., 2010 
DSC2 c.1787 
C>T 
p.A596V 12 rs148185335 M 2/99 den Haan 
 et al., 2009 
DSC2 c.2194 
T>G 
p.L732V 14 rs151024019 M 1/99 Bhuiyan 
 et al., 2009 
DSC2 c.2326 
A>G 
p.I776V 15 rs1893963 M 9/99 Yu et al., 
 2008 
DSC2 c.2393 
G>A 
p.R798Q 15 rs61731921 M 5/99 Posch et  
al., 2008 
DSC2 c.2596 
G>C 
p.A866P 16  M 1/99 Novel 
DSC2 c.2603 
C>T 
p.S868F 16 rs141873745 M 1/99 Fressart et 
 al., 2010 
DSC2 c.2686_2687 
dup 
p.A897KfsX4 16 rs200056085 Fs 
 
1/99 Syrris et 
 al., 2006 
JUP c.425 
G>A 
p.R142H 2 rs41283425 M 4/99 Koopmann  
et al., 2007 
JUP c.1372 
G>A 
p.A458T  rs139559495 M 1/99  
JUP c.1960 
G>A 
p.E654K 12 
 
 M 1/99 Novel 
JUP c.2069 
A>G 
p.N690S 13 rs147628503 M 1/99  
JUP c.2089 
A>T 
p. M697L 14 rs1126821 M 50/99 Koopmann 
 et al., 2007 
JUP c.2124 
T>A 
p.D708E 14  M 1/99 Novel 
CTNNA3 c.478 
T>A 
p.S160T 5 rs61749223 M 1/99  
CTNNA3 c.1787 
G>A 
p.S596N 13 rs4548513 M 24/99  
Table 3.3: The 81 unique variants resulting from the I-filtering step, will be subjected to 3 more 
filtering steps, Ex: exon, I: Intronic, S: synonymous, M: missense, UTR: untranslated region, N: 
nonsense, Fs: frameshift, Sp: splicing. 
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Figure 3.2: Distribution among genes of the 81 variants putative as pathogenic after the I filtering 
step. 
 
3.2.2 Alelic frequency variant filtering 
A second step filtering based on alelic frequency over the disease specific cut-of 
(0.02%), excluded 29 (36%) of the 81 variants. The excluded variants, listed on 
table 3.4 and figure 3.3, were searched in the 1000 genomes and EVS databases or 
in the internal control dataset, and were classified as not pathogenic due to high 
frequency in the general population. 
 
Of these worth mentioning that the duplication c.2686_2687dup in DSC2 gene 
leading to a frame-shift (p.A897KfsX4) was also excluded due to high MAF 
(0.006/12). Indeed this variant which was recently identified in 1.5% of the Italian 
healthy control subjects, was demonstrated to afect only DSC2 isoform a, while 
isoform b, more expressed in the heart, was not altered (De Bortoli et al., 2010). 
One variant however (p.V30M in DSP), excluded due to high MAF (0.00220), 
was re-admited as pathogenic given the curent literature information (Yang et 
al., 2006). This p.V30M variant, located in the N-terminal of DSP, was 
demonstrated in vitro to disrupt the binding ability of DSP; this last, showed a 
prevalent cytoplasmic localization instead of the normal cel membrane 
distribution, suggesting p.V30M is afecting the interaction and localization of 
DSP. According to these evidences and its labeling as ‘Pathogenic’ in the ClinVar 
database (last update Aug 9, 2013), the p.V30M variant was considered 
potentialy pathogenic in this study. 
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Gene cDNA change Predicted 
protein 
change 
Ex dbSNP ID MAF Type Index case/ 
tot 
Reference 
DSP c.88 
G>A 
p.V30M 1 rs121912998 0.0022 
/11 
M 2/99 Yang et 
 al., 2006 
DSP c.913 
A>T 
p.I305F 7 rs17604693 0.0184 
/92 
M 7/99 Rampazzo et 
 al., 2002 
DSP c.3862 
A>C 
p.K1288Q 23 rs138907450 0.0004 
/2 
M 1/99 Bao et  
al., 2013 
DSP c.4372 
C>G 
p.R1458G 23 rs28763965 0.0018 
/9 
M 1/99 Cox et  
al., 2011 
DSP c.4535 
A>G 
p.Y1512C 23 rs2076299 0.2033 
/1018 
M 2/99 Yu et al., 
 2008 
DSP c.5213 
G>A 
p.R1738Q 23 rs6929069 0.222 
/483 
M 13/99 Den Haan  
et al., 2009 
DSP c.5498 
A>T 
p.E1833V 24 rs78652302 0.008 
/18 
M 2/99 Gehmlich  
et al.,2010 
PKP2 c.76 
G>A 
p.D26N 1 rs143004808 0.003 
/6 
M 5/99 van Tintelen  
et al., 2006 
PKP2 c.209 
G>T 
p.S70I 1 rs75909145 0.009 
/20 
M 4/99 Koopman 
 et al., 2007 
PKP2 c.1012 
A>G 
p.T338A 3 rs139851304 0.001 
/2 
M 1/99 
 
Bhuiyan et  
al., 2013 
PKP2 c.1097 
T>C 
p.L366P 4 rs1046116 0.143 
/312 
M 21/99 Koopman  
et al., 2007 
PKP2 c.1592 
T>G 
p.I531S 7 rs148240502 0.003 
/6 
M 2/99 Lahtinen et 
 al., 2008 
DSG2 c.875 
G>A 
p.R292H 8 rs185821167 0.001 
/1 
M 1/99 Jiménez-Jáimez 
et al., 2014 
DSG2 c.877 
A>G 
p.I293V 8 rs2230234 0.039 
/84 
M 21/99 Posch et  
al., 2008 
DSG2 c.1543 
G>A 
p.V515I 11 rs2230235 0.0098 
/49 
M 1/99  
DSG2 c.2137 
G>A 
p.E713K 14 rs79241126 0.038 
/82 
M 8/99 Basso et  
al., 2006 
DSG2 c.2318 
G>A 
p.R773K 14 rs2278792 0.272 
/594 
M 18/99 Yu et al., 
 2008 
DSG2 c.2368 
C>T 
p.H790Y 15 rs114544564 0.002 
/4 
M 1/99 Den Haan  
et al., 2009 
DSG2 c.2759 
T>G 
p.V920G 15 rs142841727 0.0032 
/16 
M 1/99 Syrris et al., 
2007 
DSC2 c.32 
A>G 
p.N11S 1 rs868333 0.077 
/169 
M 1/99 Den Haan 
 et al., 2009 
DSC2 c.1787 
C>T 
p.A596V 12 rs148185335 0.001 
/3 
M 2/99 den Haan 
 et al., 2009 
DSC2 c.2194 
T>G 
p.L732V 14 rs151024019 0.001 
/1 
M 1/99 Bhuiyan 
 et al., 2009 
DSC2 c.2326 
A>G 
p.I776V 15 rs1893963 0.19 
/415 
M 9/99 Yu et al., 
 2008 
DSC2 c.2393 
G>A 
p.R798Q 15 rs61731921 0.029 
/64 
M 5/99 Posch et  
al., 2008 
DSC2 c.2686_2687 
dup 
p.A897KfsX4 16 rs200056085 0.006 
/12 
Fs 
 
1/99 Syrris et 
 al., 2006 
JUP c.425 
G>A 
p.R142H 2 rs41283425 0.028 
/61 
M 4/99 Koopmann  
et al., 2007 
JUP c.2089 
A>T 
p. M697L 14 rs1126821 0.429 
/936 
M 50/99 Koopmann 
 et al., 2007 
CTNNA3 c.478 
T>A 
p.S160T 5 rs61749223 0.011 
/25 
M 1/99  
CTNNA3 c.1787 
G>A 
p.S596N 13 rs4548513 0.473 
/1032 
M 24/99  
Table 3.4: 29 variants excluded due to high MAF (>0.02%) after the II- filtering step, Ex: exon, 
M: missense, Fs: frameshift. 
 
The remaining 53 unique variants after the II filtering step, are distributed 
exclusively in the 5 major desmosomal genes. The spectrum of heterozygous 
variants distribution is now changed showing a higher prevalence of PKP2 (19, 
36%), followed by DSP (19, 36%), DSG2 (8, 15%), DSC2 (3, 6%), JUP (4, 7%) 
(Figure 3.3). 
After MAF-filtering, DSP variants were reduced to 19 instead of 25 previously 
observed (see 3.2.1); of these, 12 were missense, 2 nonsense, 3 frameshift, 2 
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splicing site variants. Regarding PKP2 variants, 19 of 24 passed this filtering step: 
9 missense, 3 nonsense, 4 deletions leading to a frameshift and 3 variants 
predicted to affect splicing sites. DSG2 gene filtered variants were 8 instead of 15, 
of which 5 missense, 1 nonsense, and 2 splicing site variants. Finaly only 3 DSC2 
and 4 JUP missense variants passed to the next filtering step and none in the extra 
desmosomal genes CTNNA3, DES and PLN. 
 
The 53 nucleotide variants obtained from MAF-filtering were observed in 54 AC 
index cases (54%). Of note, assuming a less stringent MAF as 0.02%-0.1% 20 
more variants were observed in 20 additional AC patients (73%). 
 
 
Figure 3.3: Distribution among genes of the 53 remaining variants found in our AC cohort after the 
II-filtering step. 
 
3.2.3 Evolutionary conservation based filtering 
Amino acid conservation analysis excluded 9 more missense variants, as shown in 
table 3.5 and figure 3.4, and subsequently reduced the amount of putative 
pathogenic variants into 4. 
Among the 44 diferent putative pathogenic variants obtained, 18 occured in 
DSP, 16 in PKP2, 6 in DSG2, 3 in DSC2, 1 in JUP. Twenty-four (54%) of them 
changed a single nucleotide resulting in a codon that codes for a diferent amino 
acid (missense mutations), 7 (16%) of them were smal insertions or deletions that 
cause a shift of the reading frame (frameshift), 6 (14%) were nonsense mutations 
creating a premature stop codon (nonsense), 7 (16%) occured in putative donor or 
acceptor splicing site located within the exon-intron boundaries (±10bp). 
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 Thus one or more of the 44 variants resulting from the evolutionary conservation-
filtering step were present in 49 index AC cases (49%) whereas 9 variants were 
excluded in 8 AC probands. 
 
Gene cDNA change Predicted 
protein 
change 
Ex Amino acid 
conservation 
Type Index case/ 
tot 
Reference 
DSP c.7622 
 G>A 
p.R2541K 24 Weakly 
conserved 
M 1/99 Rampazzo 
 et al., 2008 
PKP2 c.535 
C>A 
p.H179N 3 Not 
Conserved 
M 1/99 Novel 
PKP2 c.2365 
A>G 
p.I789V 12 Weakly 
conserved 
M 1/99 Novel 
PKP2 c.2552 
C>T 
p.T851M 13 Weakly 
conserved 
M 1/99  
DSG2 c.44 
T>A 
p.L15Q 1 Not 
Conserved 
M 1/99 Bhuiyan  
et al., 2009 
DSG2 c.245 
G>T 
p.G82V 4 Weakly 
conserved 
M 1/99 Novel 
JUP c.1960 
G>A 
p.E654K 12 
 
Weakly 
conserved 
M 1/99 Novel 
JUP c.2069 
A>G 
p.N690S 13 Weakly 
conserved 
M 1/99  
JUP c.2124 
T>A 
p.D708E 14 Weakly 
conserved 
M 1/99 Novel 
Table 3.5: Variants excluded after the III- filtering step. the 9 variants with MAF >0.02% afecting 
not conserved or weakly conserved amino acids among species, , Ex: exon, M: missense. 
 
 
Figure 3.4: Distribution among genes of the 44 resting variants found in our AC cohort after the 
III- filtering step. 
 
3.2.4 In silico-based filtering of variants 
The resting 4 variants resulting from the previous steps were further classified 
according to specific features using an in silico algoritm proposed by van 
Spaendonck-Zwarts (see 2.5.6, van Spaendonck-Zwarts et al., 2013), into 4 
diferent classes VUS0 VUS1 VUS2 VUS3. Variants pathogenic classification in 
table 3.6 and figure 3.5, is based on additional evaluation of the protein 
conformational and functional alteration. 
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Gene VUS0 VUS1 VUS2 VUS3 Pathogenic 
DSP  c.5218G>A, 
p.E1740K 
 
c.5134A>C, 
p.N1712H 
 
c.7039A>G, 
p.I2347V 
c.2203G>A, 
p.G735S 
 
c.3774C>A, 
p.D1258E 
c.4961T>C, 
p.L1654P 
 
c.4973C>T, 
p.S1658F 
 
c.5178C>A, 
p.N1726K 
 
c.423-1G>A, 
r.spl 
 
c.448C>T, 
p.R150X 
 
c.939+1G>A, 
r.spl 
 
c.2956C>T, 
p.Q986X 
 
c.3297_3298insTTGT, 
p.C1100LfsX11 
 
c.5511dup, 
p.R1838SfsX19 
 
c.6701A>G, 
p.N2234S 
 
c.7461_7464del, 
p.D2489MfsX17 
c.88G>A, 
p.V30M 
 
c.897C>G, 
p.S299R 
PKP2 c.1576A>G, 
p.T526A 
 
 
c.184C>A, 
p.Q62K 
c.2145+3_2145+6dup, 
r.spl? 
 c.83del, 
p.S29AfsX10 
 
c.109A>T, 
p.K37X 
 
c.147_150del, 
p.T50SfsX61 
 
c.175C>T, 
p.Q59X 
 
c.1583C>T, 
p.T528M 
 
c.1643del, 
p.G548VfsX15 
 
c.1820G>A, 
p.C607Y 
 
c.1841T>C, 
p.L614P 
 
c.2009del, 
p.N670TfsX14 
 
c.2111G>A, 
p.G740E 
 
c.2119C>T, 
p.Q707X 
 
c.2299+1G>T, 
r.spl 
 
c.2489+1G>A, 
r.spl 
 
DSG2  c.166G>A, 
p.V56M 
c.722C>T, p.A241V 
 
c.378+2T>G, 
r.spl 
 
c.1652-1G>T, 
r.spl 
 
c.1672C>T, 
p.Q558X 
c.797A>G, 
p.N266S 
DSC2   c.2603C>T,  
p.S868F 
 
c.536A>G, 
p.D179G 
 
c.2596G>C, 
p.A866P 
 
JUP   c.1372G>A, 
p.A458T 
  
Table 3.6: Final classification of the resulting variants as pathogenic based on  in silico analysis.  
 
Note that only variants classified as VUS3 and VUS2 were considered pathogenic 
or potentially pathogenic for further genoype-phenotype correlation studies, 
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whereas 5 classified as VUS1 and 2 classified as VUS0 were excluded from this 
study. Therefore only 37 of the 193 variants initialy identified in disease-causing 
genes were considered pathogenic or potentialy pathogenic variants. Forty-two 
index AC cases (42%) caried one or more of these 37 variants and were finaly 
considered as positively genotyped. 
 
 
Figure 3.5: Distribution among genes of the 37 resulting variants found in our AC cohort after the 
IV- filtering step. 
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3.3 CNVs Analysis 
The entire cohort of 99 patients with AC was screened for large intragenic 
rearrangements in desmosomal genes by MLPA. 
Five of the 99 probands (6%) displayed an aberrant MLPA profile, indicating a 
copy number alteration of the gene due to the lack of one exon or eventualy the 
entire gene. These 5 index AC cases carying deletions of one or more 
exons/genes were considered as positively genotyped, increasing from 42 to 46 
(46%) the number of positively genotyped patients (see 3.2.4). 
Specificaly, a 120kb- heterozygous deletion on chr12 containing the entire PKP2 
gene was detected in 2 patients (#36, #42). Bioinformatics means estimated this 
deletion as a gene dosage reduction ranging from 0.3 to 0.6. The deletion of PKP2 
gene in these 2 patients was further confirmed by relative qPCR for 3 PKP2 exons 
(Figure 3.6 and Figure 3.7) and resulted absent in 500 healthy subjects. 
 
Figure 3.6: MLPA analysis of sample #36 a) Schematic representation of the deleted chromosomal 
region b) Raw data of MLPA runs c) Histograms ploting the DQ of the fragments corresponding 
to every exon analyzed and layout of Coffalyzer results d) qPCR validation of MLPA results, in 
red the ratio between the test sample and the reference sample. 
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Figure 3.7: MLPA analysis of sample #42 a) Schematic representation of the deleted chromosomal 
region b) Raw data of MLPA runs c) Histograms ploting the DQ of the fragments corresponding 
to every exon analyzed and layout of Coffalyzer results d) qPCR validation of MLPA results, in 
red the ratio between the test sample and the reference sample. 
 
Another patient (#39) caried a large heterozygous deletion of at least 482kb on 
chr18 which comprise both DSC2 and DSG2 genes. Bioinformatics evaluation 
estimated the gene dosage reduction ratios of 0.35 and 0.51 respectively. qPCR 
performed for 3 DSC2 and 3 DSG2 exons confirmed the deletion of both genes, 
and its absence in 500 healthy subjects. 
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Figure 3.8. MLPA analysis of sample #39 a) Schematic representation of the deleted chromosomal 
region b) Raw data of MLPA runs c) Histograms ploting the DQ of the fragments corresponding 
to every exon analyzed and layout of Coffalyzer results d) qPCR validation of MLPA results, in 
red the ratio between the test sample and the reference sample. 
 
Finaly, a single-exon heterozygous deletion was detected in 2 patients (#8 and 
#38); the deletion of only exon 4 of PKP2 gene (c.1286_1491del) is predicted to 
shift the reading frame of the protein translation and create a premature stop 
codon, ending up with a 350 amino acid-long peptide instead of a 837 amino acid 
protein (Figure 3.9 and 3.10). A ratio of 0.3 and 0.6 was estimated in these two 
patients by bioinformatics analysis. qPCR analysis for the specific exon showed a 
clear-cut reduction compared to 500 healthy control individuals, whereas the other 
two exon of the same patients did not show quantitative shifts. 
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Figure 3.9: MLPA analysis of sample #8 a) Schematic representation of the deleted chromosomal 
region b) Raw data of MLPA runs c) Histograms ploting the DQ of the fragments corresponding 
to every exon analyzed and layout of Coffalyzer results d) qPCR validation of MLPA results, in 
red the ratio between the test sample and the reference sample. 
 
 
 
Figure 3.10: MLPA analysis of sample #38 a) Schematic representation of the deleted 
chromosomal region b) Raw data of MLPA runs c) Histograms ploting the DQ of the fragments 
corresponding to every exon analyzed and layout of Coffalyzer results d) qPCR validation of 
MLPA results, in red the ratio between the test sample and the reference sample. 
 
In order to characterize the efect of this exon-specific deletion at the transcript 
level, cDNA of the patients carying the deletion was amplified with specific 
primers. Agarose gel electrophoresis clearly showed two diferent fragments at 
107 
 
approximately 387 bp and 222 bp, representing the normal transcript containing 
exon 4 (longest fragment) and the transcript lacking exon 4 of PKP2 (shortest 
fragment). Direct sequencing of these two cDNA fragments demonstrated the 
absence of exon 4 in one allele of both AC patients. (Figure 3.11). 
 
Figure 3.11: Agarose gel run showing the different PCR products and cDNA sequence of the 
222bp PCR product showing the lack of ex4 in the transcript. PC: positive control sample, PT: 
patient sample. 
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3.4 Variant analysis in the study population 
Major AC-related genes were screened in 99 index cases for point mutations by 
DHPLC and direct sequencing, and for large deletions or duplications by MLPA 
and qPCR. Subsequent stringent variants filtering led to the identification of 36 
point mutations and 3 CNVs (Table 3.7) classified as pathogenic mutations.  
 
Index 
case 
DSP PKP2 DSG2 DSC2 JUP 
N 
variants 
62 SD  
c.175 C>T, 
p.Q59X 
   1 
68 SD 
c.939+1G>A, 
r.spl 
    1 
70 SD  
c.2009 del, 
p.N670TfsX14 
   1 
2    
c.536 A>G, 
p.D179G H 
 1 
1  
c.1643 del, 
p.G548VfsX15 
   1 
16  
c.2111 G>A, 
p.G704E 
   1 
4    
c.536 A>G, 
p.D179G H 
 1 
20  
c.83 del, 
p.S29AfsX10 
   1 
5  
c.175 C>T, 
p.Q59X 
   1 
57 
c.7461_7464 del, 
p.D2489MfsX17 
   
c.1372 G>A, 
p.A458T 
2 
7 
c.6701 A>G, 
p.N2234S 
c.109 A>T, 
p.K37X 
   2 
8  
Deletion 
 ex4 
   1 
89 CT  
c.1643 del, 
p.G548VfsX15 
   1 
59 SD    
c.2603 C>T, 
p.S868F 
 1 
13 
c.3774 C>A, 
p.D1258E 
    1 
14  
c.1820 G>A, 
p.C607Y 
   1 
15 
c.5178 C>A, 
p.N1726K 
    1 
74 SD   
c.722 C>T, 
p.A241V 
  1 
75 SD  
c.2299+1 G>T, 
r.spl 
   1 
23  
c.147_150del, 
p.T50SfsX61 
   1 
24 
c.88 G>A, 
p.V30M 
 
c.378+2 T>G, 
r.spl 
  2 
25 
c.2203 G>A, 
p.G735S 
    1 
76 SD 
c.448 C>T, 
p.R150X 
    1 
40  
c.2489+1 G>A, 
r.spl 
   1 
80 CT   
c.1672 C>T, 
p.Q558X H 
  1 
28  
c.1583 C>T, 
p.T528M 
   1 
29 
c.3297_3298 
insTTGT,  
p.C1100LfsX11 
    1 
30  
c.147_150 del,  
p.T50SfsX61 
   1 
82 CT 
c.5511 dup, 
p.R1838SfsX19 
  
c.2596 G>C, 
p.A866P 
 2 
61 SD   
c.1652-1 G>T, 
r.spl 
  1 
83 CT 
c.2956 C>T, 
p.Q986X 
    1 
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32  
c.1841 T>C, 
p.L614P 
   1 
36 
c.88G>A, 
p.V30M 
Deletion  
ex1-14 
   2 
38  
Deletion  
ex4 
   1 
42  
Deletion  
ex1-14 
   1 
39   
Deletion 
 ex1-15 
Deletion 
 ex1-16 
 2 
49  
c.147_150del,  
p.T50SfsX61 
   1 
90 SD 
c.897 C>G, 
p.S299R 
    1 
98 SD 
c.897 C>G, 
p. S299R 
    1 
91 SD 
c.423-1 G>A, 
r.spl 
    1 
92 SD  
c.2009 del, 
p.N670TfsX14 
   1 
93 SD 
c.4973 C>T , 
S1658F; 
c.7039 A>G, 
I2347V 
    2 
95 CT 
c.88G>A, 
p.V30M 
    1 
96 CT   
c.797 A>G, 
p.N266S 
  1 
97 CT 
c.4961 T>C, 
L1654P 
c.2119 C>T, 
Q707X 
   1 
44  
c.1643 del, 
p.G548VfsX15 
    
Single 
Mutation 
Carriers 
11 20 4 3 0  
Multiple 
Mutation 
Carriers 
     8 
Table 3.7: Positive genotyped subjects. SD sudden death, CT cardiac transplantation H homozygous 
 
All 39 pathogenic variants were detected in 46 subjects of our cohort (46%). 
Forty-two of the 46 mutation carriers harbor one or more point mutations, 3 
probands carried larger deletions of one or more genes and 1 patient showed both 
a point mutation in DSP and a complete deletion of the PKP2-containing allele.  
Of these 46 positively genotyped patients, 20 (20%) were single mutation carriers 
for PKP2, 11 (11%) were single mutation carriers DSP and 4 probands (2%) 
carried a single nucleotide variant in DSG2 gene, one of whom was homozygote. 
Finally, 2 out of 3 (3%) single mutation DSC2 carriers were also homozygotes 
and no single mutation carriers were detected for JUP.  
Eight of the 46 index patients (8%) carried multiple mutations, 7 were digenic 
heterozygotes, showing one missense variant in one gene coupled with a “radical 
mutation” (frameshift, nonsense, splice, deletions) in a second gene, and 1 only 
was a compound heterozygote for 2 DSP missense variants. 
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Of the 46 positively genotyped index cases, 13 were cases coming of the SCD 
Veneto Registry and 7 were AC patients who underwent cardiac transplantation. 
 
Figure 3.12 summarizes relative proportion of “radical” mutations, comprising 
variants with a more drastic predicted efect i.e. frameshift, nonsense, splice site 
and insertions/deletions, versus missense mutations detected in al five 
desmosomal genes. Note that, no mutations were detected in the extra-
desmosomal genes analyzed and that in PKP2 missense mutations can be rarely 
considered as pathogenic. Indeed, 11 of the 15 (73%) PKP2 mutations were 
radical, identified in 16 AC probands whereas 4 of the 15 (27%) were missense 
PKP2 mutations caried by 4 index cases. 
 
 
Figure 3.12: Relative proportion of “radical” and missense pathogenic putative variants identified 
in 5 desmosomal encoding genes. 
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3.5 Genotype Phenotype correlation between desmosomal genes mutation 
carriers and non-mutation carriers 
Table 3.8 summarizes clinical and genetic data of index AC patients based on the 
current diagnostic criteria. 
 
INDEX CASES N=99 MUT+ MUT- 
N (%) 46 (46%) 53 (53%) 
Age (y) 38±17 (12-78) 38±16 (13-77) 
Autopsy diagnosis N=26 MUT+ MUT- 
N (%) 13 (50%) 13(50%) 
LD 
N=13 
3 (23%) 
 
10 (77%) 
 Age (y) 16±3 (range 12-20)* 24±7 (range 17-40) 
BIV 
N=13 
10 (77%) 
3 (23%) 
 Age (y) 32±12 (range 15-40) 21±4 (range 17-26) 
Clinical diagnosis N=73 MUT+ MUT- 
N (%) 33(45%) 40(55%) 
Male gender, n (%) 22 (30%) 29 (40%) 
Age (y) 37±17 (12-78) 43±16 (15-77) 
2010 AC criteria 
Definite 
N=63 
30 (41%) 33 (45%) 
 
Borderline 
N=3 
1 2 
 
Possible 
N=7 
2 5 
Table 3.8: Comparison between desmosomal genes mutation carriers and non mutation carriers. 
Mut+ : positively genotyped, Mut - : negative genotyped, LD- left dominant pattern of AC, BIV- 
AC with biventricular involvement.  Note * P<0.05 is considered statistically significant.  
 
In 99 index AC cases, including both SCD and clinically diagnosed AC cases, 46 
resulted positively genotyped patients however no difference in age was evident 
between groups. 
Focusing the attention on SCD subjects, all 26 SCD subjects were males (100%), 
half of them had predominant or even isolated left ventricular involvement (50%) 
and 13 of 26 SCD cases were positively genotyped (50%). However, only 3 of the 
13 AC patients with a left dominant pattern were positively genotyped (23%). 
Comparing positively genotyped patients was evident that only 3 had a left 
dominant AC pattern (23%) and all 3 of them died at youger age (16y±3) 
compared with patients who exhibited a BIV involevement (p 0.03). 
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The gender incidence was assessed only on clinically affected patients since SCD 
cases were all males, showing that female to male ratio of genotyped positive AC 
patients was maintained 1:3.  
Comparing mutation carriers and non mutation carriers fulfilling the established 
AC diagnostic criteria, 33 were found positively genotyped (45%): 30 classified 
as definite, 1 classified as borderline and 2 classified as possible. Interestingly, 33 
of the 40 non-mutation carriers were classified also as definite. 
No significant difference was observed in terms of clinical characteristics 
according to the task force criteria.  
 
When we divided clinically affected living subjects from SCD cases we observed 
a higher risk of SCD (5 of 11, 45%) and a significant difference in the mean age 
of the disease presentation among DSP mutation carriers (p 0.04). DSG2 mutation 
carriers died also suddenly at a younger age however the sample number is too 
low to extrapolate statistically significant information.  Although the incidence of 
PKP2 mutations is higher among AC probands (20, 44%), the risk of SCD is 
lower (4 of the 20, 20%).  
Regarding the distribution of gene mutations in 33 clinically diagnosed AC 
subjects we observed that all DSP (6 of 6, 100%) and 86% (6 of 7) of multiple 
mutation carriers exhibited definite 2010 AC criteria. Interestingly, we also 
observed that the vast majority of PKP2 mutations found in single- PKP2 carriers 
were “radical” (11 of 16, 69%), however not all of these PKP2 “radical” mutation 
carriers exhibited defined clinical diagnostic AC criteria. Specifically, 4 PKP2 
mutation carriers were clinically classified as possible based on 2010 AC criteria; 
two of these subjects (about 40y old, male) presented a PKP2 frameshift 
[p.G458VfsX15, p.T50SfsX61 respectively] showing a LD pattern of the disease, 
1 (44y-old female) displayed a complete deletion of the PKP2 allele in 
heterozygosis with absence of any clinical signs of the disease and 1 (15-y-old, 
male) carried a simple missense mutation [p.T528M] in heterozygosis. 
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Genotyped 
positive 
[MUT+] 
N=46 
  DSP PKP2 DSG2 DSC2 Multiple 
N (%)   11 (24%) 20 (44%) 4 (9%) 3 (6%) 8 (17%) 
Male, n (%)   8 (17%) 14 (30%) 2 (4%) 2 (4%) 5 (11%) 
Age (y)   
35±15 
  (12-60) 
41±18 
(12-78) 
33±21 (13-
63) 
36±22 
(13-56) 
36±18 
(15-66) 
Autopsy 
diagnosis 
N=13 
 
5 4 2 1 1 
3BIV: 
2LD 
4BIV 1BIV: 1LD 1BIV 1BIV 
Age (y)   
26±12 
(12 -37)* 
35±18 
(18-60) 
19±8 
(13-25) 
40 15 
Clinical 
diagnosis 
N=33 
  6 16 2 2 7 
Age   
43±14          
(18-60) 
41±18 
(12-78) 
47±23      
(31-63) 
35±30 
(13-56) 
39±17 
(15-66) 
 Definite  6 12 2 2 6 
 Borderline      1 
 Possible   4    
  
I Global and/or 
Regional 
Dysfunction 
and Structural 
Alterations 
5M,1m 7M,3m 2M 2M 3M,3m 
  
II Fibrofatty 
replacement on 
endomyocardial 
biopsy, n (%) 
1M     
  
III 
Repolarization 
abnormalities 
2M,1m 7M,1m 1M 2M 3M,1m 
  
IV 
Depolarization/
Conduction 
Abnormalities 
2M,2m 1M,7m 1M 1M,1m 3m 
  V Arrhythmias 1M,1m 3M,8m 2m 1m 2M, 4m 
  
VI Family 
History 
1M 2M,2m 1m  1M 
Table 3.9 Comparison between the different groups of desmosomal genes mutation carriers. Mut+: 
positively genotyped. Note * P<0.05 is considered statistically significant.  
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3.6 Next Generation Sequencing 
3.6.1 Whole Exome Sequencing 
3.6.1.1 WES raw data analysis 
Paired-end Whole Exome Sequencing of 12 genotyped subjects on the Illumina 
HiSeq2000 produced a total of 819.240.262 reads of 100 bp in length, on average 
68.270.020 per sample, consisting of a total output of 81.924.026.200 bp.    
Mapping by CLC software reduced the total number of reads to 800.428.775 after 
alignment. Further reduction of the number of reads to 581.800.573 was obtained 
by considering the number of unique aligned reads and allowing a maximum of 2 
mismatches or gaps. Table 3.10 displays mapped and unmapped reads per sample. 
The number of reads aligned varies among the different samples within each run, 
ranging from 12 k to 66.8 k, while the number of reads on target varies from a 
minimum of 48% to a maximum of 57%, depending on the sample. 
 
Sample ID Mapped Reads Unmapped Reads 
1 27.408.565 4.184.911 
2 12.865.444 1.892.534 
3 66.790.928 10.216.939 
4 57.333.247 9.864.033 
5 38.984.184 5.953.774 
6 42.198.051 6.919.797 
7 46.321.008 24.505.096 
8 19.095.462 10.016.630 
9 66.340.765 35.528.169 
10 71.037.969 37.290.933 
11 71.650.527 39.139.587 
12 61.774.423 33.115.799 
Table 3.10: Results of the alignment per sample 
 
After alignment of sequencing data against the human genome reference, the 
sequencing reads and coverage of the target regions were observed by uploading 
BAM files on IGV software. (Robinson et al., 2011). The samples showed a 
pattern of well covered regions against uncovered or low covered regions, all 
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through the genomic regions of interest. Overall mean coverage, describing the 
mean depth of sequenced targets, varied slightly among the samples, from 9.2X to 
54.3X. A coverage above 20X, which is considered the cut-off for reliable variant 
call  showing that samples are sequenced sufficiently in terms of number reads, 
was achieved only for 6 samples. The 20-fold coverage of targets was also 
different among samples, and varied from 10,20 % to 85.85 % (Table 3.11). 
 
Sample ID Mean Coverage % of Target with Coverage ≥ 20 X 
1 20,4 X 38,65 % 
2 9,2 X 11,07 % 
3 51,6 X 81,03 % 
4 41,5 X 75,08 % 
5 25,1 X 48,38 % 
6 27,4 X 53,52 % 
7 32,3 X 65,45 % 
8 10,4 X 10,20 % 
9 49,6 X 85,85 % 
10 54,3 X 85,42 % 
11 54,2 X 84,89 % 
12 46,5 X 81,06 % 
Table 3.11: The mean coverage obtained per sample, together with the fraction of the target region 
showing a coverage >20X 
 
3.6.1.2 SNP Calling analysis- sensitivity and specificity validation 
We investigated the differences between the three callers in sensitivity and 
specificity of SNP calling based on the analysis of  6 samples. GATK identified  a 
total of 1.975.223 variants, CLC identified  a total of 1.435.455 variants, and 
CASAVA identified  a total of 260.433 variants (Table 3.12). The last software 
calls a lower number of variants because SNP calling is automatically limited 
merely to the enriched target regions (most exonic), and discards the insufficiently 
covered target regions. On the contrary CLC and CASAVA perform calls also on 
low covered exonic regions and intronic regions. 
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N calls GATK CLC CASAVA 
Total calls 1.975.223 1.435.455 260.433 
Sample 12 238.186 195.672 42.691 
Sample 2 132.475 99.600 29.337 
Sample 4 382.445 289.124 48.956 
Sample 5 430.718 320.178 48.492 
Sample 6 381.801 254.541 44.268 
Sample 7 409.598 276.340 46.689 
Table 3.12: Comparison of the SNP calls across six samples performed by GATK, CLC and 
CASAVA. 
 
In order to test whether WES could be used as a reliable tool in a clinical setting, 
we evaluated the analytical sensitivity and specificity of WES for the detection of 
a series of previously characterized nucleotide changes,  by comparing WES data 
with data obtained by Sanger sequencing of 5 genes. 
Initial analysis with the CLC software was able to automatically detect 68 out of 
the 90 expected nucleotide changes (76%). 
22 changes were missed during the initial analysis. The 22 variants were manually 
searched among the aligned reads, this alternative strategy allowed the detection 
of 13 among the ‘missed’ variants. Nine variants previously identified by 
conventional sequencing remained undetected after both automatic and manual 
SNP calling. (Table 3.13). 
 
Gene cDNA Predicted 
Protein 
change 
Ex/Int Coverage Distance 
from 
probes  
DSC2 c.70 -154 G>A - Int 1 1 154 bp 
DSP c.-1_1insA  Int 1 0  
DSP c.913A>T p.I305F Ex 7 0 356 bp 
DSC2 c.2326 A>G p.I776V Ex 15 2  
PKP2 c.76G>A p.D26N Ex 1 1  
PKP2 c.2489+13_2489+14ins C  Int 12 11 203 bp 
DSG2 c.828+16C>A  Int 7 4 62 bp 
DSP c.1141-44C>T  Int 10 1 44 bp 
DSP c.1420-93C>T  Int 12 1 93 bp 
Table 3.13: 9 Variant missed by SNP calling, Ex: exon, Int: Intron 
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Six of the 9 variants were located too distant from the nearest probes to be 
detected (from 44 to 356 bp). The remaining 3 variants were not called because 
they were located in uncovered (coverage 0) or low covered (coverage 1 and 2) 
targeted regions. CLC software automatically discards every variant showing a 
coverage below 5X assigning it as a false call. The overall sensitivity of WES was 
evaluated around 90%. The specificity was calculated as >99.9%.  
3.6.1.3 SNP Calling analysis- 150 genes associated with arrhythmic inherited 
cardiomyopathies 
All successfully mapped sequence reads of the 12 samples were further analyzed 
to detect sequence variants, including single nucleotide changes and small 
insertions and deletions, within a set of 150 genes involved in different inherited 
cardiomyopathies. Variants were manually called, with the generation of a list of 
1003 known or novel nucleotide changes detected in the 12 patients. First step 
filtering consisted of nonsynonymous and novel variants against the 1000 
Genomes project and EVS database resulting in the identification of 100 
potentially pathogenic variants. The validation process by Sanger sequencing of 
these variants successfully confirmed only 3 of them (3%) in 3 patients. Variants 
were located respectively in the troponin2 gene (TNNT2), in the myosin binding 
protein C3 gene (MYBPC3), and in LMNA (Table 3.14). 
 
Gene cDNA 
Predicted 
Protein 
change 
Ex 
dbSNP 
ID 
MAF Type Reference 
TNNT2 c.113C>T p.A38V 6 rs56816490 NA M Millat et 
al., 2011 
MYBPC3 c.2198G>A p.R733H 23   M Novel 
LMNA c.949G>A p.E317K 6 rs56816490 NA M 
Arbustini 
et al., 2002 
Table 3.14: Variants detected by WES and Sanger sequencing, EX: exon, M: missense 
 
The 97 variants that have proven false positives were located in exome regions 
with low coverage (<5X), or far from the probes.  
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3.6.2 NGS- Targeted Resequencing 
Targeted resequencing has been validated (Sikkema-Raddatz et al., 2013) showing 
both a sensitivity and specificity around 100% and is routinely used as a stand-
alone diagnostic test at the Cardiogenetics Laboratory of the University of 
Groningen.  
Four AC patients from the Cardiogenetics Laboratory of the University of 
Groningen and one subject from the Cardiovascular Laboratory of the University 
of Padua, which did not show potentially pathogenic variants in other desmosomal 
genes, were subjected to targeted-NGS for 55 genes associated with different 
hereditary cardiomyopathies. 
3.6.2.1 Raw data analysis 
150 bp paired-end sequencing of the libraries on the Illumina MiSeq produced on 
average 110.185.963 reads per sample, in table 3.15 are depicted the total number 
of reads obtained per sample and mapped bases.  
 
Sample Total Numer of Reads Alligned Bases 
1 103.336.675 8964.222 
2 118.658.699 9171.513 
3 119.677.954 9720.766 
4 99.070.524 7425.109 
Table 3.15: Total number of reads obtained per sample and mapped bases. 
 
The total number of reads produced and the number of mapped reads are 
comparable among the samples. The mean depth of coverage over all samples was 
around 300X, in accordance with the theoretical coverage of 245X. The 
homogeneity of the distribution of reads between samples and the mean target 
coverage demonstrated the high performance of the sequence capture approach.  
3.6.2.2 SNP Calling analysis 
SNP calling performed on the sample from the Cardiovascular Genetics 
laboratory of Padua identified a total of 947 variants, and 197 mapped on the 
target panel regions. A first variant filtering performed by Cartagenia Bench Lab 
removed 2 variants with low quality that passed over the previous quality filters. 
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The resulting 195 variants were subjected to a series of filtering processes 
developed by the Cardiogenetics laboratory of Groningen, that take into 
consideration the presence and the frequency of the variants in several public 
databases (1000 Genomes Projects, EVS), and an in house variant database, 
radically reducing the amount of potentially pathogenic variants to 3 (table 3.16). 
 
Gene  cDNA 
Predicted 
Protein 
change 
Ex 
dbSNP  
ID 
MAF Type Reference 
TTN  c.102737 
G>A 
p.R34246H 358 rs372716177 T=0.0004/2 M Millat et 
al., 2011 
TTN  c.17279 
C>T 
p.T5760M 60   M Novel 
LAMA4  c.1552-4 
G>A 
 int13 rs368746644 NA Sp 
Arbustini 
et al., 
2002 
Table 3.16: Output of the Cartagenia filtering pipeline, Ex:exon, M: missense, Sp: splicing 
 
The three variants detected in the patient are located in extra desmosomal gene 
that have never been associated with AC (Table 3.16). 2 variants were located in 
TTN and one in the laminin-α-4 gene (LAMA4). The three novel variants were 
subsequently confirmed by Sanger sequencing. 
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3.7 Genotype Phenotype correlation 
Family members of 9 AC index probands were available both for clinical and 
genetic testing. 
 
3.7.1 Family #1 
Patient #1 (male, aged 12) met a definite diagnosis of AC according to the revised 
2010 Task Force criteria. Desmosomal genes analysis revealed a single nucleotide 
deletion c.1643del in exon 7 of PKP2 predicted to shift the reading frame and to 
introduce a premature stop codon (p.G548VfsX15) (Figure 3.13). This variant has 
been described as pathogenic in different studies (Gerull et al., 2004; Dalal et al., 
2006; Fressart et al., 2010; Bauce et al., 2011; Rigato et al., 2013; Alcalde et al., 
2014), and it resulted absent in the 1000 Genomes Project and EVS databases. 
Analysis extended to available family members showed that this mutation was 
inherited by the probands’ father (aged 55) and was also carried by his 14-year old 
sister both previously asymptomatic. 
 
 
Figure 3.13: Pedigree of the proband (arrow) and her family for PKP2 mutation p.G548VfsX15. 
Mutation status is indicated as follows: white = unaffected; black = affected; +/+ = homozygous 
for the aforementioned  mutation; +/- = heterozygous for the aforementioned mutation. 
 
3.7.2 Family #2 
Patient #2 is a male of age 13 years affected by a classic form of AC who did not 
show family history of the disease. Screening of desmosomal genes identified the 
missense mutation c.536A>G, p.D179G in exon 5 of DSC2 in homozygosis. The 
mutation involves a highly conserved amino acid located in the first cadherin 
domain, was predicted to be deleterious by SIFT and PolyPhen-2. It was absent in 
the 1000 Genomes Project and EVS databases, however it had been detected in 
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the healthy control population with an allele frequency of 2.7% (De Bortoli et al., 
2010). The patient also carries a PKP2 variant (c.1012A>G, p.T338A, 
rs139851304, MAF C= C=0.001/0), affecting a weakly conserved amino acid and 
predicted as tolerated by Polyphen-2 and SIFT.  
The DSC2 variants was carried in heterozygosis by his unaffected parents, while 
the PKP2 polymorphism was carried by his father (Figure 3.14). 
 
 
Figure 3.14: Pedigree of the proband (arrow) and his parents for DSC2 mutation p.D179G.  
Mutation status is indicated as follows: white = unaffected; black = affected; +/+ = homozygous 
for the aforementioned mutation; +/- = heterozygous for the aforementioned mutation. 
 
3.7.3 Family #4 
Patient #4 (female, aged 56) was affected by a classic form of AC. She was found 
to carry the homozygous mutation p.D179G in exon 5 of DSC2. Cascade 
screening was performed on all available family members, who were clinically 
unaffected and resulted to carry the DSC2 variants in heterozygosis (Figure 3.15). 
 
Figure 3.15: Pedigree of the proband (arrow) and her family for DSC2 mutation p.D179G. 
Mutation status is indicated as follows: white = unaffected; black = affected; +/+ = homozygous 
for the aforementioned  mutation; +/- = heterozygous for the aforementioned mutation. 
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Data on families #2 and #4 support the presence of an autosomal recessive form 
of AC with a homozygous variant on DSC2 as a cause of AC, without any sign of 
cardiocutaneous syndrome. 
 
3.7.4 Family #8 
Patient #8 (male, aged 15) was afected by a severe form of AC. Screening for 
desmosomal genes mutations by DHPLC and Sanger sequencing did not identifiy 
any pathogenic variants. Successive MLPA analysis detected the presence of a 
novel deletion on chr 18 including both DSG2 and DSC2 genes (Figure 3.16). 
This deletion was never observed in the 1000 control chromosomes and it was not 
detected in the 1000 Genomes Projects and EVS databases. 
 
 
Figure 3.16: MLPA analysis of  the probands’ mother, indicating the presence of the deletion a) 
Schematic representation of the deleted chromosomal region b) Raw data of MLPA runs c) 
Histograms ploting the DQ of the fragments corresponding to every exon analyzed and layout of 
Coffalyzer results d) qPCR validation of MLPA results, in red the ratio between the test sample 
and the reference sample. 
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The genetic study was extended the probands’ parents, showing that the deletion 
was carried by his mother, who also met a definite diagnosis of AC according to 
the revised 2010 Task Force criteria (Figure 3.17). 
 
 
Figure 3.17: Pedigree of the proband (arrow) and his family for DSC2 and DSG2 deletion.  
 
 
3.7.5 Family #9 
The proband #9 (male, age 15) met a definite diagnosis of AC according to the 
revised 2010 Task Force criteria, and did not show family history of the disease. 
Genetic testing revealed the presence of 2 missense variants in two different 
genes. One variant involving a highly conserved amino acid in the N-terminal 
region of DSG2 (c.875G>A, p.R292H), and one in DSC2 (c.2194 T>G, p. L732V) 
(Figure 3.18). The DSG2 variant were considered intolerant by Polyphen2 and 
SIFT, while the DSC2 variant, also affecting a highly conserved amino acid, was 
predicted to be benign. Although both variants were excluded in the variants 
filtering process due to high allelic frequency (MAF> 0.02%), cascade screening 
on the proband’s unaffected relatives showed that the mother was a carrier of the 
DSC2 variant and the father carried the DSG2 variant. These data suggest an 
autosomal recessive mode of transmission. This case is similar to another study 
recently describing the p.R292H mutation as pathogenic when present in the 
homozygous state (Jiménez-Jáimez et al., 2014). 
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Figure 3.18: Pedigree of the proband #9 (arrow) and his parents for DSG2 mutation p.R292H and 
for DSC2 mutation p. L732V.  Mutation status is indicated as follows: white = unaffected; black = 
affected; +/+ = homozygous for the aforementioned mutation; +/- = heterozygous for the 
aforementioned mutation. 
 
3.7.6 Family #58 
The proband #58 (male, aged 77) was affected by a biventricular form of AC and 
showed family history of the disease. DHPLC analysis followed by Sanger 
sequencing of abnormal elution profiles did not identify any mutation in 
desmosomal genes. Successive WES detected the heterozygous point mutation 
c.949G>A, p.E317K in the exon 6 of the LMNA gene (NM_170707.2) (Figure 
3.19).  
 
 
Figure 3.19: Pedigree of the proband (arrow) and his family for the LMNA mutation p.E317K. 
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The variant, located in the coil 2 rod domain, results in an amino acid substitution 
altering completely the physico-chemical properties of the amino acid. The 
mutation affects a highly conserved amino acid, and is predicted to be deleterious 
by Polyphen and SIFT. 
This variant has been described in a case of familial autosomal dominant DCM 
with atrio ventricular block, in the proband the LMNA expression of the myocyte 
nuclei was reduced or absent (Arbustini et al., 2002). This variant is present in 
ClinVar database and classified as “likely pathogenic”, it is also in dbSNP 
database (rs56816490) but not detected in the 1000 genomes or EVS dataset. The 
genetic study was extended to available family members. Three subjects, the 
probands daughter (aged 50) and one of their sons (aged 21), also clinically 
affected, resulted to carry the mutation. While the clinically unaffected son (aged 
24) did not carry the mutation. 
 
 
3.7.7 Family #59 
The proband #59 was a 40 years-old competitive athlete who died suddenly, and 
received an autoptic diagnosis of AC. Sanger sequencing identified 2 
heterozygous variants: one in DSG2, c.2137 G> A, p.E713K (rs79241126, MAF 
A=0.0260/130), and one in DSC2, c.2603 C>T, p.S868F (rs141873745, MAF 
A=0.0002/1). 
Only the DSC2 mutation is predicted as deleterious by Polyphen-2 and SIFT. 
Cascade screening showed that the brother and the sister were carriers for only 
one of the two variants. 
WES confirmed the 2 variants and identified an additional variant c.68C>T, 
p.A23V located in the cardiac troponin T gene (TNNT2), whose alterations are 
known to significantly contribute to dilated cardiomyopathy rather than AC 
(Figure 3.20).  
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Figure 3.20:  Pedigree of the proband #59  and his family for the DSG2, DSC2, TNNT2 mutations. 
 
3.7.8 Family #74 
The proband #74 was a 13 years-old competitive athlete who died suddenly, and 
had an autoptic diagnosis of AC. DHPLC analysis followed by Sanger sequencing 
identified 2 heterozygous variants: one in DSG2 and one in PKP2. The DSG2 
variant c.722 C>T, p.A241V was novel and was absent both in the 1000 alleles of 
the control population and in the 1000 Genomes and EVS dataset. Moreover it is 
located in the cadherin2 domain, it is predicted as deleterious by Polyphen and 
SIFT. The proband also carried the c.1576A>G, p.T526A PKP2 variant, predicted 
as tolerated by in silico analysis tools and affecting a weakly conserved amino 
acid. Probands’ 11-year old sister is a carrier of the only DSG2 variant (Figure 
3.21). No deeper co-segregation studies in the family were possible since the two 
children had foster parents.  
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Figure 3.21: Pedigree of the proband #74 and his family for the DSG2 and PKP2 mutations. 
 
 
3.7.9 Family #76 
The proband #76 was a 20 years old male who died suddenly and the autopsy 
showed evidences of left-dominant AC. 
Genetic analysis identified a novel heterozygous mutation (c.448C>T, p.R150X) 
in exon 4 leading to the premature truncation of DSP. 
The same mutation was shared by the father (aged 54) and the sister (aged 19) 
(Figure 3.22). Interestingly, the father appeared to be the first mutation carrier in 
the family, suggesting a dominant de novo mutation (Pilichou et al., 2014). 
 
 
Figure 3.22: Pedigree of the proband (arrow) and his family for the DSP mutation p.R150X (from 
Pilichou et al., 2014). 
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3.7.10 Family #87 
A fourteen year-old boy was transplanted at the Cardiology of Tehran and referred 
to the Laboratory of Cardiovascular Genetics for genetic screening of  
biventricular AC. Family history of sudden cardiac death was present in two 
brothers of the proband. ECG recording showed atrial fibrillation and conduction 
abnormalities (RBBB type), whereas Echo analysis showed biventricular 
enlargement. Targeted resequencing of 55 genes carried out in collaboration with 
the University of Groningen, identified 2 different missense variants in TTN 
(c.102737G>A, p.R34246H, and c.17279C>T, p.T5760M) and one variant in 
LAMA4 (c.1552-4G>A), confirmed by Sanger sequencing (Figure 3.23). The 
variant c.1552-4G>A in LAMA4 is predicted to affect the splicing process 
(MaxEnt: -5.3%; NNSPLICE: 0.7%; HSF: 0.1%). The TTN variant p.T5760M 
affects a weakly conserved amino acid, while the p.R34246H variant affects an 
highly conserved amino acid and is classified as a variant of uncertain 
significance in ClinVar (update Apr 19, 2012). 
 
 
 
Figure 3.23:  Pedigree of the proband (arrow) and his family for the LAMA4 and TTN mutations. 
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4. DISCUSSION 
 
Arrhythmogenic Cardiomyopathy is an inherited heart muscle disease that may 
result in arrhythmias and sudden death, especially in the young and athletes 
(Thiene et al., 1988; Corrado et al., 1990). The main pathological feature of AC is 
the progressive loss of myocardial cells, which are replaced by fibrous and 
adipose tissue (Nava et al., 1988; Thiene et al., 1988). Major and minor criteria 
were established and revised by an international Task Force, to be specific for AC 
diagnosis (Marcus et al., 2010). AC criteria consider cardiac morphology and 
function, tissue characterization, electric rhythm conduction and the presence of 
arrhythmic events as well as family history, including the identification of 
pathogenic mutations as a major diagnostic criterion.  
Although the first genetic sightings were accomplished on the recessive form 
known as Naxos disease, AC is nowadays most commonly considered as an 
autosomal dominant trait with variable expressivity and age-dependent penetrance 
(Nava et al., 1988; McKenna et al., 1994; Sen-Chowdhry et al., 2004; van 
Tintelen et al., 2006). Desmosomal point mutations are detected in nearly half of 
the AC probands (Basso et al., 2012; Kapplinger et al., 2011; den Haan et al., 
2009). However, recent studies highlighted the presence of desmosomal gene 
variants in the general population, intensifying the debate regarding the 
pathogenic effects of missense and “radical” mutations. At present “radical” 
mutations are considered highly pathogenic due to abnormal protein length 
advocating a haploinsufficiency mechanism, whereas missense mutations are 
cautiously interpreted using complex bioinformatics algorithms. Moreover, the 
identification of compound and digenic heterozygous carriers, associated with a 
more severe form of the disease, increased the genetic complexity of the disease 
suggesting a recessive inheritance pattern (Xu et al., 2011; Bauce et al. 2010; 
Rigato et al., 2013). Further rare CNVs other that point mutations have been also 
associated with AC, by three independent studies describing different large 
deletions encompassing PKP2 gene in Dutch and Italian AC patients (Cox et al., 
2011; Roberts et al., 2013; Li Mura et al., 2013). 
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The aim of the present study was to prospectively assess the prevalence, 
age/gender relation and underlying genetic mutations in a large series of clinically 
affected and SCD AC cases. 
4.1 Comprehensive genetic analysis in 99 index cases 
Ninety-nine index cases referred for molecular genetic screening to the 
Cardiovascular Genetics Laboratory of Padua; 73/99 probands had a clinical 
diagnosis of AC based on the 2010 Task Force criteria (Marcus et al., 2010), of 
which 14 underwent cardiac transplantation, and 26 index cases were sudden 
death victims recorded in the Veneto Registry of Cardio-Cerebro-Vascular 
Pathology. Genetic screening carried out in the entire cohort for 5 desmosomal 
genes (DSP, PKP2, DSG2, DSC2, JUP), and in 46 of the 99 probands for 3 
additional non desmosomal genes (CTNNA3, DES, PLN), identified 193 different 
nucleotide variants underlying the complex genetic status of the disease. Of note, 
the majority of the nucleotide variants resided in DSP.  
The first genetic analysis excluded all intronic, UTR and synonymous variants 
reducing the total number of variants to 81. The 81 detected variants were 
prioritized based on the frequency of variants in the general population, the 
conservation of the nucleotide and the amino acid conservation among species, as 
well as other in silico prediction analytical methods. Finally a nucleotide variant 
was classified as pathogenic once it was predicted to alter the structure or the 
function of the encoded protein, its presence was assessed in a large healthy 
ethnically matched control population and when literature or family information 
implied correlation with the disease. 
The second variant filtering was based on frequency data provided by available 
public databases such as 1000 Genomes Project and Exome Variant Server and an 
internal control group composed of 500 unrelated healthy athletes who were 
screened as controls to assess frequency of novel variants in the Italian population. 
Minor allele frequency cut-off was established at <0.02% given the prevalence of 
this rare disease as 1:5000 (0.0002, 0.02%). Twenty-nine variants above this 
threshold were excluded due to high frequency in the general population whereas 
52 unique variants advanced to the next variant filtering step. However one DSP 
variant excluded because of frequency beyond the established threshold, was 
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reclassified as a mutation due to in vitro function evidences proving its association 
with the disease (Yang et al., 2006). Of note, all 53 variants were located in 
desmosomal encoding genes: PKP2 (19, 36%), followed by DSP (19, 36%), 
DSG2 (8, 15%), DSC2 (3, 6%), JUP (4, 7%), in agreement with previous reported 
data considering AC as a desmosomal disease (Basso et al., 2012). No nucleotide 
variants were found in our cohort in extra desmosomal genes. Indeed extra 
desmosomal genes mutations in AC are rare and usually reported as founder 
mutations (p.S358L in TMEM43, p.S13F in DES, p.R14del in PLN ((Merner et al. 
2008; Bergman et al., 2007; van der Zwaag et al., 2012). Fifty-four positive-
mutation carriers were identified from this filtering step, of which 11% were 
single mutation carriers for DSP, 18% for PKP2, 4% for DSG2 and 3 % for DSC2 
and JUP respectively. Fifteen of these 54 genotype-positive AC cases were 
multiple mutation carriers (15%).  
The following variant filter was based on evolutionary conservation of amino 
acids and led to the exclusion of 8 more missense variants, weakly or not 
conserved among species, reducing the amount of putative pathogenic variants to 
44.  
The resulting variants from the evolutionary conservation- filtering step were 
underwent a final in silico evaluation regarding predicted variant pathogenicity, 
which excluded from the study 4 more variants classified as VUS1 (unlikely to be 
pathogenic) and 1 classified as VUS0 (not pathogenic) and reduced the putative 
pathogenic variants to 37. A further reduction in 42 index AC cases (42%) who 
carried one or more of these 37 variants were finally considered as positively 
genotyped. 
A parallel CNVs analysis, carried out both by MLPA and qPCR in all 99 
probands identified 3 additional large genomic rearrangements involving 
desmosomal genes, that could not have been detected by DHPLC and Sanger 
sequencing: a heterozygous deletion of 120 kb located on chr 12 comprising the 
entire PKP2 gene in 2 patients, a heterozygous deletion of at least 482 kb on chr 
18 encompassing both DSC2 and DSG2 genes in 1 patient, and a heterozygous 
deletion involving only exon 4 of PKP2 in other 2 patients. CNVs investigation 
allowed the identification of an additional 4% of desmosomal mutation carriers, 
increasing the diagnostic yield of AC genetic testing from 42% to 46% in our 
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population. We considered as mutation carriers all 46 probands (46%) who carried 
one or more of the 37 identified point variants or of the 3 large deletions.  
4.2 Genotype complexity in AC  
Forty-six (46%) index AC cases harbored at least one desmosome point mutation 
or a large deletion in desmosomal encoding genes; 20 of the 46 genotype positive 
AC probands were single PKP2 mutation carriers (43%), 11 single DSP mutation 
carriers, 4 single DSG2 mutation carriers and 3 were single DSC2 mutation 
carriers. Note that 3 homozygous carriers have been identified for 1 nonsense 
DSG2 mutation and 2 DSC2 missense mutations. Moreover, 8 of 46 genotype 
positive AC probands carried multiple mutations and most of them were digenic 
heterozygotes (7 of 8, 88%).  
4.3 Recessive inheritance pattern in AC 
Cascade genetic family screening has the power to unveil clinical features and 
improve characterization of the detected variants. However the low number of 
relatives available for clinical evaluation or the small size of the families often 
made difficult a final assessment of the role and/or the contribution of the 
different mutations identified. Herein, we report our findings in 3 AC families 
supporting the idea that AC might be present as a recessive form without 
associated palmoplantar keratoderma and wooly hair, in concordance to previous 
reported studies (Alcalde et al., 2014; Awad et al., 2006; Sato et al., 2011; 
Rasmussen et al., 2013).  
In two families we detected the presence of the same homozygous founder DSC2 
mutation (p.D179G) (Lorenzon et al., submitted), while in another family the only 
affected proband was found to carry a DSC2 mutation (p.L732V) associated with 
a DSG2 mutation (p.R292H). These data together with a high incidence of digenic 
heterozygotes (8 in 99, 8%) in our cohort, suggest an autosomal recessive mode of 
transmission, confirming the complexity of AC genetics and highlighting the need 
of cascade clinical and genetic screening in larger populations in order to better 
understand the genetic basis of the disease. We cannot exclude the possibility that 
AC cases hosting 1 AC-associated mutation do not carry a compound mutation in 
yet unknown AC susceptibility gene. 
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4.4 Prediction of missense mutations pathogenicity 
While the pathogenicity prediction value of features such as the frequency of the 
altered allele in the population and the phylogenetic conservation of the amino 
acids is well established, the utility of in silico analysis remains questionable, 
even though it represents the first tool enabling the prioritization of the increasing 
amount of VUSs emerging from the new sequencing technologies. In silico 
analysis are based on different statistical algorithms combining the outcomes of 
series of predictors that often consider MAF, conservation data, predictions about 
the possible impact of an amino acid substitution on the structure and function of 
a protein, the difference in the physicochemical properties of the amino acids, 
while they do not consider for instance any possible interaction of the protein 
inside the cell. Herein we identified 53 desmosomal gene variants after MAF-
Filtering in 54 positive-mutation carriers, of which 11% DSP single mutation 
carriers, 18% PKP2 single mutation carriers, 4% DSG2 single mutation carriers, 3 
% DSC2 single mutation carriers, 3% JUP single mutation carriers and 15% 
multiple mutation carriers. Stringent analysis, limited only to carriers of variants 
resulted from the four filtering steps reduced the number of variants to consider 
pathogenic to 37, the number of mutation carriers to 42 index cases of which 11% 
DSP single mutation carriers, 20% PKP2 single mutation carriers, 4% DSG2 
single mutation carriers, 3 % for DSC2 single mutation carriers and 8% multiple 
mutation carriers. These results showed a significant reduction in multiple 
mutation carriers and that JUP variants alone cannot cause the development of the 
disease. However, the exclusion of variants during the 4-filtering procedure due to 
statistical evaluation is still complicated since different algorithms can sometimes 
provide discordant outputs, suggesting the need of more than one in silico tool 
comparison and validation of predictions by co-segregation analysis and/or 
functional studies to finally verify the real pathogenicity of mutations. This raise 
the question whether exclusion of genetic variants during the 4-filtering fails to 
detect a large portion of mutation carriers.  
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4.5 Prediction of “radical” mutations pathogenicity 
PKP2 mutations are the most common AC-related genetic variants, representing 
13/37=35% of the total AC variants identified in this study and responsible for 
20/46=43% of our genotype positive AC cohort. 
Eleven of the 15 PKP2 mutations identified in 16 AC index cases were “radical” 
mutation (frameshift, nonsense, splice sites). The pathogenicity of missense and 
“radical” mutations in cardiac diseases and specifically in AC is a matter of 
intense debate. Recent studies have shown that stop-codon mutations in PKP2 are 
more pathogenic because they alter protein length and that truncating PKP2 
proteins may lead to haploinsufficiency due to protein instability (Kapplinger et 
al., 2011; Andreasen et al., 2013; Joshi-Mukherjee et al., 2008; Herman et al., 
2012; Rasmussen et al., 2014). Even though this study showed a clear-cut 
prevalence of “radical” PKP2 mutations compared to missense mutation, we 
found no difference in the age onset (41±19 vs 40±19) or in a higher risk of SCD 
events in PKP2 mutation carriers.  
Actually our data supports the idea that a heterozygous gene deletion might be 
insufficient to determine alone the disease. Specifically, 3 PKP2 “radical” 
mutation carriers were identified and clinically classified as possible based on 
2010 AC criteria; two of these subjects (about 40y old, males) presented a PKP2 
frameshift [p.G458VfsX15, p.T50SfsX61 respectively] showing a LD pattern of 
the disease and 1 (44y-old female) displayed a complete deletion of the PKP2 
containing allele in heterozygosis with absence of any clinical signs of the disease. 
In contrast we observed that another AC carrier of the entire PKP2 allele deletion 
and of an additional DSP missense mutation (p.V30M) fulfilled definite 
diagnostic criteria, as observed also in all the compound/digenic mutation carriers 
in this study. Further a young boy with the deletion of the allele containing both 
DSG2 and DSC2 genes was also classified as definite. Thus, in agreement with 
previous studies the pathogenicity of “radical” mutations as well as missense 
mutations should be accomplished only by co-segregation studies and clinical 
analysis in the families. 
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4.6 Genotype-phenotype correlation  
Previous studies on AC index cases consistently demonstrated a male 
predominance, suggesting that men develop a more severe disease phenotype, 
making them more likely to come to medical attention (Cox et al., 2011; Dalal et 
al., 2006; Nava et al., 2000; Rigato et al., 2013). These authors hypothesized a 
direct sex-hormone influence on the disease pathobiology and development of 
arrhythmogenic myocardial substrate, advocating the protective effect of 
estrogens to explain why females with desmosomal gene mutations tend to 
develop a less severe phenotype and fewer arrhythmic complications compared 
with males.  
Our cohort included 77 (78%) males and only 22 (22%) females presenting a 4:1 
ratio, of which 26 SCD cases were all males. Excluding this bias from our cohort 
of SCD males, the sex ratio males:females in the clinically diagnosed group was 
3:1, as previously reported elsewhere. 
Although our findings confirmed a male predominance with a ratio 3:1 among AC 
index cases, a 2:1 male to female ratio was observed among desmosomal mutation 
gene carriers with definite criteria suggesting that genotype positive females have 
the same probability of developing specific AC features and the fact that these are 
not translated to SCD events needs further investigation. 
Comparing mutation carriers and non mutation carriers fulfilling the established 
AC diagnostic criteria, 46 were found positively genotyped (46%): 30 classified 
as definite, 1 classified as borderline and 2 classified as possible. Interestingly, 33 
of the 40 non-mutation carriers were also classified as definite. 
Sorting genotyped positive patients for the different desmosomal gene mutations 
we observed no significant differences in the average age of the initial 
presentation (around 38y) of the disease. Although multiple mutation carriers and 
DSP single mutation carriers showed definite diagnostic criteria for AC, no 
significant correlations were also observed in terms of clinical characteristics and 
in the average age at diagnosis between the different single mutation carriers and 
the multiple mutation carriers. These data do not reflect previous studies reporting 
that multiple mutation carriers correlation with an earlier onset of symptoms and a 
more severe disease (Xu et al., 2010). However our results might be biased due to 
high strigency in variants filtering which relocated multiple mutation carriers in 
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the group of single mutation carriers (7 multple mutation carriers after 4-step 
filtering became single mutation carriers), and to the small number of multiple 
mutation carriers. 
Separating clinically affected living subjects from SCD cases made evident a 
higher risk of SCD (5 of 11, 45%) among DSP mutation carriers at a significantly 
younger age (p 0.04). In contrast given the higher incidence of PKP2 mutations 
among AC probands (20, 44%), the risk of SCD in PKP2 mutation carriers is 
lower (4 of the 20, 20%).  
4.7 Next generation sequencing in AC 
4.7.1 Whole exome sequencing and troubleshooting 
Twelve of the 99 genotyped patients underwent paired-end WES in 2 successive 
runs, obtaining 68.270.020 reads per sample on average. To elaborate these data 
we used 3 different pipelines: we used CLC software as the main mapping tool 
due to its ability to recognize faster the highest number of unique hits and it did 
not require indexing of the reference. However a huge variability was observed in 
the number of reads aligned against the human genome reference and the number 
of reads on target for each sample within every sequencing run. Mean coverage 
variability was also observed among different samples (inter-variability) and 
within the same sample (intra-variability) in terms of well covered regions versus 
uncovered or low covered regions of interest.  
Accordingly, we obtained in nearly 80% of the exome a mean coverage above 
20X only for 6 of the 12 samples sequenced by WES; mean coverage of 20X is 
considered the minimal coverage value for reliable variant call, showing that 
sequencing did not produce enough reads (Sims et al., 2014).  
Inter- and intra- variability observed among samples, even though the sample 
procedure was applied, depended mainly on the quality of the original sample. 
Many of our samples were obtained from post mortem sampling resulting in tissue 
and DNA degradation which was translated in this process as poor enrichment of 
target regions. We tried to overcome this difficulty by quality control of the 
starting DNA sample and libraries, however when the samples are pooled together 
calculation and pipetting cannot be perfectly accurate and this result in unbalanced 
number of reads produced for each sample during multiplex sequencing. These 
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technical problems create an enormous effect on the yield and quality of sequence 
reads obtained by NGS.   
Next, we used 3 pipelines also for SNP calling comparing them in terms of 
sensitivity and specificity of the calls. In 6 samples, GATK and CLC called 
respectively a total of 1.975.223 and 1.435.455 variants, while CASAVA called 
only about 1/6 of them. In fact CASAVA automatically calls variants located 
exclusively in the exonic target regions that reached an appropriate coverage 
>20X, thus not focusing on the low covered exonic regions or the intronic regions. 
CLC software instead was demonstrated to be user-friendly and flexibile, able to 
call a great amount of variants even in non coding regions.  
4.7.2 Whole exome sequencing: sensitivity and sensibility 
In the clinical setting a higher specificity and sensitivity of diagnostic tools is 
required (Gargis et al., 2012; Rehm et al., 2013). To this regard we compared 
WES data to the ones deriving from conventional sequencing.  
SNP calling by CLC software, automatically detected 68 out of the 90 variants 
(76%), missing 22 nucleotide changes, that were manually called looking through 
the alignment data. Thirteen of these 22 missing variants were manually detected, 
exhibiting 90% sensitivity and >99.9% specificity of WES. The rest 9 variants 
missed by automatic and manual SNP calling, 6 were intronic variants located 
from 44 to 356 bp to the nearest probe and thus of difficult detection, while 3 
exonic missense variants were located in target uncovered regions or with a 
coverage below 5X. Note that, CLC software automatically discards all calls with 
low quality parameters. 
4.7.3 Whole exome sequencing: clinical application and efficacy 
WES data of the 12 sample were further interrogated for variants located in 150 
additional genes associated with different from AC inherited cardiomyopathies. 
The pipeline used for variants filtering was the same as previously described in 
conventional sequencing, resulting in the identification of more than 100 putative 
pathogenic variants. However, conventional sequencing methods confirmed only 
3 of the 100 extra desmosomal variants detected in 3 different patients, of which 1 
in TNNT2, 1 in MYBPC3, and 1 in LMNA genes respectively. In this way 3 more 
patients were positively genotyped allowing a differential diagnosis with respect 
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to AC. For instance, LMNA mutation carrier was an AC-labeled proband who died 
shortly after cardiac transplantation. Cascade family screening enabled the study 
of his family identified 2 more mutation carriers who exhibited a DCM-like 
pattern. Indeed this variant has been previously described in a case of familial 
autosomal dominant DCM with atrio ventricular block (Arbustini et al., 2002). 
The rest 97 false positive WES calls were related not only to a low sequence 
coverage (<10x in 2 samples) but also to systematic errors due to repetitive 
elements, homopolymer stretches and small insertions or deletions resulting in an 
aberrant alignment process. The presence of false positives implies that this pilot 
WES experiments requires improvements both at the enrichment level and the set-
up of the bioinformatic pipeline, and highlights the value of confirmatory Sanger 
sequencing especially at this stage of the progress of NGS technology.  
Although, our NGS procedure still presents some limitations to overcome, the 
data obtained from these two pilot WES experiments demonstrated the utility of 
sequencing simultaneously the entire exome of every patient since a higher 
throughput of data can be analyzed at a lower cost with respect to conventional 
sequencing methods and WES data can be stored and re-analyzed after time. 
4.7.4 Targeted resequencing vs WES strategy 
Last, we evaluated another NGS strategy (Targeted Resequencing-TR) in order to 
extend out analysis from 5 desmosomal genes to a specific set of 55 inherited 
cardiomyopathy-related genes. Targeted resequencing panel was previously 
validated by the Cardiogenetics Laboratory of the University of Groningen and at 
present is used as a routine diagnostic test.  
Four AC patients from the Cardiogenetics Laboratory of Groningen and 1 
negative-genotyped AC patient from the Cardiovascular Laboratory of Padua, 
were sequenced with a paired-end strategy producing on average 110.185.963 
reads per sample to be mapped on 55 genes, corresponding to approximately 1.6 
fold the reads produced by WES which were expected to map all over the exome. 
No intra- or inter- variability was observed in terms of total number of reads 
produced and mapped, while the mean coverage was around 300X, confirming the 
good quality of the enrichment. Variant calling and filtering was performed by an 
in-house pipeline and led to the detection of 3 variants in 2 extra desmosomal 
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genes (p.R34246H and p.T5760M in TTN; c.1552-4G>A in LAMA4) in the patient 
coming from Padua. 
This work highlighted the need for improvement of the WES protocol and 
allowed a differential diagnosis of Dilated Cardiomyopathy based on genetics 
evidences.  
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5. CONCLUSIONS 
 
Comprehensive mutation screening and filtering in a large cohort of unrelated 
consecutive index AC cases identified 37 putative pathogenic mutations 
exclusively in desmosomal-related genes in 46% of cases. 
In order to provide a more stringent analysis, we limited our study to the only 
variant carriers resulting from the 4-filtering steps. The characterization of 
identified variants as pathogenic mutations or benign variants is essential for the 
understanding of their role in the disease, and this process is even more critical 
with the use of genetics as a diagnostic criterion. According to the results of the 
present study, compound/digenic heterozygosity (8%) and homozygosity (1%) in 
AC-desmosomal gene mutations suggest a different more complex mode of 
inheritance. This highlights the importance of screening the entire panel of 
desmosomal genes, even after a single mutation has been identified, and have 
significant implications for genetic counseling. 
Further CNVs investigation allowed the identification of an additional 4% of 
CNVs carriers, increasing the diagnostic yield of AC genetic testing to 46% in our 
population. These data emphasize the diagnostic impact of performing additional 
CNVs analysis in AC genetic testing and the importance of comprehensively 
analyze the entire AC cohort.  
Radical mutations in our cohort showed a lower risk of SCD event, suggesting 
that pathogenicity should be assessed carefully by studying the family co-
segregation with the disease as well. 
Clinical and familiar correlation is essential to elucidate the role of both genetic 
point/radical variants and CNVs, for genetic counselling and management.  
Finally, our pilot NGS experiments highlighted the potential of WES and 
Targeted resequencing in the clinical setting in terms of time, cost and 
effectiveness, by enabling a differential diagnosis in 4 probands with extra 
desmosomal mutations. However the application of NGS to the molecular 
diagnosis of AC raises new challenges in distinguishing pathogenic from non 
pathogenic vairiants and overall in the patients’ management and treatment. 
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